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Table S1. Inhibitory activities against BoNT/A LC and holotoxin in proteolytic and cell-based 
assay 
Compound 
In vitro 
proteolytic 
assay 
% inh 
BoNT/A 
LC at 20 
μM 
In vitro 
proteolytic 
assay 
IC50 (μM) 
mES-MNs 
pre 
intoxication 
% of full 
length 
SNAP-25 
(10 μM; 20 
μM) 
mES-MNs 
post 
intoxication 
at 20 μM 
% of full 
length 
SNAP-25 
(30 min; 60 
min) 
1 
OAc
OAcNH
H
NH
NH
N
Cl
NH
NCl
()
5
()
5
 
90 12.4 70; 84 36; 20 
14 
H
OAc
OAc
NH2
NH
NH
N
 
80 5.7 28; 67 48; 49 
15 
H
OAc
OAc
NH2
N
NH
N
 
52 1.5 70; 69 / 
16 
H
OAc
OAc
NH2
NH
NH
N
Cl  
66 4.5 72; 88 64; 45 
17 
H
OAc
OAc
NH2
NH
NH
N
 
71 2.7 67; 69 38; 22 
18 85 0.7 20; 41 / 
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H
OAc
OAc
NH2
N
NH
N
 
19 
H
OAc
OAc
NH2
NH
NH
N
 
75 3.0 86; 87 50; 22 
20 
H
OAc
OAc
NH2
N
H NH
N
Cl  
77 2.4 / / 
21 
H
OAc
OAc
NH2
N
H NH
N
Cl  
54 / / / 
22 
H
OAc
OAc
NH2
NH
NH
N
 
64 7.1 / / 
23 
H
OAc
OAc
NH2
NH
NH
N
Cl  
67 3.5 / / 
24 
H
OH
OH
NH2
NH
NH
N
Cl  
48 / 46; 58
a
 49; 
a
 /
 
 
30 
H
OAc
OAc
NH2
NH
NH
O
N
Cl
 
37 / / / 
S1 
S
F
NH NH
N
Cl
 
55 6.6 / / 
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S2 
S
F
NH NH
N
 
42 / / / 
33 
S
F
NH
NH
N
Cl  
69 / / / 
34 
S
F
NH NH
N
 
75 7.4 58; 68 16; 17 
35 
S
F
NH
NH
N
 
34 / / / 
36 
S
NC
NH
NH
N
 
61 10.2 34; 53 / 
37 
S
F
N
NH
N
 
46 / 44; 55 / 
38 
S
NC
N NH
N
 
27 / 59; 64 / 
86 
S
NC
NH
NH
N
 
84 4.6 21; 26 / 
87 
S
NC
NH
NH
N
 
75 3.3 36; 43 / 
88 
S
NH
NH
NNC
 
23 / / / 
89 
S
NH
NH
NNC
 
8 / / / 
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90 
S
F
NH
NH
N
 
56 5.9 / / 
91 
S
F
NH NH
N
 
69 8.8 62; 62 / 
92 
S
F
N NH
N  
48 / / / 
S3 
S
N NH
NH
N
Cl
 
49 / / / 
S4 
S NH
N
NH
N
Cl
 
47 / / / 
S5 
N
NH
NH
Cl
SN
 
63 2.2 / / 
42 
S
N
NH NH
N
 
63 2.1 / / 
43 
S
N NH
NH
N
 
53 6.4 / / 
44 
N
S
N
NH NH
 
49 / / / 
46 
S
NHN NH
N
 
70-80 3.4 22; 48 / 
47 
S NH NH
N
Cl 
19 / / / 
48 
S
NN
NH
N
 
55 / / / 
50 68 8.7 46; 71 / 
S7 
 
 
S N
H
N NH
N
 
93 
S
N NH
NH
N
 
77 6.8 31; 70 20; 19 
94 
S
N NH
NH
N
Cl 
14 / / / 
95 
S
NHN
NH
N
Cl 
30 / / / 
96 
S
N N
NH
N
 
35 / 54; 60 34; 22 
97 
S NH NH
N
N
Cl 
36 / / / 
98 
S
NH
NH
N
 
53 12.3 / / 
101 
S
NHN NH
N
 
67 9.3 18; 39 / 
S6 
NCl
NH NH
 
55 15.7 / / 
S7 
N
NH
NH
Cl  
55 16.6 / / 
S8 
NCl
NH
NH
 
46 / / / 
S9 
N
NH NH
Cl  
44 / / / 
S10 41 / / / 
S8 
 
 
N
NH
Cl
NH
 
S11 
N
NH
NH
Cl  
39 / / / 
56 
N
NH
N
Cl  
3 / / / 
57 
NCl
NH N
 
71 8.8 51; 56 46; 39 
58 
N
NH
N
Cl  
24 / / / 
59 
N
NH
N
Cl  
23 / / / 
60 
NCl
NH N
 
67 11.7 63; 72 15; 16 
61 
N
NH
N
Cl  
17 / / / 
62 
N
NH N
Cl  
61 21.1 / / 
63 
N
NH
Cl
N
 
63 43.3 / / 
64 13 / / / 
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N
NH
N
Cl  
65 
N
NH N
Cl  
48 / / / 
68 
N
NH N
 
 
30 / 30; 31 / 
69 
N
NH N
 
31 / / / 
77 
N
NH
NH
 
20 / / / 
78 
N
NH NH
 
46 / / / 
79 
N
NH
NH
 
24 / / / 
80 
N
NH
NH
 
59 3.2 / / 
81 
N
NH NH
 
/ / 23; 24 / 
82 
N
NH
NH
 
41 / / / 
84 3 / / / 
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N
NH N
 
 
85 
N
NH N
 
 
51 5.2 47; 46 / 
99 
N
NH NH
Cl  
64 9.1 / / 
100 
N
NH NH
 
42 / / / 
102 
NCl
NH NH
 
65 2.7 29; 30 / 
103 
NCl
NH NH
F
 
2 / 30; 29 / 
104 
NCl
NH NH
F
 
15 / 31; 35 / 
105 
N
NH NH
F
 
/ / 24; 23 / 
106 
N
NH NH
F
 
/ / 30; 32 / 
a
Compound 24 was tested at 8 and 16 μM in pre-intoxication model and at 16 μM in 30 minutes post-
intoxication model. 
Synthesis of compound 1 was published in our previous work.
1
 Syntheses of compounds S1-S5, 36, 46, 86-98, 
101 were published in our previous work.
2
 Synthesis of compound 35 was published in our previous work.
3
 
Syntheses of compounds 99, 100, 102-106, S6-S9, S11 were published in our previous work.
4
 Synthesis of 
S11 
 
 
compound S10 was published in our previous work.
5
 
 
 
 
Table S2. Protection of SNAP-25 in mES-MNs in pre-intoxication model at five concentrations 
0.1 → 20 μM (results are given as mean value of three independent experiments). 
 
Compound Concentration (μM) % of full length SNAP-25   SEM 
No toxin / 100 0 
Toxin only 500 pM 16.6 3.3 
1 
0.1 23.1 6.8 
1 23.3 4.8 
5 36.4 9.8 
10 55.5 12.9 
20 78.2 5.0 
14 
0.1 25.8 8.1 
1 23.3 7.1 
5 25.5 5.2 
10 40.1 11.4 
20 60.2 11.3 
16 
0.1 19.4 3.8 
1 21.1 4.2 
5 25.1 3.4 
10 50.6 14.6 
20 80.7 9.7 
17 
0.1 19.5 4.3 
1 19.7 4.1 
5 21.9 4.3 
10 31.7 1.3 
20 61.4 6.0 
19 
0.1 20.0 6.1 
1 22.1 6.1 
5 22.4 3.7 
10 36.1 6.0 
20 79.3 3.4 
34 
0.1 18.1 4.7 
1 17.6 4.9 
5 27.0 8.4 
10 40.9 4.1 
20 72.7 8.5 
38 
0.1 24.1 4.2 
1 24.1 7.2 
5 28.5 8.4 
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10 45.2 12.6 
20 69.3 11.4 
50 
0.1 21.1 7.0 
1 24.3 4.3 
5 26.5 2.2 
10 33.9 3.2 
20 57.3 4.2 
57 
0.1 28.5 7.0 
1 15.9 4.4 
5 20.7 5.9 
10 33.4 4.6 
20 75.6 14.6 
60 
0.1 19.6 3.8 
1 21.1 3.3 
5 26.9 6.5 
10 60.6 9.0 
20 89.8 4.5 
93 
0.1 21.3 6.1 
1 25.6 6.8 
5 26.3 2.0 
10 40.4 2.4 
20 75.9 4.2 
96 
0.1 23.7 6.3 
1 30.1 11.1 
5 42.2 15.3 
10 60.0 15.7 
20 69.7 11.7 
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Table S3. Protection of SNAP-25 in mES-MNs in 30/60 minutes post-intoxication model at 20 
μM (results are given as mean value of three independent experiments) 
 
Compound 
% of full length 
SNAP-25 (30 min) 
SEM 
% of full length 
SNAP-25 (60 min) 
SEM 
No toxin 100 0 100 0 
Toxin only 14.8 2.7 16.2 3.7 
1 35.9 6.0 19.9 3.5 
14 48.4 9.1 48.9 24.1 
16 64.4 6.1 44.9 9.6 
17 38.5 8.0 21.9 2.4 
19 49.5 12.0 22.5 1.8 
34 16.3 2.4 16.6 2.2 
57 46.4 9.8 39.4 9.8 
60 15.2 3.0 16.2 3.0 
93 19.8 3.1 18.9 3.0 
96 34.3 5.9 22.3 4.1 
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Table S4. Protection of SNAP-25 in mES-MNs by compounds 16 and 24 administered 30 min 
post-intoxication – dose response experiment 0.25 to 64 μM (results are given as mean value of 
two independent experiments) 
 
Compound Concentration (μM) % of full length SNAP-25   SEM 
No toxin / 100 0 
Toxin only 500 pM 29.6 3.7 
16 
0.25 33.2 1.8 
0.5 33.9 3.0 
1 38.8 0.3 
2 37.9 0.9 
4 47.3 6.7 
8 48.2 4.3 
16 71.9 4.0 
32 89.4 2.2 
64 100 0 
24 
0.25 33.0 3.3 
0.5 36.6 0.9 
1 38.6 5.3 
2 41.0 5.5 
4 44.0 2.5 
8 50.3 5.3 
16 49.2 2.1 
32 52.7 4.3 
64 69.2 4.1 
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Figure S1. Protection of SNAP-25 in mES-MNs by compound 24 administered 30 min pre-
intoxication – dose response experiment 0.25 to 64 μM (results are given as mean value of two 
independent experiments +/- SEM). IC50 =8-16 μM. 
 
Table S5. Protection of SNAP-25 in mES-MNs by compound 24 administered 30 min pre-
intoxication – dose response experiment 0.25 to 64 μM (results are given as mean value of two 
independent experiments). 
 
Compound Concentration (μM) % of full length SNAP-25   SEM 
Toosendanin 10 100 0 
Toxin only 500 pM 34.2 4.1 
24 
0.25 35.8 3.3 
0.5 38.9 3.2 
1 41.9 2.4 
2 40.4 5.0 
4 43.4 4.7 
8 46.4 7.3 
16 57.9 8.3 
32 70.8 5.8 
64 94.0 6.0 
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Figure S2. Protection of SNAP-25 in mES-MNs by compound 16 administered 30 min post-
intoxication – dose response experiment 0.1 to 20 μM (results are given as mean value of four 
independent experiments +/- SEM). IC50 =5-10 μM. 
Table S6. Protection of SNAP-25 in mES-MNs by compound 16 administered 30 min post-
intoxication – dose response experiment 0.1 to 20 μM (results are given as mean value of four 
independent experiments). 
Compound Concentration (μM) % of full length SNAP-25 SEM 
No toxin / 100 0 
Toxin only 500 pM 15.9 5.6 
16 
0.1 16.9 2.1 
1 21.2 3.1 
5 40.3 3.9 
10 52.9 4.4 
20 64.4 6.1 
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Fluorescence and UV-Vis spectra of binding 16 to HSA and AGP 
  
Figure S3. Changes in HSA (c=5×10
-7
 M) 
fluorescence emission spectra upon 
addition of 16 (1-20 molar equivalents); T 
=298 K, 1X PBS, pH=7.34. 
 
 Figure S4. Changes in HSA (c=5×10
-7
 M) 
UV-Vis spectra upon addition of 16 (1-20 
molar equivalents); T=298 K; 1X PBS, pH = 
7.34, scan speed 500 nm/min 
 
 
 
      
 
Figure S5. The Stern-Volmer plot for 
binding of 16 to HSA (c=5×10
-7
 M), 
T=298 K; pH = 7.34; λ=323 nm; linear 
equation: y=1+45628.8x (For the 
calculation of binding constants, only 
points within linear dependence were 
used (1-5 molar equivalents).) 
 
 Figure S6. Log-log plot for the determination 
of binding constants Kb, and the number of 
binding sites n for binding of 16 to HSA 
(c=5×10
-7
 M) T=298 K; pH = 7.34; λ=323 nm; 
linear equation: y=2.77+0.67x (For the 
calculation of binding constants, only points 
within linear dependence were used (1-5 molar 
equivalents).) 
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Figure S7. Changes in AGP (c=5×10
-7
 M) 
fluorescence emission spectra upon 
addition of 16 (1-20 molar equivalents); T 
=298 K, 30 mM PBS, pH=7.34. 
 
 Figure S8. Changes in AGP (c=5×10
-7
 M) 
UV-Vis spectra upon addition of 16 (1-20 
molar equivalents); T=298 K; 1X PBS, pH = 
7.34, scan speed 500 nm/min. 
 
 
        
Figure S9. The Stern-Volmer plot for 
binding of 16 to AGP (c=5×10
-7
 M), 
T=298 K; pH = 7.34; λ=323 nm; linear 
equation: y=1+699439.2x (For the 
calculation of binding constants, only 
points within linear dependence were 
used (1-3 molar equivalents).) 
 
 Figure S10. Log-log plot for the determination 
of binding constants Kb, and the number of 
binding sites n for binding of 16 to HSA 
(c=5×10
-7
 M) T=298 K; pH = 7.34; λ=323 nm; 
linear equation: y=4.88+0.3x (For the 
calculation of binding constants, only points 
within linear dependence were used (1-3 molar 
equivalents).) 
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Ligand interaction diagrams  
 ll ligand stru tures were  uilt  optimized and their ionization states determined using 
  hr dinger  uite 2016-4 (  hr dinger     :  ew  ork      2016  in the same manner it was 
performed before.
1  o king of the ligands were performed using grid do king from Glide ligand 
do king module (Glide    hr dinger     :  ew  ork      2017   using standard pre ision and 
flexible ligand sampling, without no additional constraints. All modeling was performed within a 
pH range of 7.0 ± 1.0, which corresponds to the pH of in vitro experiments (i.e., pH 7.3), 
according to our previously published studies.
1
 The structure of BoNT/A LC and its binding site 
(BS) corresponds with those used in aforementioned publication.  
 
 
S20 
 
 
 
 
Figure S11. Compounds 16 (A) and 24 (B) docked in the catalytic cleft of BoNT/A LC at pH 
7.0±1.0. 
 
Figure S12. Overlapped docked structures of 16 (green) and 24 (yellow) in the catalytic cleft of 
the BoNT/A LC at pH 7.0±1.0. 
S21 
 
 
 
Figure S13. A: 16-Glu55 distance (1.81 Å) and 24-Glu55 distance (3.05 Å); B: 16-Zn
2+
 distance 
(2.19 Å) and 24-Zn
2+
 distance (2.23 Å) at pH 7.0±1.0. 
 
Figure S14. Compounds 34 (A) and 86 (B) docked in the catalytic cleft of BoNT/A LC at pH 
7.0±1.0. 
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Docking scores 
 
Table S7. Docking scores for 16 and 24
a  
 
 
Compound/score 16 24 
Docking score -10.685 -9.697 
Glide score -10.685 -9.697 
Model energy -110.664 -99.034 
Asp:370 Eint -54.216 -50.774 
Tyr:366 Eint -8.81 -8.36 
Glu:252 Eint -48.758 -37.488 
Arg:231 Eint 23.86 25.911 
Glu:164 Eint -70.57 -63.814 
Glu:55 Eint -65.916 -56.733 
a
A lower score indicates better binding of a given ligand in the substrate cleft 
 
 
Docking-in vitro inhibitory activity correlations 
 
From the Figure S15, it can be seen that there is a certain correlation of IC50 and Glide emodel 
values generated after docking procedure (Emodel represents quantitative representation of the 
combination of a version of the GlideScore, the internal ligand strain and the coulomb and van 
der Waals energy). 
 
Compound IC50 
(μM) 
Glide 
eModel 
14 5.7 -112.811 
15 1.5 -119.614 
16 4.5 -115.169 
17 2.7 -117.385 
19 3.0 -123.03 
20 2.4 -125.266 
22 7.1 -110.686 
 
Figure S15. Correlation of  IC50 and Glide emodel values 
 
R² = 0.6938 
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-108
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Same structures show relatively good correlation with total potential energy of minimized 
structure of the ligand-protein complex (Figure S16). This energy was generated by further 
minimization of docking poses, using MacroModel module (Schrödinger Release 2017-2: 
MacroModel, Schrödinger, LLC, New York, NY, 2017.). Minimizations were performed using 
OPLS-2005 force field with water solvent effects (solvent effect was applied using the analytical 
Generalized-Born/Surface-Area (GB/SA) model), using Polak-Ribier Conjugate Gradient 
method with 2500 steps or 0.05 convergence threshold. In the model, the structure of ligand and 
all of the amino acid residues within 6 Å were freely moving, with the exception of His 227, His 
223, Glu 262 and Zn
2+
, that were held frozen. 
 
Compound % 
inh 
Epot 
(kJ/mol) 
14 80 -11760.4 
16 66 -10819.3 
17 71 -10748.6 
19 75 -11187.9 
20 77 -11498.8 
22 64 -10544.5 
23 67 -10643.5 
24 48 -10174.3 
30 37 -9805.05 
 
  
Figure S16. Correlation of  % of inhibition with total potential energy 
 
 
 
 
 
R² = 0.8739 
-12000
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-10000
-9500
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Chemistry 
Melting points were determined on a Boetius PMHK apparatus and were not corrected. IR 
spectra were recorded on a Thermo-Scientific Nicolet 6700 FT-IR diamond crystal 
spectrophotometer. 
1
H and 
13
C NMR spectra were recorded on a Varian Gemini-200 
spectrometer (at 200 and 50 MHz, respectively), and a Bruker Ultrashield Advance III 
spectrometer (at 500 and 125 MHz, respectively) in the indicated solvent (vide infra) using TMS 
as the internal standard. Chemical shifts are expressed in ppm (δ) values and coupling constants 
(J) in Hz. ESI–MS (HRMS) spectra of the synthesized compounds were acquired on a Agilent 
Technologies 1200 Series instrument equipped with Zorbax Eclipse Plus C18 (100 × 2.1 mm i.d. 
1.8 μm   olumn and     dete tor (190-450 nm) in combination with a 6210 Time-of-Flight 
LC/MS instrument in positive and negative ion mode. The samples were dissolved in MeOH 
(HPLC grade). The selected values were as follows: capillary voltage 4 kV; gas temperature 350 
°C; drying gas 12 L min
-1
; nebulizer pressure 45 psig; fragmentator voltage: 70 V. Mass spectral 
analyses were done using electrospray ionization in positive ion mode on a Surveyor separations 
module coupled to a ThermoFinnigan TSQ AM triple quadrupole mass spectrometer. Gas 
chromatography tandem mass spectrometry (GC-MS) analyses were performed on an Agilent 
7890A GC (Agilent) system equipped with a 5975C inert XL EI/CI MSD and a flame ionization 
detector (FID) connected by capillary flow technology through a 2-way splitter with make-up 
gas. An HP-5 MS capillary column (Agilent Technologies, 25 mm i.d., 30 m length, 0.25 μm 
film thickness) was used. The flash chromatography was performed on Biotage SP1 system 
equipped with UV detector and FLASH 12+, FLASH 25+ or FLASH 40+ columns charged with 
KP-SIL (40 – 63 µm, pore diameter 60 Å), KP-C18-HS (40 – 63 µm, pore diameter 90 Å) or KP-
NH (40 – 63 µm, pore diameter 100 Å) as an adsorbent. Elemental analyses were realized with 
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an Elemental Vario EL III microanalyser. Compounds were analyzed for purity (HPLC) using a 
Agilent 1200 HPLC system equipped with Quat Pump (G1311B), Injector (G1329B) 1260 ALS, 
TCC 1260 ( G1316A) and Detector 1260 DAD VL+ (G1315C). Compound 42 was analyzed for 
purity (HPLC) using Waters 1525 HPLC dual pump system equipped with an Alltech, Select 
degasser system  and dual λ 2487 UV-VIS detector. HPLC analysis was performed in two 
diverse systems for each compound. Method A: Zorbax Eclipse Plus C18 4.6 × 150 mm, 1.8µ, 
S.N. USWKY01594 was used as the stationary phase. Eluent was made from the following 
solvents: 0.2% formic acid in water (A) and methanol (B). The analysis were performed at the 
UV max of the compounds (at 330 nm for compounds 14-16, 18, 19, 22, 23, 34, 37, 38, 50, 56-
65, 66-69, 77-82, 84, 85 and 93, and at 254 nm for compound 17) to maximize selectivity. 
Compounds were dissolved in methanol, final concentrations were ~1 mg/mL. Flow rate was 0.5 
mL/min. Compounds 14, 16, 22, 23, 56-65, 66-69, 77-82, 84 and 85 were eluted using gradient 
protocol: 0-1.5 min 95%A, 1-5 min 95% → 5%   5-16 min 5%A, 16-18 min 5% → 95% . 
Compounds 15, 17-19, 34, 37 and 50 were eluted using gradient protocol: 0-1 min 95%A, 1-6 
min 95% → 5%   6-11 min 5%A, 11-14 min 5% → 95%   14-15 min 95%A. Compound 38 
was eluted using gradient protocol: 0-1 min 95%A, 1-6 min 95% → 5%   6-11 min 5%A, 11-
13 min 5% → 95% .  ompound 93 was eluted using gradient protocol: 0-2 min 95%A, 2-6 
min 95% → 5%   6-17 min 5%A, 17-19 min 5% → 95%   19-21 min 95%A. Method B: 
Zorbax Eclipse Plus C18 4.6 x 150 mm, 1.8µ, S.N. USWKY01594 was used as the stationary 
phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) and 
acetonitrile (B). The analysis were performed at the UV max of the compounds (at 330 nm for 
compounds 14-19, 22, 23, 34, 37, 38, 44, 50, 56-65, 66-69, 77-82, 84, 85 and 93) to maximize 
selectivity. Compounds were dissolved in methanol, final concentrations were ~1 mg/mL. Flow 
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rate was 0.5 mL/min. Compounds 14, 16, 22 and 23 were eluted using gradient protocol: 0-1.5 
min 95%A, 1-5 min 95% → 5%   5-16 min 5%A, 16-18 min 5% → 95% .  ompounds 15, 
17, 19, 34, 37, 38 and 50 were eluted using gradient protocol: 0-1 min 95%A, 1-6 min 95% → 
5%A, 6-11 min 5%A, 11-14 min 5% → 95%   14-15 min 95%A. Compound 18 was eluted 
using gradient protocol: 0-1 min 95%A, 1-4 min 95% → 5%   4-11 min 5%A, 11-14 min 
5% → 95%   14-15 min 95%A. Compound 44 was eluted using gradient protocol: 0-1.5 min 
95%A, 1-5 min 95% → 5%   5-17 min 5%A, 17-19 min 5% → 95% .  ompounds 56-65, 
66-69, 77-82, 84 and 85 were eluted using gradient protocol: 0-1.5 min 95%A, 1-5 min 95% → 
5%A, 5-16 min 5%A, 16-18 min 5% → 95%   18-20 min 95%A. Compound 93 was eluted 
using gradient protocol: 0-1.5 min 95%A, 1-5 min 95% → 5%   5-14 min 5%A, 14-15 min 
5% → 95%   15-16 min 95%. Method C: Zorbax Eclipse Plus C18 2.1 x 100 mm, 1.8µ, S.N. 
USUXU04444 was used as the stationary phase. Eluent was made from the following solvents: 
0.2% formic acid in water (A) and methanol (B). The analysis was performed at the UV max of 
the compound (at 330 nm for compounds 20, 21, 24, 43, 44, 47; at 270 nm for compound 30, and 
at 254 nm for compound 33) to maximize selectivity. Compound was dissolved in methanol, 
final concentration was ~1 mg/mL. Flow rate was 0.2 mL/min. Compound 20 was eluted using 
gradient protocol: 0-1 min 95%A, 1-6 min 95% → 5%   6-11 min 5%A, 11-15 min 5% → 
95%A, 15-20 min 95%A. Compounds 21 and 30 were eluted using gradient protocol: 0-1 min 
95%A, 1-6 min 95% → 5%   6-11 min 5%A, 11-14 min 5% → 95%   14-20 min 95%A. 
Compound 24 was eluted using gradient protocol: 0-1 min 95%A, 1-2 min 95% → 5%   2-11 
min 5%A, 11-14 min 5% → 95%   14-18 min 95%A. Compound 33 was eluted using gradient 
protocol: 0-1 min 95%A, 1-6 min 95% → 5%   6-11 min 5%A, 11-14 min 5% → 95%   14-
18 min 95%A. Compounds 43, 44 and 47 were eluted using gradient protocol: 0-1 min 95%A, 1-
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6 min 95% → 5%   6-11 min 5%A, 11-14 min 5% → 95%   14-15 min 95%A. Method D: 
Zorbax Eclipse Plus C18 2.1 x 100 mm, 1.8µ, S.N. USUXU04444 was used as the stationary 
phase. Eluent was made from the following solvents: 0.2% formic acid in water (A) and 
acetonitrile (B). The analysis was performed at the UV max of the compound (at 254 nm for 
compounds 20, 24, 33; at 270 nm for compound 30 and at 330 nm for compounds 21, 43 and 47) 
to maximize selectivity. Compound was dissolved in methanol, final concentration was ~1 
mg/mL. Flow rate was 0.2 mL/min. Compounds 20 and 21 were eluted using gradient protocol: 
0-1 min 95%A, 1-6 min 95% → 5%   6-11 min 5%A, 11-14 min 5% → 95%   14-20 min 
95%A. Compounds 24 and 33 were eluted using gradient protocol:  0-1 min 95%A, 1-6 min 
95% → 5%   6-11 min 5%A, 11-14 min 5% → 95%   14-18 min 95%A. Compound 30 was 
eluted using gradient protocol: 0-1 min 95%A, 1-8 min 95% → 5%   8-12 min 5%A, 12-16 
min 5% → 95%   16-20 min 95%A. Compounds 43 and 47 were eluted using gradient 
protocol: 0-1 min 95%A, 1-6 min 95% → 5%   6-11 min 5%A, 11-14 min 5% → 95%   14-
15 min 95%A. Method E: Poroshell 120 EC- 18  4.6 x 50mm  2.7μ   . . U  FU07797 was 
used as the stationary phase. Eluent was made from the following solvents: 0.2% formic acid in 
water (A) and acetonitrile (B). The analysis was performed at the UV max of the compound (330 
nm for compound 48) to maximize selectivity. Compound was dissolved in methanol, final 
concentration was ~1 mg/mL. Flow rate was 0.5 mL/min. Compound 48 was eluted using 
gradient protocol: 0-1 min 95%A, 1-1.5 min 95% → 5%   1.5-8 min 5%A, 8-10 min 5% → 
95%A, 10-11 min 95%A. Method F: Poroshell 120 EC- 18  4.6 x 50mm  2.7μ   . . 
USCFU07797 was used as the stationary phase. Eluent was made from the following solvents: 
0.2% formic acid in water (A) and methanol (B). The analysis was performed at the UV max of 
the compound (330 nm for compound 48) to maximize selectivity. Compound was dissolved in 
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methanol, final concentration was ~1 mg/mL. Flow rate was 0.5 mL/min. Compound 48 was 
eluted using gradient protocol: 0-1 min 95%A, 1-1.5 min 95% → 5%   1.5-8 min 5%A, 8-10 
min 5% → 95%   10-11 min 95%A. Method G:  ymmetry  18  4.6 x 150 mm  5 μm   . . 
021336278136 37 was used as the stationary phase. Eluent was made from the following 
solvents: 0.2% formic acid in water (A) and methanol (B). The analysis was performed at the UV 
max of the compound (340 nm for compound 42) to maximize selectivity. Compound was 
dissolved in methanol, final concentration was ~1 mg/mL. Compound 42 was eluted using 
gradient protocol: 0-2 min 10% → 20 %   2-4 min 20%A, 4-8 min 20% → 10 % . Method 
H:  u leosil  18  4 x 150 mm  5 μm was used as the stationary phase. Eluent was made from 
the following solvents: 0.2% formic acid in water (A) and methanol (B). The analysis was 
performed at the UV max of the compound (340 nm for compound 42) to maximize selectivity. 
Compound was dissolved in methanol, final concentration was ~1 mg/mL. Compound 42 was 
eluted using gradient protocol: 0-2 min 6% → 12 %   2-4 min 12% → 30 %   4-8 min 
30% → 6 %   8-9 min 6%A.  
Procedure A: General procedure for the synthesis of N-Cbz protected aminoquinolines 107 
and 109.
5
 The mixture of 4,7-dichloroquinoline/4-chloroquinoline (1 equiv) and mono-Cbz 
protected diaminoalkane (1.1 – 1.2 equiv) was slowly heated to 80 C for 1 h, and the mixture 
was continued for 6-8 h at 120-130 C. After cooling to r.t., reaction mixture was transferred to 
the separation funnel using CH2Cl2/1M NaOH. The organic layer was washed with 1M NaOH, 
water and brine. The organic layer was dried over anhydrous Na2SO4 and solvent was evaporated 
under reduced pressure. Crude product was purified using column chromatography. 
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Procedure B: General procedure for the obtainment of steroidal derivatives 4-11 and 29.
1
 
Alcohol (1 equiv) was dissolved in CH2Cl2. PCC (1.5 equiv) was added, and the mixture was 
stirred at r.t. for 3.5 h. Reaction mixture was filtered through a short column of SiO2 (eluent 
CH2Cl2/EtOAc = 7/3). Crude aldehyde was dissolved in dry MeOH, aminoquinoline (1.5 equiv) 
was added, and mixture was stirred at r.t. overnight. NaBH4 (2 equiv) was added, and stirring 
was continued at r.t. for 12 h. Solvent was removed under reduced pressure and crude mixture 
was prepared for column purification. 
Procedure C: General procedure for the removal of the Boc-protecting groups with TFA 
for compounds 14-23 and 30. A solution of the N-Boc-protected amine in TFA/CH2Cl2 (v:v; 
1:10), was stirred at r.t. for 6 h. Solvents were evaporated under reduced pressure and the residue 
was treated with CH2Cl2/2.5M NaOH. The organic layer was dried over MgSO4, and the solvent 
was evaporated under reduced pressure.  
Procedure D: General procedure for N-methylated aminoquinolines 12, 13, 37, 38, 48, 56-
65, 68, 69 and 84, 85.
6
 To a stirred solution of aminoquinolines (1 equiv) in MeOH containing 
37% aqueous formaldehyde (2 equiv), the mixture of ZnCl2 (2 equiv) and NaHB3CN (4 equiv) in 
MeOH was added. After the reaction mixture was stirred at r.t. for 4 h, the solution was taken up 
in 0.1 M NaOH and most of MeOH was evaporated under reduced pressure. Aqueous solution 
was extracted with CH2Cl2, the combined extracts were washed with water and brine and dried 
over anhydrous Na2SO4. The solvent was evaporated under reduced pressure. 
Procedure E: General procedure for reductive amination to produce compounds 33, 34, 42-
45, 50, 66 and 67. Amine (1.5 equiv) and appropriate aldehyde (1 equiv) were dissolved in 
MeOH/CH2Cl2 mixture (v:v; 2:1), glac. AcOH (1.5 equiv) was added, and the mixture was 
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stirred under Ar atmosphere at r.t. After 3 h, NaBH4 (6 equiv) was added, and stirring was 
continued for another 18 h. Solvent was removed under reduced pressure, and the residue was 
dissolved in CH2Cl2. The organic layer was washed with 2M NH4OH, water and then extracted 
with CH2Cl2. The combined organic layers were washed with brine and dried over anh. Na2SO4. 
Finally, the solvent was evaporeted under reduced pressure. 
Procedure F: General procedure for the Suzuki coupling reaction using PdO × 1.4 H2O for 
compounds 40 and 113.
7
 An appropriate aryl-bromide (1 equiv) was added to the mixture of 
arylboronic acid (1.2 equiv), catalyst PdO × 1.4 H2O (0.1 equiv), K2CO3 (1.2 equiv) and 
EtOH/H2O (3:1, v/v). The mixture was stirred at 60 °C for 5 h, then diluted with water and 
extracted with CH2Cl2. Combined organic layers were washed with brine and dried over anh. 
Na2SO4. After filtration, the solvent was removed under reduced pressure. The product was 
purified using silica gel flash chromatography. 
Procedure G: General procedure for the Suzuki coupling reaction using Pd(OAc)2 and 
PPh3 for compounds 49 and 111. The solution of Pd(OAc)2 (0.1 equiv) and PPh3 (0.4 equiv) in 
DME was purged with argon and stirred at r. t. for 10 min. An appropriate arylboronic acid (1 
equiv) and 2M aq. Na2CO3 were added. After 5 min, aryl-bromide (1 equiv) was added. The 
mixture is once more purged with Ar and heated in a sealed vessel in microwave reactor at 80 °C 
for 3h. The reaction mixture was cooled and extracted with ethyl-acetate. The combined organic 
layers were washed with brine and dried over anh. Na2SO4. After filtration, the solvent was 
removed under reduced pressure. The crude product was further purified in a manner provided 
for each compound. 
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Procedure H: General procedure for palladium catalyzed amination of quinolones to 
produce compounds 78, 79, 81 and 82. Vial was charged with mixture of Pd(OAc)2 (4 mol %) 
and DPEphos (8 mol %)/SPhos (8 mol %) in dioxne and stirred for a few minutes in Ar 
atmosphere on room temperature. Subsequently, haloquinoline (1.0 equiv), amine (1.2 equiv) 
and K3PO4 (2.5 equiv) were added in to reaction mixture.The resulting suspension was sparged 
with argon for several minuties. The vial was quickly capped, heated to 85 
o
C over the night and 
then cooled down to room temperature. The mixture was adsorbed onto silica gel and purified. 
N-(quinolin-4-yl)ethane-1,2-diamine (AQ11), N-(7-chloroquinolin-4-yl)butane-1,4-diamine 
(AQ4), N-(7-chloroquinolin-4-yl)hexane-1,6-diamine (AQ6), N-(quinolin-4-yl)propane-1,3-
diamine (AQ7), N-(quinolin-4-yl)butane-1,4-diamine (AQ8), N-(quinolin-4-yl)hexane-1,6-
diamine (AQ9), N-quinolin-4-yldecane-1,10-diamine (AQ12) were prepared according to known 
procedures.
8-11 8,9,10,11
 
 
N-quinolin-4-yldecane-1,10-diamine (AQ12). 
The mixture of 4-chloroquinoline (37.9 mg, 0.232 mmol) and 1,10-diaminodecane (200 mg, 1.16 
mmol) were subjected to microwave irradiation using Biotage Initiator 2.5 apparatus for 10 min 
at 80 °C, followed by 1h at 140 °C. After cooling to room temperature 0.1 M aqueous NaOH was 
added and then extracted with dichloromethane. Combined organic layers were dried over anh. 
Na2SO4. After filtration, the solvent was removed under reduced pressure. The crude product 
was purified using column chromatography (dry-flash, SiO2, eluent CH2Cl2/MeOH). Final 
product was obtained as yellow oil (19.9 mg, 53%). IR (ATR): 3329m, 2924s, 2854s, 1651m, 
1581s, 1492m, 1465m, 1390m, 1342m, 1317m, 1158w, 767w, 722w. 
1
H NMR (500 MHz, 
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CD3OD  δ): 8.33 (d, 1H, J = 5.5, H-C(2)), 8.10 (d, 1H, J = 7.6, H-C(8)), 7.81 (d, 1H, J = 7.8, H-
C(5)), 7.65 – 7.55 (m, 1H, H-C(7)), 7.48 – 7.36 (m, 1H, H-C(6)), 6.44 (d, 1H, J = 5.5, H-C(3)), 
3.35 – 3.26 (m, 2H, ArNHCH2-), 2.70 – 2.48 (m, 2H, -CH2-NH2), 1.77 – 1.65 (m, 2H, 
ArNHCH2CH2-), 1.50 – 1.08 (m, 14 H, -(CH2)7-). 
13
C NMR (125 MHz, CD3O   δ : 152.77  
151.38, 149.12, 130.52, 129.03, 125.63, 122.42, 120.49, 99.25, 44.19, 42.73, 33.97, 30.84, 30.78, 
30.69, 29.63, 28.42, 28.19. HRMS: m/z 150.62467 corresponds to molecular formula 
C19H29N3H2
2+ 
(error in ppm -4.51). 
 (3,5,7,12)-3-[(Tert-butoxycarbonyl)amino]-24-{[4-(quinolin-4-
ylamino)butyl]amino}cholane-7,12-diyl diacetate (4).  
According to general procedure B, alcohol 3 (445 mg, 0.770 mmol) was transformed into 
aldehyde using PCC (239 mg, 1.10 mmol) in CH2Cl2 (35 mL), which was further transformed 
into 4 using amine AQ8
4
 (211.5 mg, 0.9823 mmol), NaBH4 (49.5 mg, 1.31 mmol) and MeOH 
(20 mL). The product was purified using column chromatography (dry-flash, SiO2, eluent 
Hex/EtO   = 1/1 → EtO    EtO  /MeOH gradient 9/1 → MeOH  EtO  /MeOH( H3 sat.) = 
9/1). Final product 4 was obtained as colorless oil (360 mg, 60%). [α] 20
D
= +38.9 (MeOH). IR 
(ATR): 3320w, 3052w, 2935s, 2866m, 1724s, 1618w, 1582s, 1540m, 1441w, 1375m, 1342w, 
1310w, 1250s, 1171m, 1126w, 1064w, 1023w, 999w, 965w, 884w, 854w, 808w, 765w, 736m, 
702w, 610w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.54 (d, 1H, J = 5.3, H-C(2')), 7.97 (d, 1H, J = 
8.2, H-C(8')), 7.76 (d, 1H, J = 8.2, H-C(5')), 7.64-7.59 (m, 1H, H-C(7')), 7.42-7.37 (m, 1H, H-
C(6')), 6.40 (d, 1H, J = 5.2, H-C(3')), 5.77 (bs, 1H, H-N, exchangeable with D2O), 5.10-5.07 (m, 
1H, H-C(12)), 4.92-4.88 (m, 1H, H-C(7)), 4.42 (bs, 1H, H-N, exchangeable with D2O), 3.35-3.21 
(m, 3H, ArNHCH2- and H-C(3)), 2.73-2.66 (m, 2H, ArNHCH2CH2CH2CH2-), 2.65-2.54 (m, 2H-
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C(24)), 2.10 (s, 3H, CH3COO-C(12)), 2.05 (s, 3H, CH3COO-C(7)), 2.00-1.44 (m, 20H, H-
steroid), 1.44 (s, 9H, -NHCOOC(CH3)3), 1.41-0.97 (m, 9H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 
0.82 (d, 3H, J = 6.6, CH3-C(20)), 0.71 (s, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ : 
170.39, 170.27, 155.12, 151.05, 149.85, 148.42, 129.87, 128.87, 124.32, 119.57, 118.83, 98.58, 
79.16, 75.48, 70.86, 50.55, 49.29, 47.49, 44.99, 43.36, 43.18, 41.53, 37.70, 36.39, 35.48, 34.90, 
34.24, 33.36, 31.29, 28.85, 28.40, 27.85, 27.26, 26.46, 26.43, 25.49, 22.80, 22.68, 21.60, 21.37, 
17.91, 12.18. HRMS: m/z 775.53542 corresponds to molecular formula C46H70N4O6H
+ 
(error in 
ppm -1.79).  
(3,5,7,12)-3-[(tert-butoxycarbonyl)amino]-24-({4-[(7-chloroquinolin-4-
yl)amino]butyl}amino)cholane-7,12-diyl diacetate (5). 
According to general procedure B, alcohol 3 (430.0 mg, 0.7442 mmol) was transformed into 
aldehyde using PCC (230 mg, 1.1 mmol) in CH2Cl2 (35 mL), which was further transformed into 
5 using amine AQ4 (230.8 mg, 0.9242 mmol), NaBH4 (46.7 mg, 1.23 mmol) and MeOH (20 
mL). The product was purified using column chromatography (dry-flash, SiO2, eluent 
Hex/EtO   = 1/1 → EtO    EtO  /MeOH gradient 9/1 → MeOH  EtO  /MeOH( H3 sat.) = 
9/1). Final product 5 was obtained as colorless oil (396.3 mg, 66%). [α] 20
D
= +62.2 (MeOH). IR 
(ATR): 3311w, 3054w, 2935s, 2866m, 2157w, 1724s, 1610w, 1581s, 1535w, 1450w, 1370m, 
1331w, 1248s, 1170w, 1135w, 1064w, 1022w, 999w, 965w, 880w, 851w, 808w, 768w, 736w, 
702w, 647w, 609w, 411sl cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.51 (d, 1H, J = 5.5, H-C(2')), 
7.96-7.92 (m, 1H, H-C(8')), 7.71 (d, 1H, J = 8.9, H-C(5')), 7.34-7.30 (m, 1H, H-C(6')), 6.37 (d, 
1H, J = 5.2, H-C(3')), 6.03 (bs, 1H, H-N, exchangeable with D2O), 5.11-5.07 (m, 1H, H-C(12)), 
4.92-4.88 (m, 1H, H-C(7)), 4.43 (bs, 1H, H-N, exchangeable with D2O), 3.34-3.24 (m, 3H, 
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ArNHCH2- and H-C(3)), 2.73-2.67 (m, 2H, ArNHCH2CH2CH2CH2-), 2.64-2.52 (m, 2H-C(24)), 
2.10 (s, 3H, CH3COO-C(12)), 2.06 (s, 3H, CH3COO-C(7)), 2.02-1.45 (m, 20H, H-steroid), 1.44 
(s, 9H, -NHCOOC(CH3)3), 1.41-0.98 (m, 9H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 0.84-0.81 (m, 
3H, CH3-C(20)), 0.72 (s, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ : 170.38  170.26  
155.13, 152.08, 149.95, 149.19, 134.64, 128.71, 124.88, 121.38, 117.31, 98.83, 79.17, 75.46, 
70.84, 50.53, 49.15, 47.52, 44.98, 43.36, 43.19, 41.52, 37.68, 36.37, 35.47, 34.93, 34.22, 33.36, 
31.28, 28.84, 28.39, 27.87, 27.26, 26.52, 26.28, 25.48, 22.77, 22.67, 21.59, 21.36, 17.91, 12.18. 
HRMS: m/z 809.49621 corresponds to molecular formula C46H69ClN4O6H
+ 
(error in ppm -2.01).  
(3,5,7,12)-3-[(tert-butoxycarbonyl)amino]-24-{[4-(quinolin-4-
ylamino)pentyl]amino}cholane-7,12-diyl diacetate (6) (Mixture of diastereomers). 
According to general procedure B, alcohol 3 (493.6 mg, 0.8543 mmol) was transformed into 
aldehyde using PCC (265.2 mg, 1.230 mmol) in CH2Cl2 (35 mL), which was further transformed 
into 6 using amine N
4
-(quinolin-4-yl)pentane-1,4-diamine
2
 (238.9 mg, 1.042 mmol), NaBH4 
(52.6 mg, 1.39 mmol) and MeOH (10 mL). The product was purified using column 
chromatography (dry-flash, SiO2  eluent Hex/EtO   = 1/1 → EtO    EtO  /MeOH gradient 
9/1 → MeOH  EtO  /MeOH( H3 sat.) = 9/1, flash, Biotage SP1, RP column 40+M, eluent 
MeOH/H2O gradient 7/3 → MeOH . Final produ t 6 was obtained as mixture of diastereomers. 
Colorless foam (398 mg, 59%).  M.p. = 101 – 103 °C. [α] 20
D
= +48.0 (MeOH). IR (ATR): 3356w, 
3260w, 3233w, 3192w, 3122w, 2934s, 2868m, 1718s, 1622w, 1580s, 1533s, 1450m, 1374s, 
1168s, 1062w, 1023m, 965w, 890w, 857w, 809w, 764m, 691w, 655w, 609w, 533w, 500w, 
474w, 435w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.55-8.52 (m, 1H, H-C(2')), 7.98-7.95 (m, 1H, 
H-C(8')), 7.73 (d, 1H, J = 8.4, H-C(5')), 7.64-7.59 (m, 1H, H-C(7')), 7.42-7.37 (m, 1H, H-C(6')), 
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6.42 (d, 1H, J = 5.5, H-C(3')), 5.29-5.23 (m, 1H, H-N, exchangeable with D2O), 5.10-5.06 (m, 
1H, H-C(12)), 4.91-4.88 (m, 1H, H-C(7)), 4.42 (bs, 1H, H-N), 3.77-3.68 (m, 1H, 
ArNHCH(CH3)-), 3.27 (bs, 1H, H-C(3)), 2.69-2.61 (m, 2H, ArNHCH(CH3)CH2CH2CH2-), 2.61-
2.49 (m, 2H-C(24)), 2.10 and 2.09 (s and s, overlap, 3H, CH3COO-C(12)), 2.06 and 2.05 (s and 
s, overlap, 3H, CH3COO-C(7)), 2.00-1.45 (m, 20H, H-steroid), 1.44 (s, 9H, -NHCOOC(CH3)3), 
1.40-1.33 (m, 3H, H-steroid), 1.32 (d, 3H, J = 6.4, ArNHCH(CH3)-), 1.25-0.75 (m, 6H, H-
steroid), 0.90 (s, 3H, CH3-C(10)), 0.81 (d, 3H, J = 6.6, CH3-C(20)), 0.71 and 0.70 (s and s, 
overlap, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ : 170.39  170.28  155.12  151.00  
148.89, 148.63, 129.98, 128.87, 124.32, 119.35, 118.83, 98.86, 79.21, 75.48, 70.87, 50.58, 50.54, 
49.67, 48.18, 47.45, 44.98, 43.37, 41.54, 37.70, 36.40, 35.49, 34.87, 34.23, 33.32, 31.29, 28.85, 
28.40, 27.26, 26.59, 26.56, 26.47, 25.49, 22.79, 22.69, 21.60, 21.38, 20.27, 17.90, 12.18. HRMS: 
m/z 789.55312 corresponds to molecular formula C47H72N4O6H
+ 
(error in ppm 0.84).  
(3,5,7,12)-3-[(tert-butoxycarbonyl)amino]-24-{[1-methyl-4-(quinolin-4-
ylamino)butyl]amino}cholane-7,12-diyl diacetate (7) (Mixture of diastereomers). 
According to general procedure B, alcohol 3 (440.0 mg, 0.7615 mmol) was transformed into 
aldehyde using PCC (236 mg, 1.09 mmol) in CH2Cl2 (35 mL), which was further transformed 
into 7 using amine 108 (221 mg, 0.964 mmol), NaBH4 (48.6 mg, 1.28 mmol) and MeOH (20 
mL). The product was purified using column chromatography (dry-flash, SiO2, eluent 
Hex/EtO   = 1/1 → EtO    EtO  /MeOH gradient 9/1 → MeOH  EtO  /MeOH( H3 sat.) 
gradient 9/1 → 7/3 . Final produ t 7 was obtained as mixture of diastereomers. Colorless oil 
(390 mg, 65%). [α] 20
D
= +40.0 (MeOH). IR (ATR): 3337m, 3190m, 2932s, 2866s, 2654w, 1729s, 
1582s, 1537s, 1444m, 1374s, 1244s, 1170s, 1063w, 1024m, 966w, 940w, 885w, 856w, 807w, 
S36 
 
 
764m, 656w, 611w, 532w, 406w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.55 (d, 1H, J = 5.3, H-
C(2')), 7.99-7.96 (m, 1H, H-C(8')), 7.78-7.74 (m, 1H, H-C(5')), 7.64-7.59 (m, 1H, H-C(7')), 7.43-
7.38 (m, 1H, H-C(6')), 6.40 (d, 1H, J = 5.5, H-C(3')), 5.60 (bs, 1H, H-N, exchangeable with 
D2O), 5.09-5.06 (m, 1H, H-C(12)), 4.91-4.87 (m, 1H, H-C(7)), 4.46 (bs, 1H, H-N), 3.38-3.20 (m, 
3H, ArNHCH2- and H-C(3)), 2.77-2.69 (m, 1H, ArNHCH2CH2CH2CH(CH3)-), 2.67-2.47 (m, 
2H-C(24)), 2.09 and 2.08 (s and s, overlap, 3H, CH3COO-C(12)), 2.05 and 2.04 (s and s, 
overlap, 3H, CH3COO-C(7)), 2.00-1.45 (m, 20H, H-steroid), 1.44 (s, 9H, -NHCOOC(CH3)3), 
1.42-1.20 (m, 6H, H-steroid), 1.09 (d, 3H, J = 6.2, ArNHCH2CH2CH2CH(CH3)-), 1.08-1.01 (m, 
3H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 0.81 (d, 3H, J = 6.4, CH3-C(20)), 0.70 and 0.69 (s and 
s, overlap, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ): 170.38, 170.26, 155.17, 151.02, 
149.78, 148.40, 129.88, 128.88, 124.37, 119.47, 118.78, 98.62, 79.17, 75.46, 70.84, 52.68, 47.65, 
47.62, 47.44, 47.41, 44.95, 43.46, 43.35, 41.52, 37.67, 36.37, 35.47, 34.82, 34.64, 34.58, 34.21, 
33.39, 33.36, 31.27, 28.84, 28.38, 27.23, 26.70, 25.47, 25.11, 22.76, 22.66, 21.57, 21.35, 20.46, 
20.40, 17.88, 12.16. HRMS: m/z 789.54993 corresponds to molecular formula C47H72N4O6H
+ 
(error in ppm -3.21); m/z 395.27922 corresponds to molecular formula C47H72N4O6H2
2+ 
(error in 
ppm -1.64).  
(3,5,7,12)-3-[(tert-butoxycarbonyl)amino]-24-({4-[7-(chloroquinolin-4-
ylamino)pentyl}amino)cholane-7,12-diyl diacetate (8) (Mixture of diastereomers). 
According to general procedure B, alcohol 3 (150.0 mg, 0.2596 mmol) was transformed into 
aldehyde using PCC (80.6 mg, 0.374 mmol) in CH2Cl2 (15 mL), which was further transformed 
into 8 using amine N
4
-(7-chloroquinolin-4-yl)pentane-1,4-diamine
4
 (80.4 mg, 0.305 mmol), 
NaBH4 (15.4 mg, 0.406 mmol) and MeOH (10 mL). The product was purified using column 
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chromatography (dry-flash, SiO2  eluent Hex/EtO   = 1/1 → EtO    EtO  /MeOH gradient 
9/1 → MeOH  EtO  /MeOH( H3 sat.) = 9/1). Final product 8 was obtained as mixture of 
diastereomers. Colorless oil (142.9 mg, 67%). [α]
20
D = +51.1 (MeOH). IR (ATR): 3364w, 3317w, 
2934s, 2868m, 1716s, 1612w, 1578s, 1535m, 1450m, 1374s, 1335w, 1246s, 1170m, 1064w, 
1024m, 965w, 940w, 880w, 852w, 810w, 767w, 605w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 
8.52-8.49 (m, 1H, H-C(2')), 7.95-7.92 (m, 1H, H-C(8')), 7.68 (d, 1H, J = 8.9, H-C(5')), 7.34-7.30 
(m, 1H, H-C(6')), 6.40 (d, 1H, J = 5.5, H-C(3')), 5.48-5.43 (m, 1H, H-N, exchangeable with 
D2O), 5.10-5.06 (m, 1H, H-C(12)), 4.91-4.87 (m, 1H, H-C(7)), 4.43 (bs, 1H, H-N, exchangeable 
with D2O), 3.75-3.66 (m, 1H, ArNHCH(CH3)-), 3.27 (bs, 1H, H-C(3)), 2.67-2.61 (m, 2H, 
ArNHCH(CH3)CH2CH2CH2-), 2.60-2.48 (m, 2H-C(24)), 2.10 and 2.09 (s and s, overlap, 3H, 
CH3COO-C(12)), 2.06 (s, 3H, CH3COO-C(7)), 2.00-1.45 (m, 20H, H-steroid), 1.44 (s, 9H, -
NHCOOC(CH3)3), 1.40-1.32 (m, 3H, H-steroid), 1.31 (d, 3H, J = 6.4, ArNHCH(CH3)-), 1.26-
0.99 (m, 6H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 0.82 (d, 3H, J = 6.6, CH3-C(20)), 0.72 and 
0.71 (s and s, overlap, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ : 170.38  170.27  155.12  
151.99, 149.37, 149.02, 134.68, 128.79, 124.91, 121.17, 117.32, 99.13, 79.18, 75.47, 70.85, 
53.39, 50.56, 50.53, 49.51, 48.28, 47.48, 44.97, 43.35, 41.52, 37.69, 36.38, 35.47, 34.90, 34.87, 
34.22, 34.07, 33.32, 31.28, 28.84, 28.39, 27.25, 26.49, 26.48, 25.48, 22.77, 22.67, 21.59, 21.36, 
20.14, 17.89, 12.17. HRMS: m/z 823.51447 corresponds to molecular formula C47H71ClN4O6H
+ 
(error in ppm 1.19); m/z 412.26065 corresponds to molecular formula C47H71ClN4O6H2
2+ 
(error 
in ppm 0.66).  
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(3,5,7,12)-3-[(Tert-butoxycarbonyl)amino]-24-({4-[(7-chloroquinolin-4-yl)amino]-1-
methylbutyl}amino)cholane-7,12-diyl diacetate (9) (Mixture of diastereomers). 
According to general procedure B, alcohol 3 (120.0 mg, 0.2077 mmol) was transformed into 
aldehyde using PCC (64.5 mg, 0.299 mmol) in CH2Cl2 (12 mL), which was further transformed 
into 9 using amine 110 (67.3 mg, 0.255 mmol), NaBH4 (12.9 mg, 0.340 mmol) and MeOH (8 
mL). The product was purified using column chromatography (dry-flash, SiO2, eluent EtOAc, 
EtO  /MeOH gradient 9/1 → MeOH  EtO  /MeOH(NH3 sat.  gradient 95/5 → 8/2 . Final 
product 9 was obtained as mixture of diastereomers. Colorless oil (132.4 mg, 77%). [α] 20
D
= +44.6 
(MeOH). IR (ATR): 3341w, 3055w, 2935s, 2866m, 1723s, 1610w, 1581s, 1538m, 1451m, 
1371m, 1332w, 1249s, 1171m, 1065w, 1023w, 999w, 852w, 809w, 737m cm
-1
. 
1
H NMR 
(500MHz, CDCl3  δ): 8.52 (d, 1H, J = 5.2, H-C(2')), 7.96-7.94 (m, 1H, H-C(8')), 7.71-7.68 (m, 
1H, H-C(5')), 7.35-7.32 (m, 1H, H-C(6')), 6.38 (d, 1H, J = 5.5, H-C(3')), 5.82-5.77 (m, 1H, H-N 
exchangeable with D2O), 5.10-5.06 (m, 1H, H-C(12)), 4.91-4.88 (m, 1H, H-C(7)), 4.45 (bs, 1H, 
H-N), 3.35-3.20 (m, 3H, ArNHCH2- and H-C(3)), 2.76-2.69 (m, 1H, 
ArNHCH2CH2CH2CH(CH3)-), 2.67-2.46 (m, 2H-C(24)), 2.09 and 2.09 (s and s, overlap, 3H, 
CH3COO-C(12)), 2.05 i 2.04 (s and s, overlap, 3H, CH3COO-C(7)), 2.02-1.45 (m, 20H, H-
steroid), 1.44 (s, 9H, -NHCOOC(CH3)3), 1.40-1.20 (m, 6H, H-steroid), 1.09 (d, 3H, J = 6.4, 
ArNHCH2CH2CH2CH(CH3)-), 1.07-0.97 (m, 3H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 0.81 (d, 
3H, J = 6.6, CH3-C(20)), 0.71 i 0.70 (s and s, overlap, 3H, CH3-C(13)). 
13
C NMR (125 MHz, 
CDCl3  δ): 170.37, 170.27, 155.11, 151.08, 149.86, 149.20, 134.69, 128.78, 124.99, 121.23, 
117.26, 98.91, 79.17, 75.47, 70.84, 52.59, 50.78, 47.62, 47.58, 47.47, 44.98, 43.50, 43.37, 41.52, 
37.68, 36.38, 35.47, 34.87, 34.69, 34.62, 34.22, 33.41, 33.39, 31.28, 28.85, 28.40, 27.24, 26.80, 
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25.49, 24.98, 22.77, 22.67, 21.58, 21.36, 20.50, 20.46, 17.89, 12.18. HRMS: m/z 823.51237 
corresponds to molecular formula C47H71N4ClO6H
+ 
(error in ppm -1.36). 
(3,5,7,12)-3-[(Tert-butoxycarbonyl)amino]-24-{[6-(quinolin-4-ylamino) 
hexyl]amino}cholane-7,12-diyl diacetate (10). 
According to general procedure B, alcohol 3 (207.4 mg, 0.3590 mmol) was transformed into 
aldehyde using PCC (111.4 mg, 0.5170 mmol) in CH2Cl2 (17 mL), which was further 
transformed into 10 using amine AQ9
2
 (115.4 mg, 0.4742 mmol), NaBH4 (23.9 mg, 0.632 
mmol) and MeOH (5 mL). The product was purified using column chromatography (dry-flash, 
SiO2, eluent Hex/EtO   = 1/1 → EtO    EtO  /MeOH gradient 9/1 → MeOH  
EtOAc/MeOH(NH3 sat.  = 9/1 → 6/4; flash  Biotage  P1  RP  olumn 25+M  eluent MeOH/H2O 
gradient 75/25 → MeOH . Final produ t 10 was obtained as a pale yellow oil (157 mg, 54%). [α]
20
D = +22.6 (MeOH). IR (ATR): 3325w, 2932s, 2862m, 1725s, 1619w, 1582s, 1540m, 1460w, 
1376m, 1342w, 1249s, 1172w, 1127w, 1065w, 1024w, 965w, 885w, 810w, 765w, 736w, 608w 
cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.57-8.54 (m, 1H, H-C(2')), 7.98 (d, 1H, J = 8.2, H-C(8')), 
7.73 (d, 1H, J = 8.2, H-C(5')), 7.65-7.60 (m, 1H, H-C(7')), 7.45-7.39 (m, 1H, H-C(6')), 6.44-6.40 
(m, 1H, H-C(3')), 5.10-5.06 (m, 1H, H-C(12)), 5.05-5.00 (m, 1H, H-N, exchangeable with D2O), 
4.92-4.87 (m, 1H, H-C(7)), 4.44 (bs, 1H, H-N), 3.36-3.22 (m, 3H, ArNHCH2- and H-C(3)), 2.65-
2.48 (m, 4H, ArNHCH2CH2CH2CH2CH2CH2- and 2H-C(24)), 2.10 (s, 3H, CH3COO-C(12)), 
2.06 (s, 3H, CH3COO-C(7)), 2.00-1.45 (m, 24H, H-steroid), 1.44 (s, 9H, -NHCOOC(CH3)3), 
1.40-0.98 (m, 9H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 0.82 (d, 3H, J = 6.4, CH3-C(20)), 0.71 (s, 
3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ : 170.39  170.27  155.14  151.02  149.60  
148.40, 129.96, 128.90, 124.50, 119.12, 118.66, 98.72, 79.17, 75.48, 70.85, 53.38, 50.58, 49.96, 
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47.40, 44.95, 43.35, 43.14, 41.51, 37.68, 36.38, 35.47, 34.82, 34.21, 33.31, 31.28, 30.07, 28.85, 
28.38, 27.22, 27.12, 27.07, 26.41, 25.47, 22.78, 22.66, 21.58, 21.36, 17.88, 12.16. HRMS: m/z 
803.56820 corresponds to molecular formula C48H74N4O6H
+ 
(error in ppm 0.11).  
(3,5,7,12)-3-[(Tert-butoxycarbonyl)amino]-24-({6-[(7-chloroquinolin-4-
yl)amino]hexyl}amino)cholane-7,12-diyl diacetate (11). 
According to general procedure B, alcohol 3 (121.4 mg, 0.2101 mmol) was transformed into 
aldehyde using PCC (65.2 mg, 0.302 mmol) in CH2Cl2 (10 mL), which was further transformed 
into 11 using amine AQ6 (82.2 mg, 0.296 mmol), NaBH4 (15.0 mg, 0.39 mmol) and MeOH (4 
mL). The product was purified using column chromatography (dry-flash, SiO2, eluent 
Hex/EtO   = 1/1 → EtO    EtO  /MeOH gradient 9/1 → MeOH  EtO  /MeOH( H3 sat.) = 
9/1; flash, Biotage SP1, RP column 25+M, eluent MeOH/H2O gradient 75/25 → MeOH . Final 
product 11 was obtained as a colorless oil (103 mg, 58%). [α]
20
D = +87.5 (MeOH). IR (ATR): 
3344w, 3054w, 2933s, 2862m, 1724s, 1610w, 1580s, 1536w, 1451w, 1371m, 1331w, 1249s, 
1171m, 1065w, 1023w, 965w, 884w, 851w, 808w, 737m, 703w, 613w cm
-1
. 
1
H NMR (500MHz, 
CDCl3  δ : 8.53 (d, 1H, J = 5.3, H-C(2')), 7.97-7.94 (m, 1H, H-C(8')), 7.66 (d, 1H, J = 8.9, H-
C(5')), 7.37-7.34 (m, 1H, H-C(6')), 6.41 (d, 1H, J = 5.5, H-C(3')), 5.10-5.07 (m, 1H, H-C(12)), 
5.04-4.99 (m, 1H, H-N, exchangeable with D2O), 4.92-4.88 (m, 1H, H-C(7)), 4.43 (bs, 1H, H-N), 
3.35-3.22 (m, 3H, ArNHCH2- and H-C(3)), 2.65-2.48 (m, 4H, ArNHCH2CH2CH2CH2CH2CH2- 
and 2H-C(24)), 2.10 (s, 3H, CH3COO-C(12)), 2.06 (s, 3H, CH3COO-C(7)), 2.00-1.45 (m, 23H, 
H-steroid), 1.44 (s, 9H, -NHCOOC(CH3)3), 1.41-0.98 (m, 10H, H-steroid), 0.90 (s, 3H, CH3-
C(10)), 0.82 (d, 3H, J = 6.4, CH3-C(20)), 0.71 (s, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3, 
δ : 170.40  170.28  155.12  152.04  149.64  149.14  134.77  128.86  125.20  120.78  117.08  
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99.04, 79.19, 75.49, 70.86. 50.60, 49.96, 47.41, 44.96, 43.36, 43.17, 41.52, 37.69, 36.39, 35.47, 
34.83, 34.22, 33.32, 31.29, 30.09, 28.84, 28.81, 28.40, 27.24, 27.11, 27.05, 26.44, 25.48, 22.79, 
22.67, 21.60, 21.37, 17.90, 12.17. HRMS: m/z 837.52879 corresponds to molecular formula 
C48H73ClN4O6H
+ 
(error in ppm -0.42).  
(3,5,7,12)-3-[(Tert-butoxycarbonyl)amino]-24-{methyl[4-(quinolin-4-
ylamino)butyl]amino}cholane-7,12-diyl diacetate (12). 
Compound 12 was prepared by procedure D, using 4 (340.0 mg, 0.4387 mmol), 37% aqueous 
formaldehyde (65 μ   0.88 mmol   Zn l2 (30.0 mg, 0.219 mmol), NaHB3CN (28.0 mg, 0.439 
mmol) and MeOH (5 mL + 5 mL). Final product 12 was obtained as colorless foam (300 mg, 
87%). M.p. = 85 – 86 °C.  [α] 20
D
= +60.0 (MeOH). IR (ATR): 3356w, 2939s, 2865m, 2789w, 
1729s, 1711s, 1582s, 1541m, 1444w, 1372m, 1308w, 1239s, 1170m, 1123w, 1063w, 1024m, 
763w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.59-8.50 (m, 1H, H-C(2')), 8.05-7.94 (m, 1H, H-
C(8')), 7.81-7.75 (m, 1H, H-C(5')), 7.65-7.58 (m, 1H, H-C(7')), 7.44-7.36 (m, 1H, H-C(6')), 6.42-
6.37 (m, 1H, H-C(3')), 5.94 (bs, 1H, H-N, exchangeable with D2O), 5.10-5.06 (m, 1H, H-C(12)), 
4.92-4.86 (m, 1H, H-C(7)), 4.54 (bs, 1H, H-N), 3.34-3.22 (m, 3H, ArNHCH2- and H-C(3)), 2.44-
2.39 (m, 2H, ArNHCH2CH2CH2CH2-), 2.36-2.30 (m, 2H-C(24)), 2.22 (s, 3H, CH3-N), 2.07 (s, 
3H, CH3COO-C(12)), 2.03 (s, 3H, CH3COO-C(7)), 2.00-1.45 (m, 19H, H-steroid), 1.44 (s, 9H, -
NHCOOC(CH3)3), 1.40-0.97 (m, 9H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 0.83-0.80 (m, 3H, 
CH3-C(20)), 0.70 (s, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ : 170.36  170.26  155.16  
150.87, 150.02, 148.24, 129.67, 128.90, 124.29, 119.71, 118.78, 98.52, 79.13, 75.45, 70.83, 
58.11, 57.00, 53.37, 50.71, 47.57, 44.98, 43.35, 43.24, 42.44, 41.52, 37.66, 36.35, 35.47, 34.94, 
34.20, 33.54, 31.26, 28.86, 28.38, 27.24, 26.63, 25.48, 25.19, 23.56, 22.76, 22.66, 21.57, 21.33, 
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17.91, 12.16. HRMS: m/z 789.55095 corresponds to molecular formula C47H72N4O6H
+ 
(error in 
ppm -1.91); m/z 395.27983 corresponds to molecular formula C47H72N4O6H2
2+ 
(error in ppm -
0.09).  
(3,5,7,12)-3-[(tert-butoxycarbonyl)amino]-24-{methyl[4-(quinolin-4-
ylamino)pentyl]amino}cholane-7,12-diyl diacetate (13) (Mixture of diastereomers). 
Compound 13 was prepared by procedure D, using 6 (223.0 mg, 0.2826 mmol), 37% aqueous 
formaldehyde (42 μ   0.56 mmol   Zn l2 (19.3 mg, 0.141 mmol), NaHB3CN (17.8 mg, 0.283 
mmol) and MeOH (4 mL + 4 mL). Final product 13 was obtained as mixture of diastereomers. 
Colorless foam (186 mg, 82%). M.p. = 85 – 87 °C. [α]
20
D = +32.8 (MeOH). IR (ATR): 3354m, 
2939s, 2869m, 2789m, 1715s, 1639w, 1579s, 1534s, 1447m, 1374s, 1241s, 1168m, 1063w, 
1022m, 965w, 897w, 857w, 809w, 763w, 612w, 533w, 478w, 426w cm
-1
. 
1
H NMR (500MHz, 
CDCl3  δ : 8.56-8.51 (m, 1H, H-C(2')), 8.01-7.95 (m, 1H, H-C(8')), 7.77-7.72 (m, 1H, H-C(5')), 
7.64-7.59 (m, 1H, H-C(7')), 7.42-7.38 (m, 1H, H-C(6')), 6.45-6.41 (m, 1H, H-C(3')), 5.38-5.31 
(m, 1H, H-N, exchangeable with D2O), 5.10-5.06 (m, 1H, H-C(12)), 4.91-4.87 (m, 1H, H-C(7)), 
4.55 and 4.45 (bs and bs, 1H, H-N), 3.77-3.68 (m, 1H, ArNHCH(CH3)-), 3.28 (bs, 1H, H-C(3)), 
2.40-2.34 (m, 2H, ArNHCH(CH3)CH2CH2CH2-), 2.32-2.25 (m, 2H-C(24)), 2.20-2.17 (m, 3H, 
CH3-N), 2.09 and 2.07 (s and s, overlap, 3H, CH3COO-C(12)), 2.05 and 2.03 (s and s, overlap, 
3H, CH3COO-C(7)), 2.00-1.46 (m, 20H, H-steroid), 1.44 (s and s, overlap, 9H, -
NHCOOC(CH3)3), 1.40-1.33 (m, 3H, H-steroid), 1.32 (d, 3H, J = 6.4, ArNHCH(CH3)-), 1.27-
0.95 (m, 5H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 0.81 (d, 3H, J = 6.4, CH3-C(20)), 0.70 and 
0.69 (s and s, overlap, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ : 170.37  170.27  155.11  
150.80, 149.05, 148.44, 129.78, 128.92, 124.32, 124.30, 119.48, 119.44, 118.82, 118.81, 98.86, 
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79.13, 75.47, 70.85, 58.27, 58.20, 57.47, 57.34, 50.74, 48.18, 48.12, 47.61, 47.52, 44.97, 43.38, 
43.32, 42.33, 42.30, 41.52, 37.68, 37.66, 36.37, 35.47, 34.92, 34.89, 34.44, 34.22, 34.20, 33.50, 
33.45, 31.26, 28.87, 28.83, 28.39, 27.24, 25.48, 23.86, 23.75, 23.70, 23.59, 22.76, 22.67, 21.59, 
21.57, 21.35, 21.34, 20.22, 20.20, 17.91, 12.17, 12.15. HRMS: m/z 803.56681 corresponds to 
molecular formula C48H74N4O6H
+ 
(error in ppm -1.62).  
(3,5,7,12)-3-Amino-24-{[4-(quinolin-4-ylamino)butyl]amino}cholane-7,12-diyl 
diacetate (14). 
Compound 14 was prepared by procedure C using 4 (178 mg, 0.230 mmol) and TFA/CH2Cl2 (5,5 
mL). The product was purified using column chromatography (flash, Biotage SP1, RP column 
25+M, eluent MeOH/H2O gradient 75/25 → MeOH . Final produ t 14 was obtained as a 
colorless foam (75 mg, 48%). M.p. = 67 – 70 °C. [α] 20
D
= +50.0 (MeOH). IR (ATR): 3279w, 
2937s, 2864m, 1727s, 1582s, 1543w, 1440w, 1377m, 1342w, 1248s, 1126w, 1024w, 964w, 
806w, 766w, 733w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.56-8.52 (m, 1H, H-C(2')), 7.98-7.95 
(m, 1H, H-C(8')), 7.79-7.75 (m, 1H, H-C(5')), 7.64-7.59 (m, 1H, H-C(7')), 7.42-7.36 (m, 1H, H-
C(6')), 6.41-6.38 (m, 1H, H-C(3')), 5.79 (bs, 1H, H-N, exchangeable with D2O), 5.10-5.06 (m, 
1H, H-C(12)), 4.91-4.86 (m, 1H, H-C(7)), 3.36-3.28 (m, 2H, ArNHCH2-), 2.72-2.67 (m, 2H, 
ArNHCH2CH2CH2CH2-), 2.65-2.52 (m, 3H, 2H-C(24) and H-C(3)), 2.11 (s, 3H, CH3COO-
C(12)), 2.07 (s, 3H, CH3COO-C(7)), 2.05-0.95 (m, 31H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 
0.84-0.80 (m, 3H, CH3-C(20)), 0.71 (s, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ : 
170.64, 170.61, 151.01, 149.84, 148.38, 129.80, 128.84, 124.28, 119.57, 118.81, 98.55, 75.50, 
70.90, 51.62, 50.53, 49.27, 47.48, 44.98, 43.38, 43.15, 41.48, 39.48, 37.74, 35.50, 34.89, 34.34, 
33.34, 31.42, 31.22, 28.96, 27.84, 27.24, 26.48, 26.39, 25.55, 22.77, 21.62, 21.46, 17.86, 12.17. 
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HRMS: m/z 675.48325 corresponds to molecular formula C41H62N4O4H
+ 
(error in ppm -1.68); 
m/z 338.24629 corresponds to molecular formula C41H62N4O4H2
2+ 
(error in ppm 1.36). HPLC 
purity (λ = 330 nm : method  : RT 9.070  area 98.83%; method B: RT 7.811  area 96.95%. 
(3,5,7,12)-3-Amino-24-{methyl[4-(quinolin-4-ylamino)butyl]amino}cholane-7,12-diyl 
diacetate (15). 
Compound 15 was prepared by procedure C, using 12 (230 mg, 0.33 mmol) and TFA/CH2Cl2 (8 
mL). The product was purified using column chromatography (flash, Biotage SP1, RP column 
25+M, eluent MeOH/H2O gradient 75/25 → MeOH . Final produ t 15 was obtained as a 
colorless foam (110 mg, 56%). M.p. = 77 – 80 °C. [α] 20
D
= +59.1 (MeOH). IR (ATR): 3308m, 
2946s, 2867s, 2795m, 1730s, 1664w, 1642w, 1619w, 1583s, 1544m, 1460m, 1377s, 1343m, 
1246s, 1156w, 1126w, 1026m, 966w, 767m cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.53 (d, 1H, J 
= 5.5, H-C(2')), 7.99-7.95 (m, 1H, H-C(8')), 7.79-7.74 (m, 1H, H-C(5')), 7.64-7.59 (m, 1H, H-
C(7')), 7.42-7.37 (m, 1H, H-C(6')), 6.39 (d, 1H, J = 5.2, H-C(3')), 5.94 (bs, 1H, H-N, 
exchangeable with D2O), 5.10-5.05 (m, 1H, H-C(12)), 4.90-4.85 (m, 1H, H-C(7)), 3.34-3.28 (m, 
2H, ArNHCH2-), 2.64-2.55 (m, 1H, H-C(3)), 2.43-2.38 (m, 2H, ArNHCH2CH2CH2CH2-), 2.35-
2.30 (m, 2H-C(24)), 2.22 (s, 3H, CH3-N), 2.09 (s, 3H, CH3COO-C(12)), 2.07 (s, 3H, CH3COO-
C(7)), 2.05-0.94 (m, 30H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 0.81 (d, 3H, J = 6.6, CH3-C(20)), 
0.70 (s, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ : 170.64  150.89  150.02  148.25  
129.65, 128.89, 124.26, 119.70, 118.80, 98.53, 75.50, 70.90, 58.12, 57.11, 51.61, 47.64, 44.99, 
43.35, 43.24, 42.38, 41.47, 39.44, 37.73, 35.50, 34.98, 34.33, 33.56, 31.41, 31.18, 28.95, 27.24, 
26.66, 25.54, 25.26, 23.66, 22.76, 21.63, 21.43, 17.88, 12.16. HRMS: m/z 689.49878 
corresponds to molecular formula C42H64N4O4H
+ 
(error in ppm -1.82); m/z 345.25311 
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corresponds to molecular formula C42H64N4O4H2
2+ 
(error in ppm -1.56 . HP   purity (λ = 330 
nm): method A: RT 7.549, area 95.60%; method B: RT 7.483, area 97.51%. 
(3,5,7,12)-3-Amino-24-({4-[(7-chloroquinolin-4-yl)amino]butyl}amino)cholane-7,12-
diyl diacetate (16). 
Compound 16 was prepared by procedure C using 5 (590.0 mg, 0.7288 mmol) and TFA/CH2Cl2 
(25 mL). Final product 16 was obtained as a colorless foam (502.4 mg, 97%). M.p. = 79 – 82 °C. 
[α] 20
D
= +78.2 (MeOH). IR (ATR): 3554w, 3401w, 3329w, 2935s, 2863m, 1941w, 1727s, 1647w, 
1610w, 1580s, 1542w, 1448w, 1374w, 1332w, 1246m, 1134w, 1078w, 1026w, 969w, 930w, 
891w, 848w, 809w, 773w, 721w, 570w, 537w, 455w, 423w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 
8.53-8.49 (m, 1H, H-C(2')), 7.96-7.92 (m, 1H, H-C(8')), 7.72 (d, 1H, J = 8.9, H-C(5')), 7.34-7.30 
(m, 1H, H-C(6')), 6.38-6.35 (m, 1H, H-C(3')), 6.03 (bs, 1H, H-N, exchangeable with D2O), 5.10-
5.06 (m, 1H, H-C(12)), 4.91-4.86 (m, 1H, H-C(7)), 3.33-3.27 (m, 2H, ArNHCH2-), 2.73-2.68 (m, 
2H, ArNHCH2CH2CH2CH2-), 2.65-2.53 (m, 3H, 2H-C(24) and H-C(3)), 2.11 (s, 3H, CH3COO-
C(12)), 2.07 (s, 3H, CH3COO-C(7)), 2.06-1.95 (m, 31H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 
0.82 (d, 3H, J = 6.4, CH3-C(20)), 0.72 (s, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ : 
170.65, 170.62, 152.06, 149.96, 149.17, 134.65, 128.70, 124.88, 121.38, 117.30, 98.83, 75.51, 
70.91, 51.64, 50.52, 49.14, 47.54, 45.01, 43.40, 43.18, 41.50, 39.51, 37.76, 35.51, 34.95, 34.36, 
33.36, 31.43, 31.25, 28.98, 27.85, 27.26, 26.53, 26.27, 25.58, 22.78, 21.63, 21.47, 17.88, 12.19. 
HRMS: m/z 709.44393 corresponds to molecular formula C41H61ClN4O4H
+ 
(error in ppm -2.08). 
HP   purity (λ = 330 nm : method  : RT 9.189  area 95.02%; method B: RT 7.825  area 
97.26%.  
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(3,5,7,12)-3-amino-24-{[4-(quinolin-4-ylamino)pentyl]amino}cholane-7,12-diyl 
diacetate (17) (Mixture of diastereomers). 
Compound 17 was prepared by procedure C using 6 (150 mg, 0.19 mmol) and TFA/CH2Cl2 (5.5 
mL). Final product 17 was obtained as mixture of diastereomers. Colorless foam (92.9 mg, 
71%). M.p. = 82 – 83 °C. [α] 20
D
= +31.5 (MeOH). IR (ATR): 3478w, 3275m, 3190m, 3118m, 
3078m, 2930s, 2861s, 1725s, 1653w, 1538s, 1496w, 1445m, 1377s, 1342m, 1154w, 1025m, 
963w, 892w, 810w, 765m, 656w, 611w, 532w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.53 (d, 1H, 
J = 5.5, H-C(2')), 7.98-7.94 (m, 1H, H-C(8')), 7.74 (d, 1H, J = 8.4, H-C(5')), 7.64-7.59 (m, 1H, 
H-C(7')), 7.42-7.37 (m, 1H, H-C(6')), 6.41 (d, 1H, J = 5.5, H-C(3')), 5.31-5.26 (m, 1H, H-N, 
exchangeable with D2O), 5.09-5.06 (m, 1H, H-C(12)), 4.90-4.86 (m, 1H, H-C(7)), 3.76-3.69 (m, 
1H, ArNHCH(CH3)-), 2.67-2.49 (m, 5H, ArNHCH(CH3)CH2CH2CH2- and 2H-C(24) and H-
C(3)), 2.11 (s, 3H, CH3COO-C(12)), 2.07 (s, 3H, CH3COO-C(7)), 2.04-1.33 (m, 25H, H-steroid), 
1.32 (d, 3H, J = 6.4, ArNHCH(CH3)-), 1.28-0.96 (m, 6H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 
0.81 (d, 3H, J = 6.6, CH3-C(20)), 0.71 and 0.70 (s and s, overlap, 3H, CH3-C(13)). 
13
C NMR 
(125 MHz, CDCl3  δ : 170.64  170.62  150.94  148.89  148.56  129.90  128.85  124.28  119.37, 
118.81, 98.81, 75.50, 70.90, 51.63, 50.54, 50.51; 49.62, 48.16, 47.44, 44.97, 43.37, 41.49, 39.50, 
37.74, 35.50, 34.86, 34.84, 34.35, 34.18, 33.31, 31.42, 31.23, 28.96, 27.23, 26.54, 26.52, 26.45, 
25.55, 22.77, 21.62, 21.47, 20.23, 17.85, 12.16. HRMS: m/z 345.25444 corresponds to molecular 
formula C42H64N4O4H2
2+ (error in ppm 2.27 . HP   purity: method   (λ = 254 nm : RT 8.644  
area 95.76%; method B (λ = 330 nm : RT 7.455  area 95.83%. 
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(3,5,7,12)-3-amino-24-{methyl[4-(quinolin-4-ylamino)pentyl]amino}cholane-7,12-diyl 
diacetate (18) (Mixture of diastereomers). 
Compound 18 was prepared by procedure C using 13 (90 mg, 0.1 mmol) and TFA/CH2Cl2 (8 
mL). The product was purified using column chromatography (flash, Biotage SP1, RP column 
25+M, eluent MeOH/H2O gradient 8/2 → MeOH . Final produ t 18 was obtained as mixture of 
diastereomers. Colorless foam (47 mg, 60%). M.p. = 70 – 72 °C. [α]
20
D = +39.3 (MeOH). IR 
(ATR): 3353w, 3278w, 3064w, 2942s, 2863m, 2790w, 1725s, 1579s, 1537m, 1448w, 1376m, 
1341w, 1244s, 1152w, 1023w, 765w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.58-8.49 (m, 1H, H-
C(2')), 8.00-7.94 (m, 1H, H-C(8')), 7.76-7.71 (m, 1H, H-C(5')), 7.64-7.59 (m, 1H, H-C(7')), 7.43-
7.38 (m, 1H, H-C(6')), 6.45-6.40 (m, 1H, H-C(3')), 5.33-5.26 (m, 1H, H-N, exchangeable with 
D2O), 5.07 (bs, 1H, H-C(12)), 4.90-4.85 (m, 1H, H-C(7)), 3.77-3.68 (m, 1H, ArNHCH(CH3)-), 
2.61 (bs, 1H, H-C(3)), 2.39-2.33 (m, 2H, ArNHCH(CH3)CH2CH2CH2-), 2.31-2.24 (m, 2H-
C(24)), 2.18 (s, 3H, CH3-N), 2.10 (s, 3H, CH3COO-C(12)), 2.07 (s, 3H, CH3COO-C(7)), 2.04-
1.34 (m, 22H, H-steroid), 1.33-1.30 (m, 3H, ArNHCH(CH3)-), 1.26-0.94 (m, 6H, H-steroid), 
0.90 (s, 3H, CH3-C(10)), 0.82-0.79 (m, 3H, CH3-C(20)), 0.70 and 0.69 (s and s, overlap, 3H, 
CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ : 170.71  150.85  149.01  148.44  129.77  128.92  
124.30, 119.44, 118.80, 98.86, 75.52, 70.93, 58.26, 57.50, 51.59, 48.18, 48.15, 47.62, 44.98, 
43.35, 42.29, 41.45, 39.39, 37.71, 35.48, 34.95, 34.48, 34.34, 33.50, 31.40, 31.15, 28.95, 27.24, 
25.54, 23.89, 23.88, 23.73, 22.78, 21.67, 21.48, 20.22, 17.87, 12.17. HRMS: m/z 345.25306 
corresponds to molecular formula C42H64N4O4H2
2+ 
(error in ppm -1.72); m/z 230.50462 
corresponds to molecular formula C42H64N4O4H3
3+ 
(error in ppm -1.04 . HP   purity (λ = 330 
nm): method A: RT 8.574, area 95.26%; method B: RT 6.961, area 98.08%. 
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(3,5,7,12)-3-amino-24-{[1-methyl-4-(quinolin-4-ylamino)butyl]amino}cholane-7,12-
diyl diacetate (19) (Mixture of diastereomers). 
Compound 19 was prepared by procedure C using 7 (390 mg, 0.49 mmol) and TFA/CH2Cl2 (17 
mL). Final product was obtained as mixture of diastereomers. Colorless foam (319 mg, 94%). 
M.p. = 75 – 77 °C. [α] 20
D
= +45.6 (MeOH). IR (ATR): 3265m, 2938s, 2865s, 1727s, 1623w, 
1583s, 1543m, 1505w, 1442m, 1377s, 1342m, 1247s, 1154w, 1127w, 1082w, 1026m, 964w, 
890w, 809w, 766m, 609w, 540w, 423w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.54 (d, 1H, J = 
5.2, H-C(2')), 7.97 (d, 1H, J = 8.5, H-C(8')), 7.76 (d, 1H, J = 8.2, H-C(5')), 7.64-7.59 (m, 1H, H-
C(7')), 7.43-7.37 (m, 1H, H-C(6')), 6.40 (d, 1H, J = 5.2, H-C(3')), 5.62 (bs, 1H, H-N, 
exchangeable with D2O), 5.09-5.05 (m, 1H, H-C(12)), 4.90-4.86 (m, 1H, H-C(7)), 3.38-3.25 (m, 
2H, ArNHCH2-), 2.77-2.68 (m, 1H, ArNHCH2CH2CH2CH(CH3)-), 2.67-2.47 (m, 3H, 2H-C(24) 
and H-C(3)), 2.10 and 2.10 (s and s, overlap, 3H, CH3COO-C(12)), 2.07 (s, 3H, CH3COO-C(7)), 
2.05-1.20 (m, 28H, H-steroid), 1.09 (d, 3H, J = 6.2, ArNHCH2CH2CH2CH(CH3)-), 1.07-0.99 (m, 
3H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 0.81 (d, 3H, J = 6.4, CH3-C(20)), 0.70 and 0.69 (s and 
s, overlap, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ : 170.62  170.60  150.98  149.77  
148.36, 129.81, 128.85, 124.34, 119.47, 118.76, 98.58, 75.49, 70.89, 52.72, 51.60, 47.67, 47.60, 
47.44, 44.95, 43.44, 43.35, 41.46, 39.47, 37.72, 35.48, 34.84, 34.64, 34.58, 34.32, 33.39, 33.36, 
31.40, 31.20, 28.94, 27.21, 26.77, 25.52, 25.08, 22.74, 21.60, 21.44, 20.41, 20.38, 17.83, 12.14. 
HRMS: m/z 689.49852 corresponds to molecular formula C42H64N4O4H
+ 
(error in ppm -2.19); 
m/z 345.25324 corresponds to molecular formula C42H64N4O4H2
2+ 
(error in ppm -1.21). HPLC 
purity (λ = 330 nm : method  : RT 7.059  area 98.72%; method B: RT 7.502  area 97.72%. 
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(3,5,7,12)-3-amino-24-({4-[(7-chloroquinolin-4-yl)amino)pentyl}amino)cholane-7,12-
diyl diacetate (20) (Mixture of diastereomers). 
Compound 20 was prepared by procedure C using 8 (130 mg, 0.16 mmol) and TFA/CH2Cl2 (11 
mL). Final product 20 was obtained as mixture of diastereomers. Colorless foam (110.5 mg, 
97%). M.p. = 85 – 87 °C. [α]
20
D = +44.8 (MeOH). IR (ATR): 3301w, 2937s, 2864m, 2351w, 
2327w, 1727s, 1610w, 1578s, 1538w, 1451w, 1377m, 1334w, 1246s, 1154w, 1080w, 1024w, 
964w, 878w, 851w, 811w, 766w, 607w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.50 (d, 1H, J = 
5.4, H-C(2')), 7.94-7.92 (m, 1H, H-C(8')), 7.69 (d, 1H, J = 9.0, H-C(5')), 7.34-7.30 (m, 1H, H-
C(6')), 6.40 (d, 1H, J = 5.4, H-C(3')), 5.51-5.43 (m, 1H, H-N, exchangeable with D2O), 5.09-5.06 
(m, 1H, H-C(12)), 4.91-4.86 (m, 1H, H-C(7)), 3.74-3.67 (m, 1H, ArNHCH(CH3)-), 2.67-2.62 (m, 
2H, ArNHCH(CH3)CH2CH2CH2-), 2.62-2.50 (m, 3H, H-C(3) and 2H-C(24)), 2.11 (s, 3H, 
CH3COO-C(12)), 2.07 (s, 3H, CH3COO-C(7)), 2.05-1.32 (m, 24H, H-steroid), 1.31 (d, 3H, J = 
6.4, ArNHCH(CH3)-),1.26-0.99 (m, 7H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 0.81 (d, 3H, J = 
6.4, CH3-C(20)), 0.72 and 0.71 (s and s, overlap, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3, 
δ : 170.64  170.62  151.97  149.34  149.00  134.67  128.75  124.89  121.17  117.30  99.11  
75.70, 70.90, 51.63, 50.53, 50.50, 49.48, 48.27, 47.49, 44.98, 43.38, 41.49, 39.50, 37.74, 35.50, 
34.90, 34.87, 34.35, 34.05, 33.31, 31.42, 31.24, 28.97, 27.24, 26.47, 25.56, 22.77, 21.62, 21.47, 
20.13, 17.85, 12.17. HRMS: m/z 723.45837 corresponds to molecular formula C42H63ClN4O4H
+ 
(error in ppm -3.72 . HP   purity: method   (λ = 330 nm : RT 10.367  area 95.87%; method   
(λ = 254 nm): RT 8.879, area 95.63%. 
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(3,5,7,12)-3-Amino-24-({4-[(7-chloroquinolin-4-yl)amino]-1-
methylbutyl}amino)cholane-7,12-diyl diacetate (21) (Mixture of diastereomers). 
Compound 21 was prepared by procedure C using 9 (120 mg, 0.16 mmol) and TFA/CH2Cl2 (11 
mL). Final product was obtained as mixture of diastereomers. Colorless foam (75.7 mg, 72%). 
M.p. = 75 – 77 °C. [α] 20
D
= +46.9 (MeOH). IR (ATR): 3284w, 2931s, 2860s, 1725s, 1652w, 
1610w, 1578s, 1539m, 1449m, 1373m, 1331w, 1242s, 1154w, 1135w, 1078w, 1022w, 963w, 
937w, 895w, 849w, 806w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ): 8.51 (d, 1H, J = 5.2, H-C(2')), 
7.96-7.92 (m, 1H, H-C(8')), 7.72-7.68 (m, 1H, H-C(5')), 7.35-7.31 (m, 1H, H-C(6')), 6.38 (d, 1H, 
J = 5.5, H-C(3')), 5.79 (bs, 1H, H-N exchangeable with D2O), 5.09-5.05 (m, 1H, H-C(12)), 4.90-
4.86 (m, 1H, H-C(7)), 3.36-3.23 (m, 2H, ArNHCH2-), 2.76-2.69 (m, 1H, 
ArNHCH2CH2CH2CH(CH3)-), 2.67-2.47 (m, 3H, 2H-C(24) and H-C(3)), 2.11 and 2.10 (s and s, 
overlap, 3H, CH3COO-C(12)), 2.07 (s, 3H, CH3COO-C(7)), 2.05-1.20 (m, 28H, H-steroid), 1.09 
(d, 3H, J = 6.4, ArNHCH2CH2CH2CH(CH3)-), 1.07-0.97 (m, 3H, H-steroid), 0.90 and 0.90 (s 
and s, overlap, 3H, CH3-C(10)), 0.80 (d, 3H, J = 6.6, CH3-C(20)), 0.71 i 0.70 (s and s, overlap, 
3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ): 170.65, 152.04, 149.88, 149.15, 134.70, 
128.72, 124.99, 121.23, 117.25, 98.90, 75.51, 70.91, 52.64, 51.63, 47.65, 47.57, 47.52, 44.99, 
43.50, 43.39, 41.49, 39.50, 37.75, 35.51, 34.90, 34.69, 34.61, 34.35, 33.42, 33.39, 31.43, 31.23, 
28.97, 27.24, 26.87, 26.84, 25.56, 24.95, 22.77, 21.63, 21.47, 20.45, 20.42, 17.86, 12.18. HRMS: 
m/z 723.45968 corresponds to molecular formula C42H63N4ClO4H
+ 
(error in ppm -1.91). HPLC 
purity (λ = 330 nm : method  : RT 10.536  area 95.38%; method  : RT 8.430  area 95.36%.  
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(3,5,7,12)-3-Amino-24-{[6-(quinolin-4-ylamino)hexyl]amino}cholane-7,12-diyl 
diacetate (22). 
Compound 22 was prepared by procedure C using 10 (170 mg, 0.21 mmol) and TFA/CH2Cl2 (5.5 
mL). The product was purified using column chromatography (flash, Biotage SP1, RP column 
25+M, eluent MeOH/H2O gradient 8/2 → MeOH . Final produ t 22 was obtained as a colorless 
foam (112.8 mg, 76%). M.p. = 72 – 75 °C. [α]
20
D = +56.4 (MeOH). IR (ATR): 3294w, 3061w, 
2933s, 2860m, 1726s, 1582s, 1542w, 1441w, 1376m, 1341w, 1247s, 1156w, 1125w, 1084w, 
1023w, 964w, 891w, 808w, 767w, 734w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.55 (d, 1H, J = 
5.2, H-C(2')), 8.00-7.95 (m, 1H, H-C(8')), 7.74 (d, 1H, J = 7.8, H-C(5')), 7.64-7.60 (m, 1H, H-
C(7')), 7.44-7.39 (m, 1H, H-C(6')), 6.42 (d, 1H, J = 5.5, H-C(3')), 5.11-5.05 (m, 2H, H-N, 
exchangeable with D2O and H-C(12)), 4.90-4.86 (m, 1H, H-C(7)), 3.34-3.28 (m, 2H, ArNHCH2-
), 2.63-2.49 (m, 5H, ArNHCH2CH2CH2CH2CH2CH2- and 2H-C(24) and H-C(3)), 2.11 (s, 3H, 
CH3COO-C(12)), 2.07 (s, 3H, CH3COO-C(7)), 2.05-1.99 (m, 35H, H-steroid), 0.90 (s, 3H, CH3-
C(10)), 0.81 (d, 3H, J = 6.6, CH3-C(20)), 0.71 (s, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3, 
δ : 170.62  170.59  150.96  149.59  148.34  129.86  128.85  124.44  119.15  118.63  98.67  
75.48, 70.87, 51.59, 50.53, 49.90, 47.35, 44.92, 43.35, 43.09, 41.45, 39.45, 37.70, 35.47, 34.79, 
34.30, 33.26, 31.40, 31.19, 30.01, 28.93, 28.79, 27.18, 27.08, 27.02, 26.37, 25.52, 22.74, 21.59, 
21.43, 17.82, 12.12. HRMS: m/z 703.51463 corresponds to molecular formula C43H66N4O4H
+ 
(error in ppm -1.50); m/z 352.26200 corresponds to molecular formula C43H66N4O4H2
2+ 
(error in 
ppm 1.49). HPLC purity (λ = 330 nm : method  : RT 9.134  area 98.86%; method B: RT 7.830  
area 97.20%. 
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(3,5,7,12)-3-amino-24-({6-[(7-chloroquinolin-4-yl)amino]hexyl}amino)cholane-7,12-
diyl diacetate (23). 
Compound 23 was prepared by procedure C using 11 (51.5 mg, 0.0698 mmol) and TFA/CH2Cl2 
(3.5 mL). Colorless foam (41.5 mg, 92%). M.p. = 69 – 71 °C. [α]
20
D = +66.9 (MeOH). IR (ATR): 
3284w, 2934s, 2860m, 1727s, 1610w, 1581s, 1540w, 1452w, 1376m, 1332w, 1248s, 1136w, 
1080w, 1024w, 964w, 899w, 850w, 807w, 735w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.53 (d, 
1H, J = 5.3, H-C(2')), 7.98-7.93 (m, 1H, H-C(8')), 7.66 (d, 1H, J = 8.9, H-C(5')), 7.38-7.33 (m, 
1H, H-C(6')), 6.41 (d, 1H, J = 5.5, H-C(3')), 5.09-5.06 (m, 1H, H-C(12)), 5.02-4.97 (m, 1H, H-N, 
exchangeable with D2O), 4.91-4.86 (m, 1H, H-C(7)), 3.34-3.27 (m, 2H, ArNHCH2-), 2.64-2.48 
(m, 5H,  ArNHCH2CH2CH2CH2CH2CH2- and 2H-C(24) and H-C(3)), 2.11 (s, 3H, CH3COO-
C(12)), 2.08 (s, 3H, CH3COO-C(7)), 2.05-0.99 (m, 35H, H-steroid), 0.90 (s, 3H, CH3-C(10)), 
0.81 (d, 3H, J = 6.6, CH3-C(20)), 0.71 (s, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3  δ : 
170.68, 170.65, 152.06, 149.62, 149.16, 134.76, 128.89, 125.21, 120.76, 117.08, 99.06, 75.54, 
70.93, 51.66, 50.63, 49.98, 47.41, 44.99, 43.41, 43.18, 41.51, 39.52, 37.77, 35.52, 34.85, 34.37, 
33.33, 31.46, 31.26, 30.13, 28.99, 28.82, 27.25, 27.13, 27.07, 26.48, 25.58, 22.80, 21.65, 21.49, 
17.88, 12.18. HRMS: m/z 737.47556 corresponds to molecular formula C43H65ClN4O4H
+ 
(error 
in ppm -1.56); m/z 246.49683 corresponds to molecular formula C43H65ClN4O4H3
3+ 
(error in ppm 
-1.04 . HP   purity (λ = 330 nm : method  : RT 9.278  area 97.57%; method B: RT 7.853  area 
97.20%. 
 
 
S53 
 
 
 (3,5,7,12)-3-Amino-24-({4-[(7-chloroquinolin-4-yl)amino]butyl}amino)cholane-7,12-
diol (24). 
16 (20.0 mg, 0.0282 mmol) was dissolved in MeOH (1 mL), KOH (31.6 mg, 0.564 mmol) was 
added and the mixture was heated at 60 °C for 5 days. The solvent was removed under reduced 
pressure, and the residue was dissolved in CH2Cl2. The organic layer was washed with wather 
and dried over anh. Na2SO4. The product was purified using column chromatography (flash, 
Biotage SP1, RP column 12+M, eluent MeOH/H2O gradient 7/3 → MeOH . Pale yellow foam 
(12 mg, 68%). M.p. = 116 – 119 °C. [α] 20
D
= +26.2 (MeOH). IR (ATR): 3282m, 2932s, 2861m, 
1609w, 1581s, 1541w, 1453m, 1372m, 1333w, 1281w, 1251w, 1201w, 1136w, 1081w, 1038w, 
982w, 952w, 908w, 878w, 852w, 807w, 767w, 736w, 645w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ): 
8.49 (d, 1H, J = 5.5, H-C(2')), 7.97-7.92 (m, 1H, H-C(8')), 7.78 (d, 1H, J = 8.8, H-C(5')), 7.34-
7.29 (m, 1H, H-C(6')), 6.44 (bs, 1H, H-N), 6.36 (d, 1H, J = 5.4, H-C(3')), 3.97-3.91 (m, 1H, H-
C(12)), 3.85-3.79 (m, 1H, H-C(7)), 3.34-3.24 (m, 2H, ArNHCH2-), 2.75-2.67 (m, 3H, 
ArNHCH2CH2CH2CH2- and H-C(3)), 2.65-2.51 (m, 4H, 2H-C(24) and 2 H-O), 2.00-1.00 (m, 
31H, H-steroid), 0.98-0.93 (m, 3H, CH3-C(20)), 0.87 (s, 3H, CH3-C(10)), 0.64 (s, 3H, CH3-
C(13)). 
13
C NMR (125 MHz, CDCl3  δ): 152.03, 150.24, 149.17, 134.66, 128.53, 124.84, 121.90, 
117.48, 98.82, 72.80, 68.13, 51.72, 50.46, 49.10, 46.90, 46.32, 43.26, 41.94, 41.89, 39.60, 35.87, 
35.44, 34.68, 34.58, 33.42, 28.29, 27.73, 27.55, 26.59, 26.36, 26.19, 23.21, 22.67, 17.71, 12.48. 
HRMS: m/z 625.42214 corresponds to molecular formula C37H57ClN4O2H
+ 
(error in ppm -3.42). 
HP   purity: method   (λ = 330 nm : RT 8.685  area 97.90%; method   (λ = 254 nm : RT 
8.713, area 96.63%. 
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7-Chloroquinolin-4-amine (25).
12
 
4,7-Dichloroquinoline (2.00 g, 10.1 mmol) was dissolved in phenol (9.50 g, 101 mmol) and the 
mixture was heated at 110 °C. (NH4)2CO3 (4.85 g, 50.5 mmol) was added in portions, and 
stirring continued for 3 h at 165 °C. After cooling to room temperature, diethyl ether was added 
(150 mL) and organic layer washed with 10% aqueous NaOH (3 × 50 mL). The solvent was 
removed under the reduced pressure. The product was purified using column chromatography 
(dry-flash, SiO2, eluent CH2Cl2, CH2Cl2/MeOH = 9/1, MeOH). Final product 25 was obtained as 
beige powder (1.44 g, 80%). M.p. = 137-139 °C.  IR (ATR): 3443w, 3321m, 3098s, 2788w, 
2707w, 1683w, 1656m, 1635m, 1612m, 1577s, 1505m, 1444m, 1371w, 1329m, 1285w, 1204w, 
1165w, 1125w, 1107w, 1076w, 908w, 877w, 853w, 810m, 766w, 640w, 625w cm
-1
. 
1
H NMR 
(200 MHz, CD3OD  δ): 8.22 (d, 1H, J = 5.0, H-C(2)), 7.99 (d, 1H,  J = 9.0, H-C(5)), 7.76-7.78 
(m, 1H, H-C(8)), 7.37-7.25 (m, 1H, H-C(6)), 6.57 (d, 1H, J = 5.6, H-C(3)). 
13
C NMR (50 MHz, 
CD3OD  δ): 154.44, 151.80, 149.85, 136.56, 127.27, 125.80, 124.96, 118.26, 103.88. HRMS: 
m/z 179.03644 corresponds to molecular formula C9H7ClN2H
+
 (error in ppm -3.43). 
4-Chloro-N-(7-chloroquinolin-4-yl)butanamide (26). 
25 (500.0 mg, 2.799 mmol) was suspended in CH2Cl2 (20 mL), triethyl amine (0.47 mL, 3.4 
mmol) was added and the mixture was cooled in an ice bath. 4-Chlorobutanoyl chloride (0.38 
mL, 3.4 mmol) in CH2Cl2 (5 mL) was slowly added to the mixture, stirring continued for 10 
minutes at 0 °C, and 1.5 h at r.t. The solvent was removed under the reduced pressure. The 
product was purified using column chromatography (dry-flash, SiO2, eluent hexane, 
hexane/EtOAc gradient 9/1→ 3/7). The final product 26 was obtained as white crystals (707 mg, 
89%). M.p. = 89-90 °C. IR (ATR): 3318s, 3101w, 2963w, 2919w, 2815w, 1670s, 1614m, 
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1571m, 1526s, 1488s, 1443m, 1419w, 1379w, 1349w, 1323m, 1304m, 1275w, 1254w, 1208m, 
1190w, 1141w, 1107w, 1076w, 1032w, 967w, 873w, 846w, 819w, 776w, 644w, 598w, 563w, 
430w cm
-1
. 
1
H NMR (200 MHz, CD3OD  δ): 8.72 (d, 1H, J = 5.1, H-C(2)), 8.23-8.12 (m, 2H, H-
C(5) and H-C(3)), 7.96-7.93 (m, 1H, H-C(8)), 7.60-7.52 (m, 1H, H-C(6)), 3.70 (t, 2H, J = 6.5, -
CH2Cl), 2.79 (t, 2H, J = 7.3, ArNHCOCH2-), 2.27-2.12 (m, 2H, ArNHCOCH2CH2-). 
13
C NMR 
(50 MHz, CD3OD  δ): 174.21, 152.96, 143.98, 136.96, 128.42, 128.25, 124.85, 121.02, 113.83, 
97.83, 45.16, 34.72, 29.13. HRMS: m/z 283.04012 corresponds to molecular formula 
C13H12Cl2N2OH
+
 (error in ppm 0.63). 
4-Azido-N-(7-chloroquinolin-4-yl)butanamide (27). 
26 (500.0 mg, 1.766 mmol) was dissolved in DMF (2 mL) in Ar atmosphere, and sodium azide 
was added (459 mL, 7.06 mmol). Reaction mixture was stirred at 80 °C for 2 h. The solvent was 
removed under reduced pressure, and the residue was dissolved in CH2Cl2. Organic layer was 
washed with water and dried over anh. Na2SO4. The product was purified using column 
chromatography (dry-flash, SiO2, eluent hexane, hexane/EtOAc gradient 9/1 → 1/1). Final 
product 27 was obtained as white powder (383 mg, 75%). M.p.= 54-55 °C. IR (ATR): 3318s, 
2930m, 2670m, 2168w, 2101s, 1946w, 1894w, 1675s, 1613m, 1570m, 1525s, 1485s, 1443m, 
1416w, 1375w, 1343w, 1303s, 1253m, 1217m, 1189m, 1161m, 1108w, 1072w, 1040w, 965w, 
878w, 847m, 817w, 764w, 642w, 617w, 559w, 475w cm
-1
. 
1
H NMR (200 MHz, CDCl3  δ): 8.80 
(d, 1H, J = 5.6, H-C(2)), 8.32 (bs, 1H, H-N), 8.17 (d, 1H, J = 5.1, H-C(3)), 8.09-8.03 (m, 1H, H-
C(8)), 7.83-7.75 (m, 1H, H-C(5)), 7.51-7.40 (m, 1H, H-C(6)), 3.46 (t, 2H, J = 6.5, -CH2N3), 2.66 
(t, 2H, J = 7.3, ArNHCOCH2-), 2.15-1.97 (m, 2H, ArNHCOCH2CH2-). 
13
C NMR (50 MHz, 
CDCl3  δ): 170.95, 152.18, 149.24, 140.47, 135.46, 129.20, 127.34, 120.95, 118.62, 111.74, 
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50.53, 34.25, 24.29. HRMS: m/z 290.08039 corresponds to molecular formula C13H12ClN5OH
+
 
(error in ppm 0.28). 
4-Amino-N-(7-chloroquinolin-4-yl)butanamide (28). 
Syntesis was conducted according to modified procedure from the literature.
13
 27 (382 mg, 1.32 
mmol) was dissolved in THF (6 mL), Ph3P (380.4 mg  1.450 mmol  and water (26 μ   1.4 
mmol) was added and reaction mixture was stirred at 65 °C for 48h. The solvent was removed 
under reduced pressure. Crude product was purified using fast column chromatography (dry-
flash, SiO2, eluent CH2Cl2, CH2Cl2/MeOH = 9/1, CH2Cl2/MeOH (NH3 satd.) = 7/3) and without 
characterizaton was used in the next reaction. Yield 230 mg (66%). Product 28 fastly 
decomposes to amine 25 and pyrrolidin-2-one (confirmed by HRMS). 
(3,5,7,12)-3-[(Tert-butoxycarbonyl)amino]-24-({4-[(7-chloroquinolin-4-yl)amino]-4-
oxobutyl}amino)cholane-7,12-diyl diacetate (29). 
According to general procedure B, alcohol 3 (68 mg, 0.12 mmol) was transformed into aldehyde 
using PCC (36.5 mg, 0.170 mmol) in CH2Cl2 (6 mL), which was further transformed into 29 
using amine 28 (30.0 mg, 0.113 mmol), NaBH4 (6.6 mg, 0.17 mmol) and MeOH (3 mL). The 
product was purified using column chromatography (dry-flash, SiO2, eluent EtOAc, 
EtO  /MeOH gradient 9/1 → MeOH  EtO  /MeOH( H3 sat.  gradient 95/5 → 8/2 . Final 
product 29 was obtained as colorless foam (42 mg, 43%). M.p. = 80-84 °C. [α] 20
D
= +50.5 
(MeOH). IR (ATR): 3305w, 2933m, 2866w, 1710m, 1616w, 1567w, 1526m, 1450w, 1373w, 
1307w, 1240m, 1167w, 1063w, 1022w, 965w, 881w, 850w, 822w, 768w, 675w cm
-1
. 
1
H NMR 
(500MHz, CDCl3  δ): 10.26 (bs, 1H, -NHCO-),  8.82 (d, 1H, J = 5.3, H-C(2')), 8.28 (d, 1H, J = 
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5.2, H-C(3')), 8.11-8.07 (m, 1H, H-C(8')), 7.90 (d, 1H, J = 8.9, H-C(5')), 7.48-7.43 (m, 1H, H-
C(6')), 5.10-5.05 (m, 1H, H-C(12)), 4.92-4.87 (m, 1H, H-C(7)), 4.41 (bs, 1H, H-N), 3.27 (bs, 1H, 
H-C(3)), 2.84-2.78 (m, 2H, ArNHCOCH2-), 2.71-2.65 (m, 2H, ArNHCOCH2CH2CH2-), 2.63-
2.54 (m, 2H-C(24)), 2.10 (s, 3H, CH3COO-C(12)), 2.06 (s, 3H, CH3COO-C(7)), 2.01-1.49 (m, 
18H, H-steroid), 1.44 (s, 9H, -NHCOOC(CH3)3), 1.38-0.96 (m, 9H, H-steroid), 0.90 (s, 3H, CH3-
C(10)), 0.77 (d, 3H, J = 6.4, CH3-C(20)), 0.70 (s, 3H, CH3-C(13)). 
13
C NMR (125 MHz, CDCl3, 
δ): 172.46, 170.38, 170.26, 155.12, 152.48, 149.47, 141.47, 135.07, 129.25, 126.69, 121.80, 
118.96, 111.26, 79.20, 75.42, 70.84, 53.39, 50.25, 48.30, 47.68, 45.01, 43.34, 41.52, 37.69, 
36.38, 36.27, 35.47, 35.07, 34.23, 33.32, 31.28, 28.83, 28.40, 27.27, 26.61, 25.48, 24.76, 22.77, 
22.68, 21.60, 21.36, 17.86, 12.18. HRMS: m/z 823.47498 corresponds to molecular formula 
C46H67ClN4O7H
+ 
(error in ppm -2.59); m/z 845.45727 corresponds to molecular formula 
C46H67ClN4O7Na
+ 
(error in ppm -2.11).  
(3,5,7,12)-3-Amino-24-({4-[(7-chloroquinolin-4-yl)amino]-4-oxobutyl}amino)cholane-
7,12-diyl diacetate (30). 
Compound 30 was prepared by procedure C using 29 (40.0 mg, 0.0486 mmol) and TFA/CH2Cl2 
(3.3 mL). Final product 30 was obtained as colorless foam (28 mg, 80%). M.p. = 65-67 °C. IR 
(ATR): 3287w, 2940s, 2864m, 1726s, 1616w, 1567w, 1531m, 1491w, 1446w, 1377m, 1307w, 
1249s, 1159w, 1120w, 1077w, 1025w, 965w, 883w, 850w, 823w, 735w, 702w, 610w cm
-1
. 
1
H 
NMR (500MHz, CDCl3  δ): 10.28 (bs, 1H, -NHCO-), 8.82 (d, 1H, J = 5.2, H-C(2')), 8.28 (d, 1H, 
J = 5.0, H-C(3')), 8.10-8.08 (m, 1H, H-C(8')), 7.89 (d, 1H, J = 8.9, H-C(5')), 7.47-7.43 (m, 1H, 
H-C(6')), 5.08-5.05 (m, 1H, H-C(12)), 4.90-4.87 (m, 1H, H-C(7)), 2.84-2.79 (m, 2H, 
ArNHCOCH2-), 2.71-2.66 (m, 2H, ArNHCOCH2CH2CH2-), 2.64-2.54 (m, 3H, 2H-C(24) and H-
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C(3)), 2.11 (s, 3H, CH3COO-C(12)), 2.07 (s, 3H, CH3COO-C(7)), 2.05-0.95 (m, 29H, H-steroid), 
0.90 (s, 3H, CH3-C(10)), 0.77 (d, 3H, J = 6.6, CH3-C(20)), 0.70 (s, 3H, CH3-C(13)). 
13
C NMR 
(125 MHz, CDCl3  δ): 172.45, 170.62, 152.48, 149.47, 141.45, 135.07, 129.26, 126.68, 121.78, 
118.94, 111.23, 75.48, 70.90, 51.65, 50.24, 48.28, 47.68, 45.04, 43.40, 41.50, 39.51, 37.76, 
36.30, 35.51, 35.08, 34.38, 33.32, 31.44, 31.25, 28.98, 27.27, 26.62, 25.58, 24.71, 22.79, 21.65, 
21.49, 17.83, 12.20. HRMS: m/z 723.42255 corresponds to molecular formula C41H59ClN4O5H
+ 
(error in ppm -2.93); m/z 362.21612 corresponds to molecular formula C41H59ClN4O5H2
2+ 
(error 
in ppm 0.41). It must be stored under Ar atmosphere at -20 °C, otherwise it decomposes to amine 
25 and (3,5,7,12)-3-amino-24-(2-oxopyrrolidin-1-yl)cholane-7,12-diyl diacetate 
( onfirmed  y HRM  . HP   purity (λ = 270 nm : method C: RT 10.993, area 95.23%; method 
D: RT 9.394, area 96.81%. 
N-(7-chloroquinolin-4-yl)-N'-[4-(5-fluoro-1-benzothiophene-3-yl)benzyl]butane-1,4-diamine 
(33). 
Compound 33 was prepared by procedure E, using aldehyde 31
2
 (93.2 mg, 0.364 mmol), amine 
AQ4 (136.3 mg  0.5458 mmol   gla .   OH (31 μ   0.54 mmol    aBH4 (82.6 mg, 2.18 mmol) 
and MeOH/CH2Cl2 (15 mL, 2:1, v/v). The product was purified using column chromatography 
(dry-flash, SiO2  eluent hexane/EtO   gradient 1/1 → EtO    EtO  /MeOH gradient 95/5 → 
MeOH). Final product 33 was obtained as a white foam (99.1 mg, 56%). M.p. = 112 – 114 ºC. IR 
(ATR): 3266m, 3068m, 2932m, 2854m, 2565w, 1608m, 1578s, 1535m, 1490w, 1471w, 1435m, 
1367m, 1331m, 1280w, 1249m, 1195m, 1135w, 1114w, 1060w, 1019w, 970w, 902w, 881w, 
850w, 804w, 781w, 735w, 647w, 619w, 570w, 543w, 517w, 430w cm
-1
. 
1
H NMR (500MHz, 
CDCl3): 8.51 (d, 1H, J = 5.5, H-C(2')), 7.94-7.92 (m, 1H, H-C(8')), 7.85-7.80 (m, 1H, H-C(7)), 
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7.66-7.62 (m, 1H, H-C(5')), 7.58-7.50 (m, 3H, 2H-Ar and H-C(4)), 7.48-7.42 (m, 3H, 2H-Ar and 
H-C(2)), 7.23-7.19 (m, 1H, H-C(6')), 7.17-7.12 (m, 1H, H-C(6)), 6.38 (d, 1H, J = 5.5, H-C(3')), 
5.88 (s, 1H, H-N exchangeable with D2O), 3.90 (s, 2H, ArCH2NH-), 3.35-3.29 (m, 2H, 
ArNHCH2-), 2.82-2.77 (m, 2H, ArCH2NHCH2-), 1.94-1.87 (m, 2H, ArNHCH2CH2-), 1.78-1.60 
(m, 3H, ArCH2NHCH2CH2- and H-N). 
13
C NMR (125 MHz, CDCl3): 161.09 (d, J = 241.0), 
152.07, 149.90, 149.16, 139.64, 139.06 (d, J = 9.9), 137.52 (d, J = 3.6), 135.98, 134.70, 134.37, 
128.73, 128.61, 128.52, 125.68, 125.00, 124.00 (d, J = 9.0), 121.26, 117.25, 113.32 (d, J = 25.3), 
108.48 (d, J = 24.4), 98.89, 53.68, 48.68, 43.21, 27.77, 26.37. HRMS: m/z 490.15075 
corresponds to molecular formula C28H25ClN3SFH
+ 
(error in ppm -1.43 . HP   purity (λ = 254 
nm): method C: RT 10.920, area 96.15%; method D: RT 9.897, area 96.40%. 
N
4
-[4-(5-fluoro-1-benzothien-3-yl)benzyl]-N
1
-quinolin-4-ylpentane-1,4-diamine (34). 
Compound 34 was prepared by procedure E, using aldehyde 31
2
 (170 mg, 0.66 mmol), amine 
108 (213 mg  0.929 mmol   gla .   OH (50 μ   0.8 mmol    aBH4 (150.6 mg, 3.980 mmol) and 
MeOH/CH2Cl2 (24 mL, 2:1, v/v). The product was purified using column chromatography (dry-
flash, SiO2  eluent hexane/EtO   gradient 1/1 → EtO    EtO  /MeOH gradient 95/5 → 
MeOH  flash  Biotage  P1   H  olumn  eluent EtOa /hexane gradient 8/2 → EtO    
EtO  /MeOH gradient 95/5 → 1/1 and flash  Biotage  P1   iO2 column, eluent 
EtOAc/MeOH+NH3(9/1  gradient 95/5 → 65/35 . Final produ t 34 was obtained as a white foam 
(239 mg, 77%). M.p. = 41 – 44 ºC. IR (ATR): 3257m, 3070m, 2958m, 2866m, 1581s, 1540m, 
1495w, 1438m, 1374w, 1340w, 1252w, 1196w, 1117w, 1020w, 883w, 862w, 809w, 768w, 
652w, 438w cm
-1
. 
1
H NMR (500MHz, CDCl3  δ : 8.53 (d  1H, J = 5.3, H-C(2')), 7.98-7.95 (m, 
1H, H-C(8')), 7.81 (dd, 1H, J1 = 8.7, J2 = 4.8, H-C(7)), 7.73-7.70 (m, 1H, H-C(5')), 7.60-7.52 (m, 
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2H, H-C(7') and H-C(4)), 7.51-7.47 (m, 2H-Ar), 7.46-7.42 (m, 3H, 2H-Ar and H-C(2)), 7.34-
7.29 (m, 1H, H-C(6')), 7.16-7.10 (m, 1H, H-C(6)), 6.39 (d, 1H, J = 5.3, H-C(3')), 5.67 (bs, 1H, 
H-N exchangeable with D2O), 3.93, 3.82 (ABq, 2H, JAB = 13.0, ArCH2-), 3.36-3.26 (m, 2H, 
ArNHCH2-), 2.88-2.80 (m, 1H, ArNHCH2CH2CH2CH(CH3)-), 2.06 (bs, 1H, H-N exchangeable 
with D2O), 1.94-1.78 (m, 2H, ArNHCH2CH2-), 1.69-1.55 (m, 2H, ArNHCH2CH2CH2-), 1.18 (d, 
3H, J = 6.3, ArNHCH2CH2CH2CH(CH3)-). 
13
C NMR (125 MHz, CDCl3  δ : 161.08 (d  J = 
239.6), 151.02, 149.79, 148.38, 140.15, 139.08 (d, J = 9.0), 137.59 (d, J = 4.1), 135.97, 134.26, 
129.87, 128.91, 128.62, 128.57, 125.60, 124.43, 123.98 (d, J = 9.0), 119.42, 118.77, 113.31 (d, J 
= 25.3), 108.50 (d, J = 23.5), 98.67, 52.17, 50.97, 43.48, 34.60, 25.10, 20.50. HRMS: m/z 
470.20588 corresponds to molecular formula C29H28FN3SH
+ 
(error in ppm -0.40). HPLC purity 
(λ = 330 nm : method  : RT 7.766, area 95.04%; method B: RT 7.737, area 95.17%. 
N-[4-(5-fluoro-1-benzothiophene-3-yl)benzyl]-N-methyl-N'-quinolin-4-ylbutane-1,4-
diamine (37). 
Compound 37 was prepared by procedure D, using 35
3
 (30.0 mg, 0.0658 mmol), 37% aqueous 
formaldehyde (10 μ   0.1 mmol   Zn l2 (17.9 mg, 0.132 mmol), NaHB3CN (16.6 mg, 0.263 
mmol) and MeOH (1 mL + 1 mL). The product was purified using column chromatography 
(flash  Biotage  P1   H  olumn  eluent EtO  /hexane gradient 8/2 → EtO    EtO  /MeOH 
gradient 95/5 → MeOH and flash  Biotage  P1   iO2 column, eluent EtOAc/MeOH+NH3(9/1) 
gradient 95/5 → 2/8 . Final produ t 37 was obtained as a colorless oil (23 mg, 74%). IR (ATR): 
3647w, 3252m, 3069m, 2927s, 2852m, 2793m, 1730w, 1582s, 1541m, 1494w, 1438m, 1374w, 
1342m, 1252m, 1195m, 1118w, 969w, 883w, 864w, 807w, 765m, 737w, 653w, 628w, 572w, 
543w, 422w cm
-1
. 
1
H NMR (500MHz, CDCl3): 8.53 (d, 1H, J = 5.2, H-C(2')), 7.99-7.95 (m, 1H, 
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H-C(8')), 7.82 (dd, 1H, J1 = 4.6, J2 = 8.8, H-C(7)),  7.74-7.71 (m, 1H, H-C(5')), 7.61-7.54 (m, 2H, 
H-C(7') and H-C(4)), 7.51-7.48 (m, 2H-Ar), 7.47-7.44 (m, 3H, 2H-Ar and H-C(2)), 7.35-7.30 
(m, 1H, H-C(6')), 7.17-7.11 (m, 1H, H-C(6)), 6.40 (d, 1H, J = 5.3, H-C(3')), 5.76 (bs, 1H, H-N 
exchangeable with D2O), 3.60 (s, 2H, ArCH2-), 3.36-3.30 (m, 2H, ArNHCH2-),  2.52 (t, 2H, J = 
6.8, ArCH2NHCH2-), 2.27 (s, 3H, CH3-N), 2.19 (bs, 1H, H-N), 1.89 (quin, 2H, J = 6.8, 
ArNHCH2CH2-), 1.76 (quin, 2H, J = 7.0, ArNHCH2CH2CH2-). 
13
C NMR (125 MHz, CDCl3): 
161.08 (d, J = 240.1), 150.87, 150.00, 148.21, 139.05 (d, J = 9.0), 138.43, 137.58 (d, J = 4.5), 
135.98, 134.35, 129.70, 129.57, 128.96, 128.38, 125.61, 124.38, 123.98 (d, J = 9.9), 119.58, 
118.76, 113.30 (d, J = 25.3), 108.50 (d, J = 23.5), 98.62, 61.89, 56.75, 43.19, 42.51, 26.48, 
25.21. HRMS: m/z 470.20631 corresponds to molecular formula C29H28FN3SH
+ 
(error in ppm 
0.50 . HP   purity (λ = 330 nm : method  : RT 9.126, area 97.87%; method B: RT 7.770, area 
96.71%. 
3-[4-({methyl[4-(quinolin-4-ylamino)pentyl]amino}methyl)phenyl]-1-benzothiophene-5-
carbonitrile (38). 
Compound 38 was prepared by procedure D, using 36
2
 (15.8 mg, 0.0331 mmol), 37% aqueous 
formaldehyde (5.1 μ   0.066 mmol   Zn l2 (9.0 mg, 0.066 mmol), NaHB3CN (8.3 mg, 0.283 
mmol) and MeOH (1 mL + 1 mL). The product was purified using column chromatography 
(flash  Biotage  P1   H  olumn  eluent EtOa /hexane gradient 8/2 → EtO    EtO  /MeOH 
gradient 95/5 → MeOH and flash  Biotage  P1   iO2 column, eluent EtOAc/MeOH+NH3(9/1) 
gradient 95/5 → 65/35 . Final produ t 38 was obtained as a colorless oil (12.1 mg, 74%). IR 
(film): 3375s, 3104s, 2971s, 2796m, 2346w, 2306w, 2227m, 1963w, 1703m, 1601s, 1553s, 
1498m, 1460s, 1405m, 1342m, 1264m, 1224m, 1146m, 1058m, 1014w, 888w, 860w, 805m, 
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767m, 735m, 702w, 654m, 614w cm
-1
. 
1
H NMR (500 MHz, CDCl3  δ): 8.51 (d, 1H, J = 5.2, H-
C(2')), 8.21-8.19 (m, 1H, H-C(4)), 8.01-7.98 (m, 1H, H-C(8')), 7.98-7.95 (m, 1H, H-C(7)), 7.74-
7.71 (m, 1H, H-C(5')), 7.63-7.57 (m, 2H, H-C(6) and H-C(7')), 7.52 (s, 1H, H-C(2)), 7.49-7.44 
(m, 4H-Ar), 7.39-7.35 (m, 1H, H-C(6')), 6.42 (d, 1H, J = 5.6, H-C(3')), 5.20-5.16 (m, 1H, H-N 
exchangeable with D2O), 3.79-3.70 (m, 1H, ArNHCH(CH3)-), 3.58 (s, 2H, ArCH2-), 2.50-2.45 
(m, 2H, ArCH2NHCH2-), 2.24 (s, 3H, CH3-N), 2.10 (bs, 1H, H-N exchangeable with D2O), 1.84-
1.67 (m, 4H, ArNHCH(CH3)CH2CH2-), 1.35 (d, 3H, J = 6.2, ArNHCH(CH3)-). 
13
C NMR (125 
MHz, CDCl3  δ : 150.77  149.03  148.36  144.78  139.28  137.96  137.92  133.28  129.79  
129.64, 129.00, 128.50, 127.76, 126.27, 125.50, 124.42, 123.91, 119.46, 119.32, 118.76, 108.12, 
98.91, 62.02, 57.03, 48.14, 42.39, 34.27, 23.90, 20.35. HRMS: m/z 491.22662 corresponds to 
molecular formula C31H30N4SH
+ (error in ppm 0.45 . HP   purity (λ = 330 nm : method  : RT 
8.785, area 96.50%; method B: RT 7.734, area 97.90%. 
4-{5-[4-({[2-(quinolin-4-ylamino)ethyl]amino}methyl)phenyl]-2-thienyl}benzonitrile (42). 
Compound 42 was prepared by procedure E using aldehyde 39
2
 (40 mg, 0.14 mmol), amine 
AQ11 (38.8 mg  0.207 mmol   gla .   OH (12 μ   0.21 mmol    aBH4 (31.3 mg, 0.828 mmol) 
and MeOH/CH2Cl2 (3 mL, 2:1, v/v). The product was purified using column chromatography 
(dry-flash, SiO2  eluent EtO    EtO  /MeOH gradient 9/1 → MeOH and flash Biotage  P1  
 H  olumn  eluent hexane/EtO   gradient 36/65 → EtO   . Final produ t 42 was obtained as a 
yellow solid (41.3 mg, 65%). M.p. = 107 – 111 ºC. IR (film): 3296w, 3064w, 2223w, 1581s, 
1539m, 1495w, 1452m, 1393w, 1337w, 1278w, 1177w, 1129w, 836m, 800m, 765m, 734w cm
-1
. 
1
H NMR (500 MHz, CDCl3  δ): 8.54 (d, 1H, J = 5.3, H-C(2)), 8.01 – 7.96 (m, 1H, H-C(8)), 7.82 
– 7.76 (m, 1H, H-C(5)), 7.72 – 7.67 (m, 2H-ArCN), 7.67 – 7.62 (m, 3H, 2H-ArCN and H-C(7)), 
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7.61 – 7.56 (m, 2H-Ar), 7.47 – 7.42 (m, 1H, H-C(6)), 7.41 – 7.35 (m, 3H, 2H-Ar and H-
thiophene), 7.32 – 7.28 (m, 1H, H-thiophene), 6.40 (d, 1H, J = 5.4, H-C(3)), 5.82 (bs, 1H, N-H, 
exchangeable with D2O), 3.89 (s, 2H, -ArCH2NH-), 3.40 – 3.36 (m, 2H, -CH2CH2NHAr), 3.10 – 
3.06 (m, 2H, -CH2CH2NHAr). 
13
C NMR (125 MHz, CDCl3  δ : 150.93, 149.84, 148.27, 145.70, 
140.89, 140.09, 138.48, 132.72, 129.78, 129.03, 128.75, 126.08, 125.91, 125.67, 124.62, 124.32, 
119.51, 118.90, 118.82, 110.43, 98.92, 52.99, 46.99, 42.17. HRMS: m/z 461.17978 corresponds 
to molecular formula C29H24N4SH
+ (error in ppm 0.73 . HP   purity (λ = 330 nm : method G: 
RT 2.132, area 95.55%; method H: RT 1.879, area 95.01%. 
4-{5-[4-({[10-(quinolin-4-ylamino)decyl]amino}methyl)phenyl]-2-thienyl}benzonitrile (43).  
Compound 43 was prepared by procedure E using aldehyde 39
2
 (57.9 mg, 0.200 mmol), amine 
AQ12 (90 mg  0.30 mmol   gla .   OH (18 μ   0.30 mmol    aBH4 (45.4 g, 1.20 mmol) and 
MeOH/CH2Cl2 (4.5 mL, 2:1, v/v). The product was purified using column chromatography (dry-
flash, SiO2  eluent hexane  EtO    EtO  /MeOH gradient 9/1 → MeOH  MeOH ( H3 sat.) and 
flash  Biotage  P1  H  olumn  eluent EtO    gradient EtO   → EtO  /MeOH 4/6 . Final 
product 43 was obtained as a yellow solid (45.9 mg, 40 %). M. p. = 115 – 116 °C. IR (film): 
3266m, 2922s, 2851m, 2221m, 1725w, 1668w, 1580s, 1530m, 1492w, 1445m, 1375m, 1342m, 
1278m, 1234w, 970w, 875w, 836w, 799m, 762m cm
-1
. 
1
H NMR (500 MHz, CDCl3  δ): 8.55 (d, 
1H, J = 5.3, H-C(2)), 7.98 (d, 1H, J = 7.8, H-C(8)), 7.75 – 7.55 (m, 8H, 4H-ArCN, 2H-Ar, H-
C(5) and H-C(7)), 7.45 – 7.34 (m, 4H, H-C(6), H-thiophene, 2H-Ar), 7.30 (d, 1H, J = 3.9, H-
thiophene), 6.42 (d, 1H, J = 5.3, H-C(3)), 4.96 (bs, 1H, H-N), 3.81 (s, 2H, ArCH2NH), 3.35 – 
3.27 (m, 2H, -CH2NHAr), 2.64 (t, J = 7.2, ArCH2NHCH2-), 1.80 – 1.25 (m, 16H, -(CH2)8-). 
13
C 
NMR (125 MHz, CDCl3  δ : 151.10  149.64  148.46  146.04  140.86  140.72  138.56  132.75  
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132.34, 130.05, 128.94, 128.77, 126.09, 125.79, 125.66, 124.55, 124.18, 119.12, 118.88, 118.69, 
110.38, 98.79, 53.72, 49.54, 43.27, 30.14, 29.52, 29.49, 29.36, 28.97, 27.33, 27.15. HRMS: m/z 
573.30186 corresponds to molecular formula C37H40N4SH
+ 
(error in ppm – 4.85). HPLC purity 
(λ = 330 nm : method  : RT 8.038, area 96.27%; method D: RT 6.152, area 95.99%. 
(4-{5-[4-({[2-(quinolin-4-ylamino)ethyl]amino}methyl)phenyl]-2-thienyl}phenyl)acetonitrile 
(44). 
Compound 44 was prepared in two steps from 114. The general procedure F was followed using 
114 (95 mg, 0.34 mmol), 4-formylphenylboronic acid (118.6 mg, 0.4099 mmol), PdO × 1.4 H2O 
(5 mg, 0.03 mmol), K2CO3 (56.6 mg, 0.409 mmol), EtOH/H2O (9.6 mL, 3:1, v/v). The product 
40 was roughly purified using column chromatography (flash Biotage SP1, SiO2 column, eluent 
toluene  toluene/EtO   gradient 9/1 → EtO   . The  rude produ t was su je ted to the next 
reaction step following procedure E using amine AQ11 (32.3 mg, 0.172 mmol), AcOH (10 µL, 
0.172 mmol), NaBH4 (26.1 mg, 0.690 mmol), MeOH/CH2Cl2 (3 mL, 2:1, v/v). The product was 
purified using column chromatography (dry-flash, SiO2, eluent EtOAc, EtOAc/MeoH gradient 
9/1 → 1/1 and flash  Biotage  P1   H  olumn  eluent hexane/EtO   gradient 6/4 → EtO   . 
The final product 44 was obtained as a yellow solid. (20 mg, 12 %) M. p. = 110 – 112 °C. IR 
(ATR): 3638m, 3358s, 3315m, 3079m, 3027m, 2934m, 2900m, 2860m, 2815m, 1647w, 1620m, 
1581s, 1542s, 1500m, 1458m, 1438m, 1417m, 1402m, 1370m, 1336s, 1277m, 1261m, 1223w, 
1126m, 1047w, 1015w, 965w, 912m, 815m, 795s, 766m, 738m, 650w, 476w, 401w cm
-1
. 
1
H 
NMR (500 MHz, CDCl3 + CD3O   δ): 8.55 – 8.45 (m, 1H, H-C(2)), 8.02 – 7.95 (m, 1H, H-
C(8)), 7.85 – 7.78 (m, 1H, H-C(5)), 7.67 – 7.57 (m, 5H, 2H-Ar, 2H-ArCH2CN and H-C(7)), 7.47 
– 7.42 (m, 1H, H-C(6)), 7.40 – 7.32 (m, 4H, 2H-Ar and 2H-ArCH2CN), 7.31 – 7.27 (m, 2H-
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thiophene), 6.40 (d, 1H, J = 5.5, H-C(3)), 4.73 (bs, 1H, H-N), 3.86 (s, 2H, ArCH2NH), 3.77 (s, 
2H, CH2CN), 3.42 – 3.36 (m, 2H, -CH2NHAr), 3.13 – 3.03 (m, 2H, ArCH2NHCH2-). 
13
C NMR 
(125 MHz, CDCl3 + CD3O   δ : 150.36  150.21  147.50  143.58  142.38  138.82  134.10  
133.23, 129.38, 128.74, 128.60, 128.46, 126.12, 125.76, 124.77, 124.43, 124.04, 119.92, 118.75, 
117.71, 98.51, 52.95, 46.78, 42.10, 23.20. HRMS m/z 475.19470 corresponds to molecular 
formula C30H26N4SH
+
 (error in ppm -0.82). HP   purity (λ = 330 nm : method B: RT 7.922, 
area 95.73%; method C: RT 7.974, area 95.24%. 
N-(7-chloroquinolin-4-yl)-N'-[4-(5-{4-[(trimethylsilyl)ethynyl]phenyl}-2-
thienyl)benzyl]ethane-1,2-diamine (45). 
Compound 45 was prepared by procedure E using aldehyde 41
2 
(25.9 mg, 0.0718 mmol), amine 
AQ2 (23.9 mg, 0.108 mmol), glac. AcOH (7 µL, 0.108 mmol), NaBH4 (16.3 mg, 0.431 mmol) 
and MeOH/CH2Cl2 (3 mL, 2:1, v/v). The product was purified using column chromatography 
(dry-flash, SiO2  eluent EtO    EtO  /MeoH gradient 9/1 → MeOH and flash  Biotage  P1  
 H  olumn  eluent hexane/EtO   gradient 6/4 → EtO   . The final produ t 45 was obtained as 
a yellow foam (23.9 mg, 59 %). IR (ATR): 3298m, 3070w, 2958m, 2853w, 2158w, 1608m, 
1584s, 1536w, 1495w, 1453w, 1372w, 1332w, 1280w, 1250w, 1139w, 867m, 844m, 802w cm
-1
. 
1
H NMR (500 MHz, CDCl3 + D2O  δ): 8.50 (d, 1H, J = 5.5, H-C(2)), 7.96 – 7.94 (m, 1H, H-
C(8)), 7.71 – 7.67 (m, 1H, H-C(5)), 7.60 – 7.52 (m, 4H-Ar), 7.52 – 7.44 (m, 2H-Ar), 7.40 – 7.33 
(m, 3H, H-C(6) and 2H-Ar), 7.32 – 7.29 (m, 1H, H-thiophene), 7.28 – 7.26 (m, 1H, H-thiophene, 
overlap with CHCl3), 6.36 (d, 1H, J = 5.5, H-C(2)), 3.85 (s, 2H, ArCH2NH-), 3.40 – 3.26 (m, 2H, 
ArNHCH2-), 3.10 – 3.01 (m, 2H, ArNHCH2CH2-), 0.26 (s, 9H, (CH3)3Si). 
13
C NMR (125 MHz, 
CDCl3  δ : 151.95  149.86  148.99  143.80  142.72  139.42  139.37  134.88  134.17  133.23  
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132.66, 132.50, 128.69, 125.78, 125.31, 125.13, 124.69, 124.56, 124.11, 122.04, 121.18, 117.32, 
104.86, 99.19, 95.34, 52.95, 46.79, 42.02, 0.04. HRMS m/z 566.18315 corresponds to molecular 
formula C33H32ClN3SSiH
+
 (error in ppm -2.83). 
N-(7-chloroquinolin-4-yl)-N'-{4-[5-(4-ethynylphenyl)-2-thienyl]benzyl}ethane-1,2-diamine 
(47). 
Compound 45 (17.8 mg, 0.314 mmol) was dissolved in dry methanol (0.5 mL). Anh. K2CO3 (2.2 
mg, 0.016 mmol) was added and reaction mixture was stirred at r.t. for 24 h. After extraction 
with ethyl-acetate, combined organic layers were washed with satd. aqueous solution of NaHCO3 
and dried over anh. Na2SO4. After filtration, the crude product was purified using column 
chromatography (flash, Biotage SP1, NH column, eluent CH2Cl2, CH2Cl2/MeOH gradient 9/1 → 
1/1). The final product 47 was obtained as a yellow solid (7.6 mg, 49 %). M.p. = 163 – 167 °C. 
IR (ATR): 3292m, 2924w, 2854w, 1611m, 1583s, 1539m, 1493w, 1453m, 1372w, 1334w, 
1281w, 1246w, 1211w, 1139w, 1113w, 837m, 803m cm
-1
. 
1
H NMR (500 MHz, CDCl3 + 
CD3OD  δ): 8.36 (d, 1H, J = 5.5, H-C(2)), 7.99 (d, 1H, J = 8.9, H-C(5)), 7.90 – 7.80 (m, 1H, H-
C(8)), 7.65 – 7.58 (m, 4H-Ar), 7.54 – 7.48 (m, 2H-Ar), 7.43 – 7.40 (m, 1H, H-C(6)), 7.39 – 7.33 
(m, 3H, 2H-Ar and H-thiophene), 7.32 – 7.27 (m, 1H, H-thiophene), 6.50 – 6.41 (m, 1H, H-
C(3)), 3.88 (s, 2H, ArCH2NH-), 3.54 – 3.46 (m, 2H, ArNHCH2), 3. 26 (s, 1H, CH), 3.12 – 2.98 
(m, 2H, ArNHCH2CH2). 
13
C NMR (125 MHz, CDCl3 + CD3OD  δ : 150.97  150.16  147.20  
143.47, 142.25, 137.87, 135.42, 134.21, 133.05, 132.29, 128.64, 126.14, 125.44, 125.26, 124.91, 
124.42, 123.91, 122.22, 120.76, 116.97, 98.33, 83.04, 77.92, 52.56, 46.24, 41.83. HRMS m/z 
494.14419 corresponds to molecular formula C30H24ClN3SH
+
 (error in ppm -2.09). HPLC purity 
(λ = 330 nm : method  : RT 8.075, area 96.46%; method D: RT 5.738, area 95.31%. 
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4-{5-[4-({methyl[6-(quinolin-4-ylamino)hexyl]amino}methyl)phenyl]-2-thienyl}benzonitrile 
(48). 
Compound 48 was prepared by procedure D using 46
2
 (36.5 mg, 0.071 mmol) in methanol (1.5 
mL), 37% aqueous formaldehyde (11.5 µL, 0.141 mmol), and solution of NaBH3CN (17.8 mg, 
0.282 mmol) and ZnCl2 (19.2 mg, 0,141 mmol) in methanol (1.5 mL). The crude product was 
purified using column chromatography (flash, Biotage SP1, NH column, eluent hexane/EtOAc, 
gradient 1/1 → EtO   → MeOH . The final produ t 48 was obtained as a yellow solid (18.6 mg, 
50 %). M.p. = 135 – 140 ºC. IR (film): 3271w, 3068w, 2928m, 2853m, 2793w, 2224m, 1734w, 
1652w, 1601m, 1581s, 1540m, 1496m, 1455m, 1373w, 1342m, 1279w, 1223w, 1177w, 1123w, 
1015w, 837w, 800m, 765m, 730w, 668w cm
-1
. 
1
H NMR (500 MHz, CDCl3  δ): 8.54 (d, 1H, J = 
5.3, H-C(2)), 8.05 – 7.95 (m, 1H, H-C(8)), 7.72 – 7.60 (m, 6H, 4H-ArCN, H-C(5)) and H-C(7)), 
7.59 – 7.54 (m, 2H-Ar), 7.44 – 7.39 (m, 1H, H-C(6)), 7.38 – 7.33 (m, 3H, 2H-Ar and H-
thiophene), 7.31 – 7.28 (m, 1H, H-thiophene), 6.44 – 6.40 (m, 1H, H-C(3)), 4.95 (bs, 1H, H-N), 
3.50 (s, 2H, ArCH2N(CH3)CH2-), 3.35 – 3.27 (m, 2H, ArNHCH2-), 2.44 – 2.35 (m, 2H, 
ArCH2N(CH3)CH2-), 2.22 (s, 3H, CH3-), 1.81 – 1.74 (m, 2H, ArNHCH2CH2-), 1.61 – 1.52 (m, 
2H, ArNH(CH2)4CH2-), 1.52 – 1.37 (m, 4H, -(CH2)2CH2CH2(CH2)2-). 
13
C NMR (125 MHz, 
CDCl3  δ : 152.34  151.36  149.66  147  57  142.27  141.09  140.11  134.42, 134.31, 133.97, 
132.11, 131.30, 131.23, 131.17, 130.65, 127.65, 127.51, 127.22, 127.17, 126.20, 125.73, 120.71, 
120.44, 120.17, 111.95, 100.30, 63.60, 58.70, 44.80, 43.90, 30.50, 28.84, 28.62, 28.57. HRMS: 
m/z 531.25859 corresponds to molecular formula C34H34N4SH
+ 
(error in ppm 1.69).  HPLC 
purity (λ = 330 nm : method E: RT 4.358  area 95.79%; method F: RT 4.042  area 95.71%. 
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4-[5-(3-formylphenyl)thiophen-2-yl]benzonitrile (49). 
Compound 49 was prepared by procedure G using Pd(OAc)2 (8.7 mg, 0.039 mmol), PPh3 (40.7 
mg, 0.155 mmol), 4-cyanophenylboronic acid (57.1 mg, 0.388 mmol), aq. 2M Na2CO3 (1.5 mL), 
112 (103.8 mg, 0.388 mmol) and DME (10 mL). The product was purified using column 
chromatography (dry-flash, SiO2, eluent hexane, hexane/EtO   gradient 9/1 → 7/3 . Final 
product 49 was precipitated with ethyl acetate as a yellow solid (42.7 mg, 38 %). M.p. = 178 °C. 
IR (film): 3096m, 3066m, 2873m, 2760w, 2222s, 1685s, 1636m, 1600s, 1581s, 1507m, 1485m, 
1458m, 1435m, 1414m, 1389m, 1340m, 1314m, 1286s, 1240m, 1177s, 1092m, 1003w, 883w, 
842m, 809m, 786m, 751w, 724m, 696m, 677w, 650w, 542m cm
-1
. 
1
H NMR (500 MHz, CDCl3, 
δ): 10.08 (s, 1H, H-CO), 8.13 (bs, 1H, H- (2’    7.89 – 7.82 (m, 2H, H- (4’  and H- (6’    7.73 
– 7.67 (m, 4H, H-ArCN), 7.60 (t, 1H, J = 7.7, H- (5’ ), 7.44 – 7.42 (m, 2H, H-C(3) and H-C(4)). 
13
C NMR (125 MHz, CDCl3  δ : 191.81  144.12  142.03  138.18  137.05  134.71  132.81  131.32  
129.80, 129.40, 126.23, 126.20, 125.83, 125.33, 118.72, 110.84. GC/MS (m/z (%)): 289.0 ([M
+
], 
100); 259.0 (20).  
4-{5-[3-({[6-(quinolin-4-ylamino)hexyl]amino}methyl)phenyl]-2-thienyl}benzonitrile (50). 
Compound 50 was prepared by procedure E using aldehyde 49 (37.6 mg, 0.129 mmol), amine 
AQ9
2
 (47.4 mg, 0.195 mmol), glac, AcOH (12 µL, 0.195 mmol), NaBH4 (29.3 mg, 0.774 mmol) 
and MeOH/CH2Cl2 (3 mL, 2:1, v/v). The product was purified using column chromatography 
(dry-flash, SiO2, eluent hexane  EtO    EtO  /MeOH gradient 9/1 → MeOH and flash Biotage 
 P1  H  olumn eluent hexane/EtO   gradient 6/4 → EtO    MeOH . The final produ t 50 was 
obtained as a yellow solid (28.2 mg, 54 %). M.p. = (143 – 146) °C. IR (film): 3402w, 3300w, 
3062w, 2930m, 2855m, 2225m, 1602m, 1583s, 1541m, 1505w, 1456w, 1394w, 1372w, 1342w, 
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1280w, 1176w, 1125w, 837w, 808w, 787w, 766w, 732w, 698w, 542w cm
-1
. 
1
H NMR (500 MHz, 
CDCl3  δ): 8.54 (d, 1H, J = 5.3, H- (2”    7.98 (d  1H, J = 8.5, H- (8”    7.71 – 7.60 (m, 7H, H-
C(7”   4H-ArCN, H- (5”  and H- (2’    7.51 (d  1H, J = 7.3, H- (6’    7.42 – 7.32 (m, 4H, H-
 (6”   2H-ArS and H- (5’    7.29 – 7.27 (m, 1H, H- (4’    6.40 (d  1H, J = 5.3, H- (3”    4.99 
(bs, 1H, H-N), 3.84 (s, 2H, Ar-CH2), 3.31 – 3.28 (m, 2H, ArNHCH2-), 2.69 – 2.66 (m, 2H, -
CH2NHCH2CH2-), 1.79 – 1.73 (m, 2H, ArNHCH2CH2-), 1.60 – 1.55 (m, 2H, -CH2NHCH2CH2-), 
1.52 – 1.44 (m, 4H, ArNHCH2CH2CH2CH2-). 
13
C NMR (125 MHz, CDCl3  δ : 150.87  149.68  
148.22, 146.04, 141.41, 140.91, 138.48, 133.79, 132.72, 129.84, 129.09, 129.01, 127.94, 126.04, 
125.63, 125.45, 124.58, 124.41, 119.12, 118.83, 118.61, 110.41, 98.72, 53.88, 49.27, 43.17, 
29.98, 28.88, 27.05. HRMS m/z 517.24204 corresponds to molecular formula C33H32N4SH
+
 
(error in ppm -1.04). HP   purity (λ=330 nm : method A: RT 9.390, area 97.66%; method B: 
RT 7.586, area 95.23%. 
N-(1-Adamantylmethyl)-N'-(7-chloroquinolin-4-yl)-N-methylethane-1,2-diamine (56). 
Compound 56 was prepared from aminoquinoline N-(1-adamantylmethyl)-N'-(7-chloroquinolin-
4-yl)ethane-1,2-diamine
5
 (87 mg, 0.24 mmol) and 37% formaldehyde (35 µL, 0.48 mmol) using 
ZnCl2 (65 mg, 0.48 mmol) and NaBH3CN (60 mg, 0.96 mmol) by procedure D and was obtained 
after column chromatography (SiO2, eluent: CH2Cl2/MeOH(NH3 satd) = 95/5) as a white solid 
(74 mg, 82%) softenes at 135-137 °C. IR (ATR): 3207w, 3062w, 2901s, 2844m, 2792w, 1612w, 
1581s, 1489w, 1453m, 1432w, 1374w, 1339w, 1313w, 1283w, 1243w, 1208m, 1183w, 1166w, 
1135w, 1101w, 1080w, 1046w, 986w, 949w, 902w, 874w, 847w, 823w, 804m, 772w, 735w, 
645w, 623w, 567w, 488w, 425w cm
-1
. 
1
H-NMR (200 MHz, CDCl3): 8.53 (d, 1H, J = 5.0 Hz, H-
C(2)), 7.96 (d, 1H, J = 2.4 Hz, H-C(8)), 7.77 (d, 1H, J = 9.0 Hz, H-C(5)), 7.35 (dd, 1H, J = 2.2 
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Hz, J = 9.0 Hz, H-C(6)), 6.36 (d, 1H, J = 5.6 Hz, H-C(3)), 6.30 (bs, 1H, -NH), 3.30-3.15 (m, 2H, 
ArNHCH2-), 2.90-2.70 (m, 2H, ArNHCH2CH2-), 2.29 (s, 3H, -N(CH3)), 2.14 (s, 2H, -CH2Ad), 
1.99 (bs, 3H, -Ad), 1.70-1.50 (m, 12H, -Ad).
 13
C-NMR (50 MHz, CDCl3): 152.09; 149.87; 
149.01; 134.74; 128.67; 125.08; 121.24; 117.37; 99.20; 77.41; 57.96; 44.21; 41.31; 40.13; 37.13; 
35.03; 28.31. (+)ESI-HRMS (m/z (%)): 384.21997 (M+H+, 100); calculated 384.22010 (error 
in ppm: -0.34). Anal. (C23H30ClN3 × H2O) Calcd: C, 70.30; H, 7.95; N, 10.69. Found: C, 70.50; 
H  7.97;    10.58. HP   purity (λ=330 nm : method  : RT 7.872  area 98.49%; method B: RT 
9.624, area 98.88%. 
N-(1-Adamantylmethyl)-N'-(7-chloroquinolin-4-yl)-N-methylpropane-1,3-diamine (57). 
Compound 57 was prepared from aminoquinoline N-(1-adamantylmethyl)-N'-(7-chloroquinolin-
4-yl)propane-1,3-diamine
5
 (93 mg, 0.24 mmol) and 37% formaldehyde (36 µL, 0.48 mmol) 
using ZnCl2 (65 mg, 0.48 mmol) and NaBH3CN (60 mg, 0.96 mmol) by procedure D and was 
obtained after column chromatography: (SiO2, eluent: CH2Cl2/MeOH(NH3 satd) = 95/5) as a 
white solid (85 mg, 87%) softenes at 137-139 °C. IR (ATR): 3246m, 3064w, 2900s, 2844m, 
1612w, 1580s, 1540w, 1451m, 1429w, 1367, 1330w, 1283w, 1233w, 1202w, 1167w, 1139m, 
1103w, 1079w, 1036w, 901w, 876w, 850w, 804m, 766w, 731w, 644w cm
-1
. 
1
H-NMR (200 
MHz, CDCl3): 8.52 (d, 1H, J = 5.0 Hz, H-C(2)), 7.94 (d, 1H, J = 2.2 Hz, H-C(8)), 7.80 (d, 1H, J 
= 9.0 Hz, H-C(5)), 7.32 (dd, 1H, J = 2.2 Hz, J = 9.0 Hz, H-C(6)), 7.21 (bs, 1H, -NH), 6.35 (d, 
1H, J = 5.2 Hz, H-C(3)), 3.45-3.30 (m, 2H, ArNHCH2-), 2.65-2.55 (m, 2H, ArNHCH2CH2CH2-), 
2.39 (s, 3H, -N(CH3)), 2.08 (s, 2H, -CH2Ad), 2.00-1.40 (m, 17 H, -Ad, -ArNHCH2CH2-). 
13
C-
NMR (50 MHz, CDCl3): 152.09; 150.45; 149.10; 134.61; 128.51; 124.70; 122.06; 117.53; 98.59; 
72.47; 60.87; 46.14; 44.06; 41.46; 36.87; 34.69; 28.24; 25.46. (+)ESI-HRMS (m/z (%)): 
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398.23579 (M+H+, 100); calculated 398.23575 (error in ppm: -0.09). Anal. (C24H32ClN3  1/2 
H2O) Calcd: C, 70.83; H, 8.17; N, 10.32. Found: C, 71.01; H, 8.12; N, 10.14. HPLC purity 
(λ=330 nm : method  : RT 7.834  area 96.12%; method B: RT 9.633  area 96.86%. 
N-[2-(1-Adamantyl)ethyl]-N'-(7-chloroquinolin-4-yl)-N-methylpropane-1,3-diamine (58). 
Compound 58 was prepared from aminoquinoline N-(1-adamantylmethyl)-N'-(7-chloroquinolin-
4-yl)butane-1,4-diamine
5
 (127 mg, 0.32 mmol) and 37% formaldehyde (48 µL, 0.64 mmol) 
using ZnCl2 (87 mg, 0.64 mmol) and NaBH3CN (80 mg, 1.28 mmol) by procedure D and was 
obtained after column chromatography: (SiO2, eluent: CH2Cl2/MeOH(NH3 satd) = 95/5) as a 
white solid (123 mg, 93%) softenes at 157-159 °C. IR (ATR): 3234m, 3063w, 2900s, 2844m, 
2790w, 1611w, 1578s, 1541w, 1508w, 1489w, 1473w, 1452m, 1429w, 1368m, 1331w, 1281w, 
1252w, 1203w, 1164w, 1140m, 1102w, 1080w, 1034w, 898w, 873w, 847m, 804m, 767w, 637w, 
564w cm
-1
. 
1
H-NMR (200 MHz, CDCl3): 8.52 (d, 1H, J = 5.6 Hz, H-C(2)), 7.94 (d, 1H, J = 2.4 
Hz, H-C(8)), 7.71 (d, 1H, J = 9.0 Hz, H-C(5)), 7.32 (dd, 1H, J = 1.7 Hz, J = 8.9 Hz, H-C(6)), 
6.40 (d, 1H, J = 5.6 Hz, H-C(3)), 5.40 (bs, 1H, -NH), 3.40-3.20 (m, 2H, ArNHCH2-), 2.50-2.30 
(m, 2H, -CH2N(CH3)CH2Ad), 2.25 (s, 3H, -N(CH3)), 2.10-1.40 (m, 21H, -CH2Ad, 
ArNHCH2CH2-, ArNHCH2CH2CH2-, -Ad). 
13
C-NMR (50 MHz, CDCl3): 152.01; 149.81; 
149.14; 134.72; 128.71; 125.03; 121.12; 117.15; 98.98; 71.05; 60.20; 46.41; 43.15; 41.35; 37.11; 
34.70; 28.42; 26.42; 25.69. (+)ESI-HRMS (m/z (%)): calculated 412.25123 (M+H+, 100); 
calculated 412.25140 (error in ppm: -0.42). Anal. (C25H34ClN3  1/2 H2O) Calcd: C, 71.32; H, 
8.38;    9.98. Found:    71.73; H  8.77;    10.02. HP   purity (λ=330 nm : method  : RT 
7.856, area 99.06%; method B: RT 9.641, area 98.70%. 
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N
1
-(1-Adamantylmethyl)-N
2
-(7-chloroquinolin-4-yl)-N
1
-methylpropane-1,2-diamine (59). 
Compound 59 was prepared from aminoquinoline N
1
-(1-adamantylmethyl)-N
2
-(7-
chloroquinolin-4-yl)propane-1,2-diamine
4 
(61 mg, 0.16 mmol) and 37% formaldehyde (24 µL, 
0.32 mmol) using ZnCl2 (45 mg, 0.32 mmol) and NaHB3CN (40 mg, 0.64 mmol) by procedure D 
and was obtained after dry-flash chromatography: (SiO2, eluent: CH2Cl2/MeOH(NH3 satd) = 
100/2) as white solid (58 mg, 91%) softenes at 134-136 °C. IR (ATR): 3257m, 3067w, 2980w, 
2901s, 2844s, 2795w, 2611w, 1574s, 1546m, 1490w, 1453m, 1426w, 1377m, 1332m, 1313w, 
1283w, 1250w, 1208m, 1173w, 1152m, 1105w, 1079w, 1038w, 956w, 902w, 874w, 862w, 
843w, 824w, 803w, 772w, 757w, 610w, 600w, 567w, 495w cm
-1
. 
1
H-NMR (500 MHz, CDCl3): 
8.54 (d, 1H, J = 5.0 Hz, H-C(2)), 7.96 (d, 1H, J = 2.0 Hz, H-C(8)), 7.82 (d, 1H, J = 9.0 Hz, H-
C(5)), 7.35 (dd, 1H, J = 2.2 Hz, J = 8.8 Hz, H-C(6)), 6.45 (d, 1H, J = 5.5 Hz, H-C(3)), 6.26 (bs, 
1H, ArNH-), 3.60-3.50 (m, 1H, ArNHCH(CH3)-), 2.70-2.60 (m, 1H, ArNHCH(CH3)CH2-), 2.60-
2.50 (m, 1H, ArNHCH(CH3)CH2-), 2.19 (m, 3H, -N(CH3)), 2.15 (ABq, 1H, HA, J = 14.0 Hz, -
CH2Ad), 2.10 (ABq, 1H, HB, J = 14.0 Hz, -CH2Ad), 1.98 (m, 3H, -Ad), 1.85-1.60 (m, 6H, -Ad), 
1.60-1.50 (m, 6H, -Ad), 1.29 (d, 3H, J = 6.0 Hz, -CH3).
 13
C-NMR (125 MHz, CDCl3): 152.04; 
150.24; 149.21; 134.75; 128.79; 125.14; 121.49; 118.21; 99.85; 71.62; 65.98; 46.18, 44.72; 
41.37; 37.20; 35.15; 28.40; 18.60. (+)ESI-HRMS (m/z (%)): 398.23694 (M+H+, 100); 
calculated 398.23575 (error in ppm: 2.99). Anal. (C24H32ClN3×2/3H2O) Calcd: C, 70.31; H, 
8.19;    10.25. Found:    70.29; H  8.40;    10.15. HP   purity (λ=330 nm : method  : RT 
7.838, area 98.86%; method B: RT 9.645, area 99.04%. 
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N
1
-(1-Adamantylmethyl)-N
3
-(7-chloroquinolin-4-yl)-N
1
-methylbutane-1,3-diamine (60). 
Compound 60 was prepared from aminoquinoline N
1
-(1-adamantylmethyl)-N
3
-(7-
chloroquinolin-4-yl)butane-1,3-diamine
4
 (248 mg, 0.62 mmol) and 37% formaldehyde (93 µL, 
1.25 mmol) using ZnCl2 (169 mg, 1.24 mmol) and NaBH3CN (156 mg, 2.48 mmol) by procedure 
D and was obtained after column chromatography: (SiO2, eluent: CH2Cl2/MeOH(NH3 satd) = 
95/5) as a white solid (222 mg, 87%) softenes at 48-50 °C. IR (ATR): 3251m, 3063w, 2902s, 
2845s, 1655w, 1611w, 1576s, 1538m, 1489w, 1452m, 1372w, 1332w, 1280w, 1201w, 1149m, 
1102w, 1080w, 1045w, 1007w, 983w, 877w, 850w, 806m, 766w, 737w, 648w cm
-1
. 
1
H-NMR 
(500 MHz, CDCl3): 8.49 (d, 1H, J = 5.5 Hz, H-C(2)), 7.95 (d, 1H, J = 2.5 Hz, H-C(8)), 7.83 (d, 
1H, J = 9.0 Hz, H-C(5)), 7.31 (dd, 1H, J = 9.0 Hz, J = 2.0 Hz, H-C(6)), 7.07 (bs, 1H, -NH), 6.40 
(d, 1H, J = 5.5 Hz, H-C(3)), 3.90-3.80 (m, 1H, ArNHCH(CH3)-), 2.75-2.65 (m, 1H, -
CH2N(CH3)CH2Ad), 2.65-2.40 (m, 1H, -CH2N(CH3)CH2Ad), 2.34 (m, 3H, -N(CH3)), 2.12 
(ABq, 1H, HA, J = 13.5 Hz, -CH2Ad), 2.04 (ABq, 1H, HB, J = 13.5 Hz, -CH2Ad), 1.95-1.85 (m, 
4H, -Ad, ArNHCH(CH3)CH2-), 1.80-1.45 (m, 14H, ArNHCH(CH3)CH2-, -Ad), 1.33 (d, 3H, J = 
6.5 Hz, ArNHCH(CH3)-).
 13
C-NMR (125 MHz, CDCl3): 151.68; 149.87; 149.04; 134.82; 
128.39; 124.75; 122.09; 117.68; 98.90; 72.28; 58.14; 48.64; 46.45; 41.61; 36.96; 34.74; 33.28; 
28.39; 19.63. (+)ESI-HRMS (m/z (%)): 412.25136 (M+H+, 100); calculated 412.25140 (error 
in ppm: -0.11). Anal. (C25H34ClN3  1/2 H2O) Calcd: C, 71.32; H, 8.38; N, 9.98. Found: C, 
71.32; H  8.20;    9.85. HP   purity (λ=330 nm : method A: RT 7.851, area 96.80%; method B: 
RT 9.605, area 96.30%. 
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N-[2-(1-Adamantyl)ethyl]-N'-(7-chloroquinolin-4-yl)-N-methylethane-1,2-diamine (61). 
Compound 61 was prepared from aminoquinoline N-[2-(1-adamantyl)ethyl]-N'-(7-
chloroquinolin-4-yl)ethane-1,2-diamine
5
 (54 mg, 0.14 mmol) and 37% formaldehyde (21 µL, 
0.28 mmol) using ZnCl2 (38 mg, 0.28 mmol) and NaBH3CN (35 mg, 0.56 mmol) by procedure D 
and was obtained after column chromatography (SiO2, eluent CH2Cl2/MeOH(NH3 satd) = 95/5) 
as a white solid (50 mg, 89%) softenes at 157-159 °C. IR (KBr): 3264m, 3064w, 2902s, 2843s, 
2787w, 1611w, 1581s, 1550w, 1508w, 1489w, 1451m, 1431w, 1366m, 1355w, 1333m, 1282w, 
1248w, 1203w, 1169w, 1145m, 1104w, 1083w, 1059w, 1041w, 1014w, 911w, 876m, 869w, 
838m, 818m cm
-1
. 
1
H-NMR (200 MHz, CDCl3): 8.53 (d, 1H, J = 5.6 Hz, H-C(2)), 7.95 (d, 1H, J 
= 2.2 Hz, H-C(8)), 7.68 (d, 1H, J = 9.0 Hz, H-C(5)), 7.36 (dd, 1H, J = 1.9 Hz, J = 8.7 Hz, H-
C(6)), 6.37 (d, 1H, J = 5.6 Hz, H-C(3)), 6.01 (bs, 1H, -NH), 3.35-3.20 (m, 2H, ArNHCH2-), 
2.80-2.65 (m, 2H, ArNHCH2CH2-), 2.55-2.40 (m, 2H, -CH2CH2Ad), 2.61 (s, 3H, -N(CH3)), 1.94 
(bs, 3H, -Ad), 1.80-1.55 (m, 6H, -Ad), 1.55-1.45 (m, 6H, -Ad), 1.40-1.20 (m, 2H, -CH2Ad). 
13
C-
NMR (50 MHz, CDCl3): 152.10; 149.85; 149.08; 134.75; 128.65; 125.16; 121.32; 117.35; 99.20; 
54.95; 51.93; 42.61; 41.42; 41.31; 39.58; 37.05; 31.86; 28.55. (+)ESI-HRMS (m/z (%)): 
398.23665 (M+H+, 100); calculated 398.23575 (error in ppm: 2.25). Anal. (C24H32ClN3  1/2 
H2O) Calcd: C, 70.83; H, 8.17; N, 10.32. Found: C, 70.36; H, 8.11; N, 10.30. HPLC purity 
(λ=330 nm : method  : RT 7.898  area 98.86%; method B: RT 9.851  area 95.82%. 
N-[2-(1-Adamantyl)ethyl]-N'-(7-chloroquinolin-4-yl)-N-methylpropane-1,3-diamine (62). 
Compound 62 was prepared from aminoquinoline N-[2-(1-adamantyl)ethyl]-N'-(7-
chloroquinolin-4-yl)propane-1,3-diamine
5
 (132 mg, 0.33 mmol) and 37% formaldehyde (50 µL, 
0.66 mmol) using ZnCl2 (90 mg, 0.66 mmol) and NaBH3CN (83 mg, 1.32 mmol) by procedure D 
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and was obtined after column chromatography (SiO2, eluent: CH2Cl2/MeOH(NH3 satd) = 95/5) 
as a white solid (113 mg, 84%) softenes at 101-103 °C. IR (ATR): 3245m, 3064w, 2899s, 
2844m, 2786w, 1610w, 1578s, 1541w, 1508w, 1497w, 1473w, 1452m, 1430w, 1396w, 1366m, 
1331w, 1282w, 1231w, 1202w, 1168w, 1140w, 1098w, 1080w, 1038w, 900w, 870w, 845w, 
804w, 769w, 644w cm
-1
. 
1
H-NMR (200 MHz, CDCl3): 8.49 (d, 1H, J = 5.6 Hz, H-C(2)), 8.08 
(bs, 1H, -NH), 7.92 (d, 1H, J = 1.6 Hz, H-C(8)), 7.61 (d, 1H, J = 9.0 Hz, H-C(5)), 7.31 (dd, 1H, J 
= 2.3 Hz, J = 8.9 Hz, H-C(6)), 6.29 (d, 1H, J = 5.6 Hz, H-C(3)), 3.45-3.30 (m, 2H, ArNHCH2-), 
2.70-2.55 (m, 2H, ArNHCH2CH2CH2-), 2.55-2.40 (m, 2H, -CH2CH2Ad), 2.33 (s, 3H, -N(CH3)), 
1.91 (bs, 3H, -Ad), 1.80-1.50 (m, 8H, ArNHCH2CH2-, Ad), 1.46 (bs, 6H, -Ad), 1.40-1.30 (m, 
2H, -CH2Ad). 
13
C-NMR (50 MHz, CDCl3): 152.12; 150.68; 149.14; 134.50; 128.45; 124.67; 
122.15; 117.62; 98.19; 58.06; 52.28; 44.37; 42.42; 42.01; 41.48; 37.00; 31.68; 28.48; 24.07. 
(+)ESI-HRMS (m/z (%)): 412.25106 (M+H+, 100); calculated 412.25140 (error in ppm: -0.83). 
Anal. (C25H34ClN3  1/2 H2O) Calcd: C, 71.32; H, 8.38; N, 9.98. Found: C, 71.54; H, 8.02; N, 
10.07. HP   purity (λ=330 nm : method  : RT 7.999  area 99.74%; method B: RT 9.940  area 
99.04%. 
N-[2-(1-Adamantyl)ethyl]-N'-(7-chloroquinolin-4-yl)-N-methylbutane-1,4-diamine (63). 
Compound 63 was prepared from aminoquinoline N-[2-(1-adamantyl)ethyl]-N'-(7-
chloroquinolin-4-yl)butane-1,4-diamine
5
 (194 mg, 0.47 mmol) and 37% formaldehyde (71 µL, 
0.94 mmol) using ZnCl2 (128 mg, 0.94 mmol) and NaBH3CN (118 mg, 1.88 mmol) by procedure 
D and was obtained after column chromatography (SiO2, eluent: CH2Cl2/MeOH(NH3 satd) = 
95/5) as a white solid (172 mg, 86%) softenes at 136-138 °C. IR (ATR): 3232m, 3064w, 2906s, 
2844m, 2367w, 1610w, 1580s, 1542w, 1522w, 1508w, 1490w, 1454m, 1430w, 1386w, 1367m, 
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1331m, 1279w, 1256w, 1225w, 1200w, 1167w, 1139w, 1074w, 1039w, 1028w, 898w, 869w, 
852w, 821w, 805w, 770w, 734w, 644w, 637w cm
-1
. 
1
H-NMR (200 MHz, CDCl3): 8.49 (d, 1H, J 
= 5.6 Hz, H-C(2)), 7.92 (d, 1H, J = 2.2 Hz, H-C(8)), 7.73 (d, 1H, J = 9.0 Hz, H-C(5)), 7.29 (dd, 
1H, J = 1.9 Hz, J = 8.7 Hz, H-C(6)), 6.61 (bs, 1H, -NH), 6.34 (d, 1H, J = 5.6 Hz, H-C(3)), 3.35-
3.15 (m, 2H, ArNHCH2CH2CH2CH2N(CH3)-), 2.50-2.30 (m, 4H, ArNHCH2CH2CH2-, -
CH2CH2Ad), 2.19 (s, 3H, -N(CH3)), 1.94 (bs, 3H, -Ad), 1.80-1.55 (m, 10H, ArNHCH2CH2-, 
ArNHCH2CH2CH2-, -Ad), 1.48 (bs, 6H, -Ad), 1.40-1.20 (m, 2H, -CH2Ad). 
13
C-NMR (50 MHz, 
CDCl3): 151.98; 150.28; 149.10; 134.52; 128.42; 124.67; 121.83; 117.38; 98.72; 56.90; 51.42; 
43.28; 42.61; 42.41; 40.99; 37.00; 31.63; 28.50; 26.60; 25.36. (+)ESI-HRMS (m/z (%)): 
426.26631 (M+H+, 100); calculated 426.26705 (error in ppm: -1.75). Anal. (C26H36ClN3  1/3 
H2O   al d:    72.28; H  8.55;    9.73. Found:    72.17; H  8.82;    9.71. HP   purity (λ=330 
nm): method A: RT 7.898, area 99.37%; method B: RT 9.855, area 99.17%. 
N
1
-[2-(1-Adamantyl)ethyl]-N
2
-(7-chloroquinolin-4-yl)-N
1
-methylpropane-1,2-diamine (64). 
Compound 64 was prepared from aminoquinoline N
1
-[2-(1-adamantyl)ethyl]-N
2
-(7-
chloroquinolin-4-yl)propane-1,2-diamine
4
 (27 mg, 0.07 mmol) and 37% formaldehyde (11 µL, 
0.14 mmol) using ZnCl2 (19 mg, 0.14 mmol) and NaBH3CN (18 mg, 0.28 mmol) by procedure D 
and was obtained after column chromatography (SiO2, eluent; CH2Cl2/MeOH(NH3 satd) = 95/5) 
a white solid (27 mg, 93%) softenes at 138-140 °C. IR (ATR): 3275m, 2964w, 2901s, 2844m, 
2799w, 2346w, 1610w, 1575s, 1541m, 1500w, 1490w, 1451m, 1425w, 1381w, 1366w, 1341w, 
1331w, 1273w, 1254w, 1198w, 1153w, 1126w, 1104w, 1078w, 1045w, 909w, 872m, 839w, 
820w, 802w, 769w cm
-1
. 
1
H-NMR (500 MHz, CDCl3): 8.52 (d, 1H, J = 5.0 Hz, H-C(2)), 7.95 (d, 
1H, J = 2.0 Hz, H-C(8)), 7.71 (d, 1H, J = 9.0 Hz, H-C(5)), 7.35 (dd, 1H, J = 2.5 Hz, J = 9.0 Hz, 
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H-C(6)), 6.44 (d, 1H, J = 5.5 Hz, H-C(3)), 5.96 (d, 1H, J = 3.0 Hz, ArNH-), 3.70-3.55 (m, 1H, 
ArNHCH(CH3)-), 2.70-2.55 (m, 1H, ArNHCH(CH3)CH2-), 2.50-2.30 (m, 3H, 
ArNHCH(CH3)CH2-, -CH2CH2Ad), 2.20 (s, 3H, -N(CH3)), 1.90 (bs, 3H, -Ad), 1.75-1.50 (m, 6H, 
-Ad), 1.45 (bs, 6H, -Ad), 1.30 (d, 3H, J = 6.0 Hz, ArNHCH(CH3)-), 1.30-1.15 (m, 2H, -CH2Ad). 
13
C-NMR (125 MHz, CDCl3): 151.98; 149.87; 149.22; 134.68; 128.66; 125.13; 121.44; 118.06; 
99.70; 62.58; 52.04; 45.59; 42.55; 42.10; 41.36; 37.06; 31.82; 28.58; 18.69. (+)ESI-HRMS (m/z 
(%)): 412.25217 (M+H+, 100); calculated 412.25140 (error in ppm: 1.86). Anal. (C25H34ClN3  
1/2 H2O) Calcd: C, 71.32; H, 8.38; N, 9.98. Found: C, 71.57; H, 8.72; N, 9.98. HPLC purity 
(λ=330 nm : method  : RT 7.811  area 98.20%; method B: RT 9.832  area 98.83%. 
N
1
-[2-(1-Adamantyl)ethyl]-N
3
-(7-chloroquinolin-4-yl)-N
1
-methylbutane-1,3-diamine (65). 
Compound 65 was prepared from aminoquinoline N
1
-[2-(1-adamantyl)ethyl]-N
3
-(7-
chloroquinolin-4-yl)butane-1,3-diamine
4 
(140 mg, 0.34 mmol) and 37% formaldehyde (54 µL, 
0.68 mmol) using ZnCl2 (93 mg, 0.68 mmol) and NaBH3CN (85 mg, 1.36 mmol) by procedure D 
and was obtained after column chromatography (SiO2, eluent: CH2Cl2/MeOH(NH3 satd) = 95/5) 
as a white solid (116 mg, 80%) softenes at 54-56 °C. IR (ATR): 3236m, 2902s, 2845s, 2611w, 
1578s, 1541m, 1488w, 1450m, 1428w, 1375w, 1330w, 1281w, 1243w, 1200w, 1152m, 1098w, 
1078w, 1048w. 878w, 849w, 806m, 765w, 644w cm
-1
. 
1
H-NMR (500 MHz, CDCl3): 8.47 (d, 
1H, J = 5.0 Hz, H-C(2)), 8.00 (d, 1H, J = 4.9 Hz, -NH), 7.92 (d, 1H, J = 2.0 Hz, H-C(8)), 7.65 (d, 
1H, J = 9.0 Hz, H-C(5)), 7.30 (dd, 1H, J = 2.0 Hz, J = 9.0 Hz, H-C(6)), 6.34 (d, 1H, J = 5.5 Hz, 
H-C(3)), 3.90-3.80 (m, 1H, ArNHCH(CH3)-), 2.85-2.75 (m, 1H, ArNHCH(CH3)CH2CH2-), 2.50-
2.40 (m, 3H, ArNHCH(CH3)CH2CH2-, -CH2CH2Ad), 2.31 (s, 3H, -N(CH3)), 2.05-1.95 (m, 1H, 
ArNHCH(CH3)CH2-), 1.92 (bs, 3H, -Ad), 1.75-1.55 (m, 7H, ArNHCH(CH3)CH2, -Ad), 1.44 (m, 
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6H, -Ad), 1.35-1.25 (m, 5H, -CH2Ad, -CH3).
 13
C-NMR (125 MHz, CDCl3): 151.86; 149.94; 
149.27; 134.61; 128.42; 124.65; 122.25; 117.85; 98.50; 54.42; 52.32; 48.65; 42.47; 42.08; 41.37; 
37.07; 31.75; 31.50; 28.58; 18.90. (+)ESI-HRMS (m/z (%)): 426.26541 (M+H+, 100); 
calculated 426.26705 (error in ppm: -3.85). Anal. (C26H36ClN3  H2O) Calcd: C, 70.32; H, 8.63; 
   9.46. Found:    69.70; H  9.05;    9.38. HP   purity (λ=330 nm : method  : RT 8.531  area 
97.77%; method B: RT 9.909, area 96.78%. 
N-(1-Adamantylmethyl)-N'-quinolin-4-ylpropane-1,3-diamine (66). 
Compound 66 was prepared from AQ7 (1.4 g, 6.96 mmol) and adamantane-1-carboxaldehyde 
(952 mg, 5.80 mmol) using AcOH (370 µL, 6.96 mmol) and NaBH4 (1.36 g, 34.80 mmol) by 
procedure E and was obtained after flash chromatography (SiO2, gradient: Hex/EtOAc = 
4/6→1/9) as a colorless foam (1.21 g, 60%). IR (ATR): 3290m, 2901s, 2846s, 1657w, 1619w, 
1584s, 1544m, 1451m, 1372w, 1340w, 1285w, 1225w, 1151w, 1131w, 1100w, 1041m, 807w, 
762m cm
-1
. 
1
H-NMR (500 MHz, CDCl3): 8.51 (d, 1H, J = 5.3 Hz, H-C(2)), 7.94 (d, 1H, J = 8.5 
Hz, H-C(8)), 7.89 (d, 1H, J = 8.2 Hz, H-C(5)), 7.58 (t, 1H, J = 7.7 Hz, H-C(7)), 7.32 (t, 1H, J = 
7.6 Hz, H-C(6)), 7.14 (bs, 1H, -NH), 6.33 (d, 1H, J = 5.3 Hz, H-C(3)), 3.36 (s, 2H, ArNHCH2-), 
2.90-2.78 (m, 2H, -CH2NHCH2Ad), 2.29 (s, 2H, -CH2Ad), 2.05-1.95 (m, 3H, -Ad), 1.93-1.83 (m, 
2H, ArNHCH2CH2-), 1.8-1.67 (m, 6H, -Ad), 1.65-1.55(m, 6H, -Ad). 
13
C-NMR (125 MHz, 
CDCl3): 150.89; 150.48; 148.11; 129.33; 128.81; 123.94; 120.66; 118.94; 98.13; 63.56; 50.62; 
43.86; 41.05; 37.10; 33.24; 28.38; 27.60. (+)ESI-HRMS (m/z (%)): 350.25906 (M+H+, 100); 
calculated 350.25907 (error in ppm: -0.05 . HP   purity (λ=330 nm : method  : RT 7.531  area 
95.70%; method B: RT 8.193, area 95.60%. 
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N-[2-(1-Adamantyl)ethyl]-N'-quinolin-4-ylpropane-1,3-diamine (67). 
Compound 67 was prepared from AQ7 (185 mg, 0.92 mmol) and adamantyl-1-acetaldehyde 
(136mg, 0.77 mmol) using AcOH (63 µL, 1.10 mmol) and NaBH4 (209 mg, 5.52 mmol) by 
procedure E and was obtained after flash chromatography (SiO2, gradient: Hex/EtOAc = 
4/6→1/9) as a colorless foam (195 mg, 70%). IR (ATR): 3250m, 3072w, 2902s, 2844m, 1612w, 
1583s, 1544m, 1446m, 1399w, 1371w, 1339w, 1284w, 1242w, 1131w, 808w, 762w cm
-1
. 
1
H-
NMR (500 MHz, CDCl3): 8.52 (d, 1H, J = 5.3 Hz, H-C(2)), 7.95 (dd, 1H, J = 0.8 Hz, J = 8.5 Hz,  
H-C(8)), 7.82 (dd, 1H, J = 0.9 Hz, J = 8.4 Hz, H-C(5)), 7.74 (bs, 1H, -NH), 7.65-7.58 (m, 1H, H-
C(7)), 7.42-7.25 (m, 1H, H-C(6)), 6.32 (d, 1H, J = 5.2 Hz, H-C(3)), 3.45-3.35 (m, 2H, 
ArNHCH2-), 2.95-2.85 (m, 2H, -CH2NHCH2Ad), 2.75-2.60 (m, 2H, -CH2CH2Ad), 2.00-1.85 (m, 
5H, ArNHCH2CH2-, -Ad), 1.75-1.60 (m, 6H, -Ad), 1.55-1.45 (m, 6H, -Ad), 1.45-1.35 (-CH2Ad). 
13
C-NMR (125 MHz, CDCl3): 150.99; 150.61; 148.26; 129.40; 128.80; 124.02; 120.61; 119.13; 
97.88; 49.61; 44.94; 44.42; 43.84; 42.65; 37.06; 31.83; 28.59; 27.47. HP   purity (λ=330 nm : 
method A: RT 7.661, area 96.48%; method B: RT 7.311, area 95.26% 
N-(1-Adamantylmethyl)-N-methyl-N'-quinolin-4-ylpropane-1,3-diamine (68). 
Compound 68 was prepared from aminoquinoline 66 (1.2 g, 3.43 mmol) and 36% formaldehyde 
(529 µL, 6.87 mmol) using ZnCl2 (936 mg, 6.87 mmol) and NaHB3CN (862 mg, 13.72 mmol) by 
procedure D and was obtained after multiple chromatography: dry-flash (SiO2, eluent: 
CH2Cl2/MeOH(NH3 satd) = 95/5) and flash chromatography (Biotage SP1 NH column, gradient: 
Hex/EtOAc = 3/7→1/9) as a white foam. Yield: 900 mg (72%). IR (ATR): 3291m, 3078w, 
2901s, 2846s, 1659w, 1619w, 1584s, 1544m, 1454m, 1374w, 1342w, 1229w, 1176w, 1132w, 
1104w, 1042m, 984w, 887w, 809w, 764m, 738w, 598w cm
-1
. 
1
H-NMR (500 MHz, CDCl3): 8.55 
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(d, 1H, J = 5.3 Hz, H-C(2)), 7.98 (d, 1H, J = 8.5 Hz, H-C(8)), 7.87 (d, 1H, J = 7.8 Hz, H-C(5)), 
7.65-7.55 (m, 1H, H-C(7)), 7.45-7.33 (m, 1H, H-C(6)), 6.98 (bs, 1H, -NH), 6.38 (d, 1H, J = 5.3 
Hz, H-C(3)), 3.47-3.35 (m, 2H, ArNHCH2-), 2.68-2.55 (m, 2H, -CH2NHCH2Ad), 2.39 (s, 3H, -
NCH3), 2.08 (s, 2H, -CH2Ad), 1.95-1.83 (m, 5H, ArNHCH2CH2-, -Ad) 1.70-1.40 (m, 12H, -Ad). 
13
C-NMR (125 MHz, CDCl3): 150.86; 150.50; 148.15; 129.42; 128.90; 124.13; 120.36; 119.04; 
98.29; 72.53; 60.76; 46.11; 43.86; 41.47; 36.95; 34.77; 28.35; 25.82. (+)ESI-HRMS (m/z (%)): 
364.27455 (M+H+, 100); calculated 364.27472 (error in ppm: -0.48). Anal. (C24H33N3  
1/2H2O) Calculated: C, 77.37; H, 9.20; N, 11.28 Found: C, 77.49; H, 9.11; N, 11.36. HPLC 
purity (λ=330 nm : method  : RT 7.800  area 99.24%; method B: RT 9.268  area 98.89%. 
N-[2-(1-Adamantyl)ethyl]-N-methyl-N'-quinolin-4-ylpropane-1,3-diamine (69). 
Compound 69 was prepared from aminoquinoline 67 (220 mg, 0.60 mmol) and 36% 
formaldehyde (93 µL, 1.20 mmol) using ZnCl2 (165 mg, 1.20 mmol) and NaHB3CN (151 mg, 
2.4 mmol) by procedure D and was obtained after dry-flash chromatography (SiO2, eluent: 
CH2Cl2/MeOH(NH3 satd) = 95/5) as a white solid (167 mg, 73%). IR (ATR): 3236m, 3070w, 
2901s, 2844s, 1582s, 1544m, 1445m, 1397w, 1372w, 1339w, 1235w, 1133w, 1046w, 857w, 
808w, 764w cm
-1
. 
1
H-NMR (500 MHz, CDCl3): 8.53 (d, 1H, J = 5.3 Hz, H-C(2)), 7.98 (d, 1H, J 
= 8.4 Hz, H-C(8)), 7.88 (bs, 1H, -NH), 7.75 (d, 1H, J = 8.2 Hz, H-C(5)), 7.67-7.55 (m, 1H, H-
C(7)), 7.45-7.35 (m, 1H, H-C(6)), 6.33 (d, 1H, J = 5.3 Hz, H-C(3)), 3.47-3.33 (m, 2H, 
ArNHCH2-), 2.70-2.65 (m, 2H, -CH2NHCH2CH2Ad), 2.53-2.40 (m, 2H, -CH2CH2Ad), 2.35 (s, 
3H, -NCH3), 2.00-1.85 (m, 5H, ArNHCH2CH2-, -Ad) 1.75-1.65 (m, 6H, -Ad) 1.47 (m, 6H, -Ad), 
1.40-1.30 (m, 2H, -CH2Ad). 
13
C-NMR (125 MHz, CDCl3): 150.85; 150.69; 147.94; 129.91; 
128.92; 124.16; 120.54; 119.10; 97.91; 57.83; 52.29; 44.18; 42.46; 41.98; 41.36; 37.06; 31.74; 
S81 
 
 
28.56; 24.35. (+)ESI-HRMS (m/z (%)): 378.29024 (M+H+, 100); calculated 378.29037 (error 
in ppm: -0.36). Anal. (C25H35N3  1/2H2O) Calculated: C, 77.67; H, 9.39; N, 10.87. Found: C, 
77.22; H  9.44;    11.03. HP   purity (λ=330 nm : method  : RT 7.931  area 98.67%; method 
B: RT 9.534, area 96.77%. 
N
2
-(1-Adamantylmethyl)-N
1
-quinolin-4-ylpropane-1,2-diamine (77). 
Compound 77 was prepared from amine linker 70
4
 (110 mg, 0.49 mmol) and 4-chloroquinoline 
(81 mg, 0.49 mmol) in phenol (692 mg, 7.35 mmol). The mixture was heated at 120-130 °C for 
24 h, cooled to r.t. and taken up in CH2Cl2. The organic layer was washed several times with 
NaOH and brine. The organic layer was dried over anh. Na2SO4 and solvent was removed under 
reduced pressure. The final product was obtained after multiple chromatography: dry-flash 
(SiO2, eluent: CH2Cl2/MeOH(NH3 satd) = 9/1) and flash chromatography (Biotage SP1 RP 
column, eluent: MeOH/H2O = 9/1) as a yellow solid (102 mg, 60%). IR (ATR): 3364m, 3303w, 
2897s, 2843s, 1589s, 1534s, 1483w, 1453m, 1395w, 1366w, 1300w, 1246w, 1161w, 803w, 
757w cm
-1
. 
1
H-NMR (500 MHz, CDCl3): 8.55 (d, 1H, J = 5.0 Hz, H-C(2)), 7.99 (d, 1H, J = 8.0 
Hz, H-C(8)), 7.81 (d, 1H, J = 8.0 Hz, H-C(5)), 7.66-7.61 (m, 1H, H-C(7)), 7.46-7.40 (m, 1H, H-
C(6)), 6.38 (d, 1H, J = 5.5 Hz, H-C(3)), 6.26 (bs, 1H, -NH), 3.38-3.31 (m, 1H, 
ArNHCH2CH(CH3)-), 3.07-3.01 (m, 1H, -(CH2CH3)CHNHCH2Ad), 3.00-2.93 (m, 1H, -
(CH2CH3)CHNHCH2Ad), 2.44 (ABq, 1H, HA, J = 11.4 Hz, -CH2Ad), 2.17 (ABq, 1H, HB, J = 
11.4 Hz, -CH2Ad), 2.00 (s, 3H, -Ad), 1.80-1.49 (m, 12H, -Ad), 1.24 (d, 3H, J = 6.2 Hz, -CH3).
 
13
C-NMR (125 MHz, CDCl3): 150.98; 150.12; 148.28; 129.70; 128.93; 124.42; 119.66; 119.04; 
98.87; 59.17; 52.29; 46.91; 40.93; 37.22; 33.47; 28.44; 19.53. (+)ESI-HRMS (m/z (%)): 
367.25596 (M+H+, 100); calculated 367.28562 (error in ppm: +1.28). Anal. (C23H31N3 2/3 
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H2O) Calcd.:    76 41; H  9 01;    11 62; Found:    76 33; H  8 56;    11 34. HP   purity (λ= 
330 nm) method A: RT 7.904 min., area 95.56%; method B: RT 9.308 min., area 95.43%. 
N
3
-(1-Adamantylmethyl)-N
1
-quinolin-4-ylbutane-1,3-diamine (78). 
Compound 78 was prepared from amine linker 71
4
 (370 mg, 1.54 mmol) and 4-chloroquinoline 
(233 mg, 1.42 mmol) using Pd(OAc)2 (12.8 mg, 0.057 mmol), SPhos (51.4 mg, 0.11 mmol) and 
K3PO4 (750 mg, 3.55 mmol) by procedure H and was obtained after dry-flash chromatography 
(SiO2, gradient: EtOAc/[MeOH/(NH3 aq.) = 9/1] = 9/1→7/3). Yield: 473 mg (91%). IR (ATR): 
3263s, 3067w, 2900s, 2845m, 1711w, 1582s, 1541m, 1450m, 1373w, 1340w, 1251w, 1224w, 
1134w, 808w, 763m, 735w cm
-1
. 
1
H-NMR (500 MHz, CDCl3): 8.53 (d, 1H, J = 5.3 Hz, H-C(2)), 
7.96 (d, 1H, J = 8.5 Hz, H-C(8)), 7.89 (d, 1H, J = 8.25 Hz, H-C(5)), 7.60 (t, 1H, J = 7.6 Hz, H-
C(7)), 7.34 (t, 1H, J = 7.6 Hz, H-C(6)), 7.22 (bs, 1H, -NH), 6.36 (d, 1H, J = 5.5 Hz, H-C(3)), 
3.55-3.30 (m, 2H, ArNHCH2-), 2.93-2.80 (m, 1H, ArNHCH2CH2CH(CH3)-), 2.40 (ABq, 1H, HA, 
J = 11.4 Hz, -CH2Ad), 2.30 (ABq, 1H, HB, J = 11.4 Hz, -CH2Ad), 1.99 (s, 3H, -Ad), 1.80-1.68 
(m, 6H, -Ad), 1.67-1.50 (m, 8H, ArNHCH2CH2-, -Ad), 1.17 (d, 3H, J = 6.6 Hz, -CH3).
 13
C-NMR 
(125 MHz, CDCl3): 151.01; 150.45; 148.25; 129.48; 128.83; 123.97; 120.68; 119.06; 98.24; 
60.89; 54.28; 41.52; 41.11; 37.15; 33.41; 33.26; 28.42; 19.82. (+)ESI-HRMS (m/z (%)): 
364.27468 (M+H+, 100); calculated 364.27472 (error in ppm: -0.12). Anal. (C24H33N3  H2O) 
 al d:    75.55; H  9.25;    11.01. Found    75.20; H  8.74;    10.86. HP   purity (λ= 330 nm  
method A: RT 7.898 min. area 97.80%; method B: RT 9.348 min., area 97.14%. 
N
4
-(1-adamantylmethyl)-N
1
-quinolin-4-ylpentane-1,4-diamine (79). 
Compound 79 was prepared from amine linker 72
4
 (389 mg, 1.54 mmol) and 4-chloroquinoline 
(231 mg, 1.41 mmol) using Pd(OAc)2 (12.7 mg, 0.056 mmol), SPhos (46.3 mg, 0.11 mmol) and 
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K3PO4 (749 mg, 3.52 mmol) by procedure H and was obtained after dry-flash chromatography 
(SiO2, gradient: CH2Cl2/[MeOH/(NH3 aq.) = 9/1] = 9/1→7/3). Yield: 235 mg (44%). IR (ATR): 
3324m, 3219m, 3057m, 2903s, 2847m, 1582s, 1460m, 1435s, 1396m, 1339w, 1261w, 1220m, 
1175m, 1123m, 1072w, 805w, 764m, 696m, 646w, 545m cm
-1
. 
1
H-NMR (500 MHz, CDCl3): 
8.54 (d, 1H, J = 5.5 Hz, H-C(2)), 7.98 (d, 1H, J = 7.8 Hz, H-C(8)), 7.79 (d, 1H, J = 7.8 Hz, H-
C(5)), 7.60 (t, 1H, J = 7.0 Hz, H-C(7)), 7.45-7.35 (m, 1H, H-C(6)), 6.41 (d, 1H, J = 5.5 Hz, H-
C(3)), 5.54 (bs, 1H, -NH), 3.40-3.25 (m, 2H, ArNHCH2-), 2.75-2.60 (m, 1H, -
(CH3)CHNHCH2Ad), 2.29 (ABq, 1H, HA, J = 11.3 Hz, -CH2Ad), 2.20 (ABq, 1H, HB, J = 11.3 
Hz, -CH2Ad), 1.96 (s, 3H, -Ad), 1.89-1.76 (m, 2H, ArNHCH2CH2-), 1.74-1.59 (m, 6H, -Ad), 
1.58-1.45 (m, 8H, ArNHCH2CH2CH2-, -Ad), 1.08 (d, 3H, J = 6.4 Hz, -CH3). 
13
C-NMR (125 
MHz, CDCl3): 150.73; 149.98; 148.08; 129.58; 129.01; 124.44; 119.67; 118.74; 98.59; 59.34; 
53.11; 43.40; 40.95; 37.17; 34.08; 33.28; 28.42; 24.95; 20.48. (+)ESI-HRMS (m/z (%)): 
378.28996 (M+H+, 100); calculated 378.29037 (error in ppm: -1.08). Anal. (C25H35N3x3/2H2O) 
 al d:    77.08; H  9.40;    10.79. Found:    77.10; H  8.95;    10.87. HP   purity (λ=330 
nm): method A: RT 7.560, area 95.16%; method B: RT 8.832, area 95.67%. 
N
2
-[2-(1-Adamantyl)ethyl]-N
1
-quinolin-4-ylpropane-1,2-diamine (80). 
Amine linker 73
4
 (260 mg, 1.10 mmol) and 4-chloroquinoline (180 mg, 1.10 mmol) were mixed 
in NMP (1.5 ml) in MW cuvette under argon. The reaction mixture was subjected to MW 
irradiation using a Biotage Initiator 2.5 apparatus, 1 h, 180 
o
C. Compound 80 was obtained after 
multiple chromatography: dry-flash (SiO2, eluent: EtOAc/MeOH/(NH3 aq.) 90/9/1 = 95/5) and 
flash chromatography (Biotage SP1-NH column, eluent: Hex/EtOAc = 6/4; RP column eluent: 
MeOH/H2O = 8/2). Yield: 253 mg (63%); mp = 112-113 
o
C. IR (ATR): 3251 m, 3059 m, 2962 
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m , 2902 s, 2844 s, 1708 w, 1618 w, 1578 s, 1543 s, 1451 s, 1396 s, 1374 m, 1343 m, 1280 w, 
1258 w, 1159 w, 1130 w, 1108 w, 909 w, 807 w, 763 m, 733 w cm
-1
. 
1
H-NMR (500 MHz, 
CDCl3): 8.53 (d, 1H, J = 5.3 Hz, H-C(2)), 7.97 (d, 1H, J = 8.0 Hz, H-C(8)), 7.81-7.76 (m, 1H, H-
C(5)), 7.65-7.59 (m, 1H, H-C(7)), 7.46-7.37 (m, 1H, H-C(6)), 6.45 (d, 1H, J = 5.4 Hz, H-C(3)), 
5.69 (bs, 1H, -NH), 3.87-3.73 (m, 1H, ArNHCH(CH3)-), 2.91-2.81 (m, 2H, -
CH2NHCH2CH2Ad), 2.70-2.61 (m, 2H, -CH2CH2Ad), 1.93 (m, 3H, -Ad), 1.73-1.57 (m, 7H, -NH 
-Ad), 1.55-1.44 (m, 6H, -Ad), 1.36-1.24 (m, 2H, -CH2Ad), 1.18 (d, 3H, J = 6.2 Hz, -CH3).
 13
C-
NMR (125 MHz. CDCl3): 150.94; 149.21; 148.52; 129.81; 128.93; 124.45; 119.59;119.12; 
99.13; 54.69; 47.52; 44.79; 44.53; 42.69; 37.10; 31.91; 28.63; 18.30. (+)ESI-HRMS (m/z (%)): 
364.27554 (M+H+, 100); calculated 364.27472 (error in ppm: -0.59). Anal. (C24H33N3  H2O) 
 al ulated:    75.55; H  9.25;    11.01. Found:    75.91; H  8.82;    11.08. HP   purity (λ= 
330 nm) method A: RT 7.840 min. area 96.96%; method B: RT 9.480 min., area 96.39%. 
N
3
-[2-(1-Adamantyl)ethyl]-N
1
-quinolin-4-ylbutane-1,3-diamine (81). 
Compound 81 was prepared from amine linker 74
4
 (22.6 mg, 0.09 mmol) and 4-chloroquinoline 
(13.4 mg, 0.08 mmol) using Pd(OAc)2 (0.7 mg, 0.003 mmol), SPhos (2.7 mg, 0.007 mmol) and 
K3PO4 (43.5 mg, 0.20 mmol) by procedure H and was obtained after multiple chromatography: 
dry-flash (SiO2, gradient: pure EtOAc; gradient: CH2Cl2/[MeOH/(NH3 aq.) = 9/1] =9/1→7/3) 
and flash chromatography (Biotage SP1-NH column, eluent: Hex/EtOAc = 7/3; RP column 
eluent: MeOH/H2O = 9/1). Yield: 6.5 mg (21%). IR (ATR): 3250m, 3065w, 2902s, 2845s, 
2675w, 1664w, 1618w, 1584s, 1543m, 1449m, 1372w, 1341w, 1248w, 1134w, 808w, 763w, 
734w cm
-1
.
 1
H-NMR (500 MHz, CDCl3): 8.52 (d, 1H, J = 5.3 Hz, H-C(2)), 8.08 (bs, 1H, -NH), 
7.95 (d, 1H, J = 8.5 Hz, H-C(8)), 7.82 (dd, 1H, J = 0.9 Hz, J = 8.4 Hz, H-C(5)), 7.65-7.57 (m, 
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1H, H-C(7)), 7.40-7.35 (m, 1H, H-C(6)), 6.31 (d, 1H, J = 5.2 Hz, H-C(3)), 3.50-3.40 (m, 1H, 
ArNHCH2-), 3.40-3.30 (m, 1H, ArNHCH2-), 3.05-2.90 (m, 1H, ArNHCH2CH2(CH3)CH-), 2.85-
2.70 (m, 1H, -NHCH2CH2Ad), 2.70-2.55 (m, 1H, -NHCH2CH2Ad), 1.94 (s, 3H, -Ad), 1.80-1.55 
(m, 7H, ArNHCH2CH2-, -Ad), 1.55-1.40 (m, 7H, ArNHCH2CH2-, -Ad), 1.40-1.25 (m, 1H, -
CH2Ad), 1.20 (d, 3H, J = 6.6 Hz, -CH3).
 13
C-NMR (125 MHz, CDCl3): 151.18; 150.60; 148.43; 
129.59; 128.76; 123.92; 120.80; 119.27; 97.86; 45.51; 42.83; 42.41; 41.90; 41.67 37.10; 33.30; 
31.93; 28.63; 20.23. (+)ESI-HRMS (m/z (%)): 378.29011 (M+H+, 100); calculated 378.29037 
(error in ppm: -0.70). Anal. (C25H33N3  1/2H2O) Calculated: C, 77.67; H, 9.39; N, 10.87. Found 
   77.62; H  9.38;    10.82. HP   purity (λ= 330 nm  method  : RT 7.919 min. area 99.19%; 
method B: RT 8.491 min., area 98.62%. 
N
4
-[2-(1-Adamantyl)ethyl]-N
1
-quinolin-4-ylpentane-1,4-diamine (82). 
Compound 82 was prepared from amine linker 75 (410 mg, 1.55 mmol) and 4-chloroquinoline 
(231 mg, 1.41 mmol) using Pd(OAc)2 (12.7 mg, 0.056 mmol), SPhos (46.3 mg, 0.11 mmol) and 
K3PO4 (749 mg, 3.52 mmol) by procedure H and was obtained after multiple chromatography: 
dry-flash (SiO2, eluent: pure EtOAc; gradient: CH2Cl2/[MeOH/(NH3 aq.) = 9/1] = 9/1→7/3) and 
flash chromatography (Biotage SP1 NH column, eluent: Hex/EtOAc =1/9). Yield: 293 mg 
(53%). IR (ATR): 3245w, 3067w, 2902s, 2845m, 1616w, 1582s, 1543m, 1448m, 1373w, 1341w, 
1130w, 765w, 638w, 596w, 524w, 495w, 410w cm
-1
. 
1
H-NMR (500 MHz, CDCl3): 8.54 (d, 1H, 
J = 5.5 Hz, H-C(2)), 7.98 (d, 1H, J = 8.3 Hz, H-C(8)), 7.77 (d, 1H, J = 8.3 Hz, H-C(5)), 7.63 (t, 
1H, J = 7.0 Hz, H-C(7)), 7.42 (t, 1H, J = 7.6 Hz, H-C(6)), 6.41 (d, 1H, J = 5.5 Hz, H-C(3)), 5.65 
(bs, 1H, -NH), 3.40-3.27 (m, 2H, ArNHCH2-), 2.78-2.73 (m, 1H, -CHNHCH2CH2Ad), 2.72-2.64 
(m, 1H, -CH2CH2Ad), 2.63-2.53 (m, 1H, -CH2CH2Ad), 2.05-1.90 (m, 3H, -Ad), 1.89-1.75 (m, 
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2H, ArNHCH2CH2-), 1.73-1.60 (m, 8H, ArNHCH2CH2CH2-, -Ad), 1.52-1.45 (m, 6H, -Ad), 
1.32-1.24 (m, 2H, -CH2Ad), 1.11 (d, 3H, J = 6.2 Hz, -CH3). 
13
C-NMR (125 MHz, CDCl3): 
150.93; 149.91; 148.32; 129.72; 128.91; 124.39; 119.73; 118.83; 98.58; 52.91; 44.64; 43.41; 
42.59; 41.29; 37.07; 34.43; 31.85; 28.61; 24.96; 20.12. (+)ESI-HRMS (m/z (%)): 392.30476 
(M+H+, 100); calculated 392.30602 (error in ppm: -0.88). Anal. (C26H37N3  2H2O) Calcd: C, 
73.03; H  9.56;    9.83. Found:    73.34; H  9.30;    9.81. HP   purity (λ=330 nm : method  : 
RT 7.675, area 97.58%; method B: RT 9.162, area 96.45%. 
N
3
-(1-Adamantylmethyl)-N
3
-methyl-N
1
-quinolin-4-ylbutane-1,3-diamine (84). 
Compound 84 was prepared from aminoquinoline 78 (260 mg, 0.72 mmol) and 36% 
formaldehyde (110 µL, 1.43 mmol) using ZnCl2 (195 mg, 1.43 mmol) and NaBH3CN (180 mg, 
2.86 mmol) by procedure D and was obtained after multiple chromatography: dry-flash (SiO2, 
eluent: CH2Cl2/MeOH(NH3 satd) = 95/5) and flash chromatography (Biotage SP1 NH column, 
gradient: Hex/EtOAc = 3/7→1/9). Yield: 240 mg (89%). IR (ATR): 3355m, 3055w, 2957m, 
2902s, 2845s, 2792w, 1616w, 1578s, 1538m, 1494w, 1455m, 1400w, 1373m, 1346m, 1289w, 
1258w, 1233w, 1179w, 1152w, 1125w, 1104w, 1074w, 1046w, 1014w, 984w, 950w, 889w, 
871w, 802m, 764m, 470w, 448w, 406w cm
-1
. 
1
H-NMR (500 MHz, CDCl3): 8.55 (d, 1H, J = 5.2 
Hz, H-C(2)), 7.96 (d, 1H, J = 7.8 Hz, H-C(8)), 7.83 (d, 1H, J = 7.6 Hz, H-C(5)), 7.65-7.55 (m, 
1H, H-C(7)), 7.45-7.35 (m, 1H, H-C(6)), 6.63-6.50 (bs, 1H, -NH), 6.40 (d, 1H, J = 5.2 Hz, H-
C(3)), 3.55-3.45 (m, 1H, ArNHCH2-), 3.44-3.30 (m, 1H, ArNHCH2-), 2.85-2.75 (m, 1H, 
ArNHCH2CH2(CH3)CH-), 2.33 (s, 3H, -NCH3), 2.15-2.05 (m, 2H, -CH2Ad), 2.00-1.88 (m, 1H, 
ArNHCH2CH2-), 1.81 (s, 3H, -Ad), 1.72-1.62 (m, 1H, ArNHCH2CH2-), 1.60-1.35 (m, 12H, -
Ad), 1.00 (d, 3H, J = 6.7 Hz, -CH3).
 13
C-NMR (125 MHz, CDCl3): 150.91; 150.37; 148.24; 
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129.53; 128.90; 124.16; 120.20; 119.13; 98.57; 69.04; 61.23; 42.94; 41.30; 38.77; 36.97; 35.07; 
32.57; 28.35. (+)ESI-HRMS (m/z (%)): 378.28906 (M+H+, 100), calculated 378.29037 (error 
in ppm: -0.12). Anal. (C25H35N3  2/3H2O) Calculated: C, 77.08; H, 9.40; N, 10.79. Found C, 
76.98; H, 9.06; N, 10.78. HPLC purity (λ= 330 nm  method  : RT 7.896 min. area 98.74%; 
method B: RT 9.244 min., area 97.79%.  
N
1
-(1-Adamantylmethyl)-N
1
-methyl-N
3
-quinolin-4-ylbutane-1,3-diamine (85). 
Compound 85 was prepared from aminoquinoline N
1
-(1-adamantylmethyl)-N
3
-quinolin-4-
ylbutane-1,3-diamine
4
 (169 mg, 0.46 mmol) and 36% formaldehyde (72 µL, 0.93 mmol) using 
ZnCl2 (126 mg, 0.93 mmol) and NaBH3CN (117 mg, 1.85 mmol) by procedure D and was 
obtained after multiple chromatography: dry-flash (SiO2, eluent: CH2Cl2/MeOH(NH3 satd) = 
95/5) and flash chromatography (Biotage SP1 NH column, gradient: Hex/EtOAc = 3/7→1/9 and 
RP column, gradient: MeOH/H2O = 8/2→9/1) as a white solid (123 mg, 70%). IR (ATR): 
3288m, 3073w, 2901s, 2845s, 1618w, 1581s, 1541m, 1451m, 1396w, 1375w, 1342w, 1262w, 
1184w, 1150w, 1045m, 983w, 945w, 872w, 809w, 763m, 737w, 603w cm
-1
. 
1
H-NMR (500 
MHz, CDCl3): 8.52 (d, 1H, J = 5.2 Hz, H-C(2)), 7.96 (d, 1H, J = 8.4 Hz, H-C(8)), 7.86 (d, 1H, J 
= 8.4 Hz, H-C(5)), 7.65-7.58 (m, 1H, H-C(7)), 7.43-7.35 (m, 1H, H-C(6)), 6.79 (bs, 1H, -NH), 
6.42 (d, 1H, J = 5.5 Hz, H-C(3)), 3.93-3.80 (m, 1H, ArNHCH(CH3)-), 2.72-2.62 (m, 1H, 
ArNHCH(CH3)CH2CH2-), 2.52-2.42 (m, 1H, ArNHCH(CH3)CH2CH2-), 2.33 (s, 3H, -NCH3), 
2.08 (ABq, 1H, HA, J = 14.0 Hz, -CH2Ad), 2.03 (ABq, 1H, HB, J = 14.0 Hz, -CH2Ad), 1.95-1.67 
(m, 4H, ArNHCH(CH3)CH2-, -Ad), 1.95-1.85 (m, 1H, ArNHCH(CH3)CH2-), 1.66-1.50 (m, 12H, 
-Ad), 1.33 (d, 3H, J = 6.4 Hz, -CH3).
 13
C-NMR (125 MHz, CDCl3):150.06; 149.86; 129.23; 
128.98; 124.27; 120.42; 119.03; 98.49; 72.33; 58.07; 48.45; 46.42; 41.56; 36.97; 34.76; 33.44; 
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28.41; 19.62. (+)ESI-HRMS (m/z (%)): 378.29037 (M+H+, 100); calculated 378.29037 (error 
in ppm: -0.02). Anal. (C25H35N3  1/2H2O) Calcd: C, 77.67; H, 9.39; N, 10.87. Found: C, 77.20; 
H  9.51;    10.92. HP   purity (λ= 330 nm  method  : RT 7.851 min.  area 97.80%; method B: 
RT 9.284 min., area 95.71%. 
Benzyl [1-methyl-4-(quinolin-4-ylamino)butyl]carbamate (107). 
Compound 107 was prepared by procedure A using 4-chloroquinoline (195 mg, 1.18 mmol) and 
benzyl (4-amino-1-methylbutyl)carabamate
4
 (335 mg, 1.42 mmol). The product was purified 
using column chromatography (flash, Biotage SP, NH column, 40+M, eluent hexane, 
hexane/EtO   gradient 9/1 → EtO    EtO  /MeOH gradient 9/1 → MeOH . Final produ t 107 
was obtained as a yellow oil (320 mg, 72%). IR (ATR): 3344m, 3063w, 3031w, 2964w, 2934w, 
2866w, 1696s, 1616w, 1582s, 1539s, 1454m, 1395w, 1374w, 1343m, 1257m, 1081m, 1029w, 
808w, 764m, 697w cm
-1
. 
1
H NMR (500 MHz, CDCl3  δ): 8.54 (d, 1H, J = 5.2, H-C(2)), 8.00-
7.95 (m, 1H, H-C(8)), 7.84-7.78 (m, 1H, H-C(5)), 7.65-7.59 (m, 1H, H-C(7)), 7.44-7.39 (m, 1H, 
H-C(6)), 7.37-7.29 (m, 5H, -Ph), 6.43-6.36 (m, 1H, H-C(3)), 5.30 (bs, 1H, NH), 5.11 (s, 2H, -
CH2Ph), 4.73-4.64 (bs, 1H, NH), 3.89-3.80 (m, 1H, CbzNHCH(CH3)), 3.37-3.30 (m, 2H, 
CbzNHCH(CH3)CH2CH2CH2-), 1.85-1.75 (m, 2H, CbzNHCH(CH3)CH2-), 1.65-1.56 (m, 2H, 
CbzNHCH(CH3)CH2CH2-), 1.18 (d, 3H, J = 6.5, CH3). 
13
C NMR (125 MHz, CDCl3  δ): 156.02, 
151.00, 149.70, 148.40, 136.45, 129.84, 128.94, 128.53, 128.16, 128.09, 124.54, 119.52, 118.77, 
98.70, 66.68, 46.76, 43.07, 35.12, 25.13, 21.37. HRMS: m/z 364.20267 corresponds to molecular 
formula C22H25N3O2H
+
 (error in ppm 1.98). 
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N
1
-(quinolin-4-yl)pentane-1,4-diamine (108). 
The Cbz-protected amine 107 (305 mg, 0.839 mmol) was hydrogenated using palladium on 
carbon 10% (30 mg, 10% mw) as catalyst under 30 psi of hydrogen in MeOH (150 mL). After 
the mixture was stirred at r.t. for 8 h, the catalyst was removed by filtration and the solvent was 
evaporated under reduced pressure. Final product 108 was obtained as a yellow oil (192 mg, 
99.8%). IR (ATR): 3353m, 3077w, 2958w, 1584s, 1545m, 1441w, 1376w, 1343m, 1258w, 
1228w, 1127w, 1037w, 884w, 810w, 766w cm
-1
. 
1
H NMR (500 MHz, CD3OD  δ): 8.34 (d, 1H, J 
= 5.5, H-C(2)), 8.12-8.07 (m, 1H, H-C(8)), 7.83-7.78 (m, 1H, H-C(5)), 7.65-7.60 (m, 1H, H-
C(7)), 7.45-7.41 (m, 1H, H-C(6)), 6.50 (d, 1H, J = 5.8, H-C(3)), 3.38 (t, 2H, J = 7.1, ArNHCH2-
), 3.03-2.95 (m, 1H, NH2CH(CH3)-), 1.85-1.74 (m, 2H, ArNHCH2CH2-), 1.61-1.48 (m, 2H,  
ArNHCH2CH2CH2-), 1.14 (d, 3H, J = 6.4, NH2CH(CH3)-). 
13
C NMR (125 MHz, CD3OD  δ): 
152.67, 151.14, 148.82, 130.49, 128.72, 125.59, 122.21, 120.28, 99.14, 47.92, 43.87, 36.88, 
26.12, 22.28. HRMS: m/z 230.16532 corresponds to molecular formula C14H19N3H
+ 
(error in 
ppm 0.64); m/z 115.58652 corresponds to molecular formula C14H19N3H2
2+ 
(error in ppm 2.52). 
Benzyl {4-[(7-chloroquinolin-4-yl)amino]-1-methylbutyl}carbamate (109). 
Compound 109 was prepared by procedure A using 4,7-dichloroquinoline (400.0 mg, 2.019 
mmol) and benzyl (4-amino-1-methylbutyl)carbamate
4
 (525 mg, 2.22 mmol). The product was 
purified using column chromatography (flash, Biotage SP, NH column, 40+M, eluent hexane, 
hexane/EtO   gradient 9/1 → 1/9  EtO  /MeOH gradient 9/1 →1/9 . Final produ t 109 was 
obtained as yellow oil (477 mg, 59%). IR (ATR): 3314m, 3033w, 2938m, 1698s, 1610w, 1581s, 
1537m, 1452m, 1370w, 1333w, 1256m, 1139w, 1080w, 1026w, 901w, 878w, 851w, 808w, 
738w, 698w cm
-1
. 
1
H NMR (500 MHz, CD3OD  δ): 8.30 (d, 1H, J = 5.5, H-C(2)), 8.10-8.04 (m, 
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1H, H-C(5)), 7.78-7.75 (m, 1H, H-C(8)), 7.38-7.34 (m, 1H, H-C(6)), 7.34-7.22 (m, 5H, -Ph), 
6.50-6.44 (m, 1H, H-C(3)), 5.10-5.01 (s, 2H, -CH2Ph), 3.76-3.66 (m, 1H, CbzNHCH(CH3)-), 
3.38-3.32 (m, 2H, CbzNHCH(CH3)CH2CH2CH2-), 1.81-1.71 (m, 2H, CbzNHCH(CH3)CH2-), 
1.63-1.54 (m, 2H, CbzNHCH(CH3)CH2CH2-), 1.15 (d, 3H, J = 6.6, CbzNHCH(CH3)-). 
13
C 
NMR (125 MHz, CD3OD  δ): 158.44, 152.69, 152.36, 149.64, 138.48, 136.26, 129.42, 128.90, 
128.69, 127.54, 125.89, 124.32, 118.75, 99.60, 67.23, 47.92, 43.78, 35.38, 26.04, 21.51. HRMS: 
m/z 398.16435 corresponds to molecular formula C22H24ClN3O2H
+
 (error in ppm 3.43). 
N
1
-(7-chloroquinolin-4-yl)pentane-1,4-diamine (110). 
According to the procedure described in literature,
14
 Cbz-protected amine 109 (120 mg, 0.30 
mmol) was dissolved in TFA (2 mL) and the mixture was stirring under the reflux for 2 h. TFA 
was removed under the reduced pressure. Crude product was dissolved in CH2Cl2/2.5 M NaOH, 
organic layer washed twice with 2.5 M NaOH and dried over anh. Na2SO4. Final product was 
obtained as white powder (77 mg, 97%). M.p. = 109 – 111 ºC. IR (ATR): 3294m, 3104w, 
3010w, 2959w, 2931m, 2857m, 1610w, 1577s, 1542m, 1473w, 1452m, 1369m, 1331w, 1283w, 
1248w, 1197w, 1149w, 1131w, 1085w, 1025w, 953w, 919w, 901m, 850w, 824w, 800m, 767w 
cm
-1
. 
1
H NMR (500 MHz, CD3OD  δ): 8.32 (d, 1H, J = 5.5, H-C(2)), 8.07 (d, 1H, J = 9.2, H-
C(5)), 7.76-7.74 (m, 1H, H-C(8)), 7.38-7.34 (m, 1H, H-C(6)), 6.48 (d, 1H, J = 5.7, H-C(3)), 3.34 
(t, 2H, J = 7.2, ArNHCH2-), 2.89 (sext, 1H, J = 6.4, NH2CH(CH3)-), 1.83-1.69 (m, 2H, 
ArNHCH2CH2-), 1.54-1.42 (m, 2H, ArNHCH2CH2CH2-), 1.09 (d, 3H, J = 6.4, NH2CH(CH3)-). 
13
C NMR (125 MHz, CD3OD  δ): 152.71, 152.44, 149.71, 136.26, 127.60, 125.90, 124.30, 
118.77, 99.61, 47.66, 44.06, 37.79, 26.23, 23.26. HRMS: m/z 264.12514 corresponds to 
molecular formula C14H18ClN3H
+ 
(error in ppm -4.02). 
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3-(thiophen-2-yl)benzaldehyde (111). 
Compound 111 was prepared by procedure G using Pd(OAc)2 (36.4 mg, 0.162 mmol), PPh3 (170 
mg, 0.648 mmol), 2-thienylboronic acid (207.4 mg, 1.621 mmol), aq. 2M Na2CO3 (3.1 mL), 3-
bromobenzaldehyde (189 mg, 1.62 mmol) and DME (16 mL). The product was purified using 
column chromatography (dry-flash, SiO2  eluent hexane  hexane/EtO   gradient 9/1 → 7/3 and 
flash Biotage SP1, RP column, eluent MeOH/H2O gradient 7/3 → MeOH . Final product 111 
was obtained as a white foam (162 mg, 53 %). IR (ATR): 3370w, 3105w, 3072w, 2924w, 
2834w, 2727w, 1699s, 1599w, 1581w, 1532w, 1480w, 1442w, 1387w, 1350w, 1312w, 1270m, 
1220w, 1165m, 1119w, 1084w, 1055w, 1000w, 896w, 842w, 793m, 703m, 651w, 544w cm
-1
. 
1
H 
NMR (500 MHz, CDCl3  δ): 10.06 (s, 1H, H-CO), 8.10 – 8.09 (m, 1H, H-C(2)), 7.87 – 7.85 (m, 
1H, H-C(6)), 7.79 – 7.77 (m, 1H, H-C(4)), 7.55 (t, 1H, J = 7.7, H-C(5)), 7.40 (dd, 1H, J1 = 3.6, J2 
= 1.1, H- (3’    7.34 (dd  1H, J1 = 5.2, J2 = 1.1, H- (5’    7.12 (dd  1H, J1 = 5.0, J2 = 3.7, H-
 (4’  . 13C NMR (125 MHz, CDCl3  δ : 192.04  142.68  136.95  135.41  131.57  129.59  128.64  
128.25, 126.61, 125.79, 124.06. GC/MS (m/z (%)): 188.0 ([M
+
], 100); 159.0 (36); 115.1 (50). 
3-(5-bromothiophen-2-yl)benzaldehyde (112). 
According to known procedure,
15
 111 (136 mg, 0.722 mmol) was dissolved in 1,2-
dichloroethane (2.5 mL). The solution of Br2 (41 µL, 0.79 mmol)  in 1,2-dichloroethane (2.5 mL) 
was added slowly at 0 °C, then warmed to r.t. and stirred for 2h. Aqueous Na2S2O3 solution was 
added, and the desired product was extracted with 1,2-dichloroethane. Combined organic layers 
were washed with brine and dried over anh. Na2SO4. After filtration, the solvent was removed 
under reduced pressure. The product was purified using column chromatography (flash, Biotage 
SP1, RP column, eluent MeOH/H2O gradient 8/2 → MeOH . The final produ t 112 was obtained 
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as a white foam (144 mg, 75 %). M.p. = 58 – 59 °C. IR (ATR): 3357w, 3097w, 3025w, 2857w, 
2812w, 2761w, 1738w, 1685s, 1601w, 1480w, 1449w, 1429w, 1398w, 1284w, 1258w, 1183w, 
1158w, 1005w, 872w, 783m, 681w, 653w cm
-1
. 
1
H NMR (500 MHz, CDCl3  δ): 10.05 (s, 1H, H-
CO), 8.01 – 8.00 (m, 1H, H-Ar), 7.81 – 7.79 (m, 1H, H-Ar), 7.77 – 7.75 (m, 1H, H-Ar), 7.57- 
7.54 (m, 1H, H-Ar), 7.15 (d, 1H, J = 3.9, H-C(thiophene)), 7.07 (d, 1H, J = 3.7, H-C(thiophene)). 
13
C NMR (125 MHz, CDCl3  δ : 191.80  144.08  137.03  134.63  131.20  131.10  129.77  129.10  
126.15, 124.27, 112.61. GC/MS (m/z (%)): 267.9 ([M
+
], 100); 158.0 (60). 
[4-(2-thienyl)phenyl]acetonitrile (113). 
Compound 113 was prepared by procedure F using 2-bromothiophene (200 mg, 1.23 mmol), [4-
(cyanomethyl)phenyl]boronic acid (217.2 mg, 1.349 mmol), PdO × 1.4 H2O (18 mg, 0.12 
mmol), K2CO3 (186.4 mg, 1.349 mmol) and EtOH/H2O (12 mL, 3:1, v/v). The product was 
purified using column chromatography (dry-flash, SiO2, eluent hexane, hexane/toluene gradient 
9/1 → toluene . The final produ t 113 was obtained as an ocher solid (157.9 mg, 65 %). M.p. = 
98 – 102 °C. IR (film): 3120m, 3024w, 2956w, 2906w, 2359w, 2247m, 2171w, 1609w, 1534m, 
1500m, 1428m, 1412m, 1353w, 1300w, 1260m, 1211w, 1119w, 1078w, 1055w, 957w, 910w, 
851m, 824m, 802s, 702s cm
-1
. 
1
H NMR (500 MHz, CDCl3  δ): 7.64 – 7.60 (m, 2H-Ar), 7.35 – 
7.31 (m, 3H, 2H-Ar and H-C(2)), 7.30 (dd, 1H, J1 = 5.1, J2 =1.2, H-C(4)), 7.11 – 7.07 (m, 1H, H-
C(3)), 3.76 (s, 2H, Ar-CH2-CN). 
13
C NMR (125 MHz, CDCl3  δ : 143.30  134.34  128.85  
128.46, 128.11, 126.54, 125.26, 123.52, 117.65, 23.32. GC/MS (m/z (%)): 199.1 ([M
+
], 100); 
171.1 (27). 
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[4-(5-bromo-2-thienyl)phenyl]acetonitrile (114). 
N-bromosuccinimide (82.4 mg, 0.463 mmol) was added to the stirring solution of 113 (86.3 mg, 
0.433 mmol) in dry THF (9 mL) in the dark, at room temperature. Reaction progress was 
monitored by TLC (RP, MeOH). After 1h of stirring, an aq. Na2S2O3 solution was added, and the 
desired product was extracted with CH2Cl2. Combined organic layers were washed with brine, 
and dried over anh. Na2SO4. After filtration, the solvent was removed under reduced pressure. 
The product was purified using column chromatography (flash Biotage SP1 RP column, eluent 
MeOH/H2O gradient 6/4 → MeOH . The final produ t 114 was obtained as an ocher solid (64.2 
mg, 53 %). M.p. = 142 – 145 °C. IR (film): 3094w, 3032w, 2923w, 2315w, 2248m, 1913w, 
1749w, 1568w, 1538w, 1500m, 1431s, 1407m, 1330w, 1299w, 1246w, 1209w, 1124w, 1065w, 
979w, 946w, 910w, 820w, 794s, 673w, 632w cm
-1
. 
1
H NMR (500 MHz, CDCl3  δ): 7.55 – 7.49 
(m, 2H-Ar), 7.37 – 7.32 (m, 2H-Ar), 7.07 – 7.03 (m, 2H-thiophene), 3.76 (s, 2H, Ar-CH2-CN).
 
13
C NMR (125 MHz, CDCl3  δ : 144.70  133.56  130.94  129.36  128.60  126.22  123.70  117.51  
111.95, 23.33. GC/MS (m/z (%)): 279.0 ([M
+
], 100); 198.1 (40). 
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